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3SUMMARY
Resistance to airflow in the respiratory tract is largely determined by the degree of tone 
in the smooth muscle layer surrounding the airways.
The tone of the airway smooth muscle in vivo is regulated by neural control 
mechanisms, locally released mediators as well as humoral factors. Environmental 
factors, such as hypoxia, may also influence the tone of the airway smooth muscle and 
in addition, alter its responsiveness to various pharmacological agonists. Since hypoxia 
can be a feature of respiratory disorders, such as asthma and chronic obstructive 
pulmonary disease, it may be of importance to determine if airway smooth muscle 
function is altered under hypoxic conditions.
Using various techniques, I assessed:
(i) The effect of acute changes in oxygen tension on responses to contractile agents and 
relaxatory agents in bovine isolated bronchi.
(ii) The effect of chronic hypoxia on contractile responses in rat isolated airways.
(iii) The effect of chronic hypoxia on endothelin receptor-mediated responses in rat 
isolated airways.
(iv) The effect of hypoxia on the proliferation of cultured human airway smooth muscle 
cells.
(v) The effect of changes in inspired oxygen tension on salbutamol-mediated 
bronchodilation and methacholine- and histamine-mediated bronchoconstriction in 
asthmatic patients in vivo.
In rings of bovine bronchi (3rd-5th order, 3-5mm internal diameter), isometric 
contractions were significantly potentiated when the oxygen tension in the Krebs- 
Henseleit solution was lowered from 524mm Hg (hyperoxia) to either 147 mm Hg 
(normoxia) or 26mm Hg (hypoxia). The ability of the dilator agents salbutamol, atrial 
natriuretic peptide (ANP), sodium nitroprusside (SNP) and isosorbide dinitrate (ISDN) 
to reverse methacholine-induced tone was also altered by changing the oxygen tension, 
although the pattern of response differed between the various agents: The ability of 
salbutamol to reverse the induced tone was attenuated in hypoxia, whereas ANP was 
more effective in hypoxia than either hyperoxia or normoxia. ISDN and SNP were 
similar in that they were both more effective in either hypoxia or normoxia than in 
hyperoxia.
In addition, the ability of these four dilators to confer protection against subsequent 
challenge with methacholine was compared under hyperoxic, normoxic and hypoxic 
conditions. Salbutamol attenuated responses to methacholine, but only under hyperoxic 
conditions, in normoxia and hypoxia it was ineffective. In hyperoxia, ANP protected 
against methacholine challenge, but in hypoxia, ANP actually potentiated the
methacholine-induced contractions. The ability of both SNP and ISDN to protect 
against methacholine challenge was enhanced when the oxygen tension was reduced 
from hyperoxia to either normoxia or hypoxia.
Tracheal rings (internal diameter ~2mm) isolated from rats exposed to 14 days of 
chronic hypobaric hypoxia (500-550mBar) produced contractions to methacholine, 
endothelin-1 (ET-1) and potassium chloride which were significantly less than 
responses in control rats. In both control and hypoxic rats, responses to methacholine 
and ET-1 were not altered by indomethacin (a cyclooxygenase inhibitor) but were 
potentiated by either L-NAME (a nitric oxide synthase inhibitor) or by removal of the 
epithelium. Responses to the nitric oxide donor, SNP, but not the |3 adrenoceptor 
agonist salbutamol were enhanced in chronically hypoxic rats. Taken together, these 
results indicate that nitric oxide or a nitric oxide-like substance is released from the 
epithelium of both control and chronically hypoxic rats and that this subsequently 
attenuates the contractile responses to methacholine and ET-1. In chronically hypoxic 
rats, however, the airway smooth muscle appears to be more sensitive to nitric oxide 
than control rats, which may explain why contractile responses are significantly smaller 
in the chronically hypoxic rats.
ET-1 acts via at least two G protein-coupled receptor subtypes, termed ETa and ETb .
Contractile responses to ET-1 were attenuated in chronically hypoxic rats, whereas 
responses to sarafotoxin S6c (an ETb receptor agonist) were not altered. The ETa
receptor antagonist, FR 139317 at a concentration of 10-8M potentiated contractile 
responses to ET-1 in trachea from control but not chronically hypoxic rats. The ETb
receptor antagonist, BQ 788, potentiated responses to ET-1 in both control and 
chronically hypoxic rat trachea. It was found that ET-1 responses were only blocked by 
simultaneous blockade of both ETa and ETb receptors, either by using the non-
selective ET receptor antagonist, SB 209670, or by combining BQ 788 and FR 139317.
The proliferative response of cultured human airway smooth muscle cells was 
examined under different environmental oxygen tensions. Cell proliferation was 
assessed by cell counting and by measuring uptake of tritiated [3H] thymidine. Cells 
were quiesced for 24 hours in normoxia and then stimulated with either ET-1 or 
platelet-derived growth factor (PDGF) for 24 hours, either in a normal CO2 incubator
under an oxygen tension of 147mm Hg or in a hypoxic incubator under an oxygen 
tension of 30mm Hg. Hypoxia stimulated proliferation of the cultured airway smooth 
muscle cells per se, and potentiated the mitogenic effects of both ET-1 and PDGF. ET- 
1-induced mitogenesis in hypoxia was blocked by the ETa receptor antagonist BQ 123, 
but not by the ETb receptor antagonist BQ 788, indicating that this is an ETA-mediated 
response. In the presence of the protein kinase C inhibitor, staurosporine, the hypoxic 
enhancement of ET-1- and PDGF-induced mitogenesis was abolished. This suggests
that the stimulatory effect of hypoxia on mitogenesis in these cell is mediated via 
activation of protein kinase C.
Bronchodilator responses to salbutamol and bronchoconstrictor responses to 
methacholine and histamine were measured in asthmatic patients inspiring gas mixtures 
containing different oxygen contents. In parallel, responses to each of these agonists 
were measured in human isolated bronchial rings under hyperoxic, normoxic and 
hypoxic conditions.
The bronchodilator response to salbutamol in asthmatic patients was not altered by 
changing the inspired oxygen tension, whereas responses in vitro were significantly 
attenuated in hypoxia. In human isolated bronchial rings, contractile responses to both 
methacholine and histamine were significantly attenuated when the oxygen tension was 
reduced from hyperoxic levels. In asthmatic patients, methacholine-induced 
bronchoconstriction was enhanced when inspiring the hypoxic gas mixture, whereas 
responses to histamine were unaltered by changing the gas mixture.
In conclusion, changes in oxygen tension can have a significant effect on airway 
smooth muscle function.
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LIST OF ABBREVIATIONS
ANP atrial natriuretic peptide
Ca2+ calcium
cAMP cyclic adenosine 3', 5'-monophosphate
cGMP cyclic guanoosine 3', 5'-monophosphate
C 02 carbon dioxide
DAG diacylglycerol
dpm disintegrations per minute
EC400mg the concentration of an agonist which evokes a contraction of 
400mg wt
ERK extracellular regulated kinase
ETC02 end-tidal carbon dioxide
ET-1 endothelin-1
ETa , -b endothelin receptor subtypes, A and B.
FEVi forced expiratory volume in one second
i.d. internal diameter
IP3 inositol 1,4,5-trisphosphate
ISDN isosorbide dinitrate
MAPK mitogen activated protein kinase
mbar millibar
NO nitric oxide
NOS nitric oxide synthase
O2 oxygen
PC20 the concentration of agonist evoking a 20% fall in FEV1
pD2 the negative log of the concentration of agonist which evokes 
50% of the maximum response
PGI2 prostacyclin
PIP2 phosphatidylinositol, 4,5-bisphosphate
PKC protein kinase C
p l a 2 phospholipase A2
PLC phospholipase C
PLD phospholipase D
RTK receptor tyrosine kinase
Sa02 partial pressure of 0 2 in arterial blood
SAPK stress activated protein kinase
SxS6c sarafotoxin S6c
SEM standard error of the mean
SNP sodium nitroprusside
~ approximately
% percentage
CHAPTER 1 
INTRODUCTION TO RESEARCH
1.1 CONTROL OF RESPIRATION
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1.1.1 INTRODUCTION
Oxygen is required for the survival of all higher life forms due to its central role in the 
synthesis of ATP by oxidative phosphorylation. Even transient, localised oxygen 
deficits can produce irreversible cellular damage, causing tremendous morbidity and 
mortality in humans. Breathing is therefore a tightly controlled event, so that even in 
the face of wide changes in metabolic demand, the arterial oxygen tension (Pao2) is
normally kept within restricted limits (-85 to 95mmHg). The respiratory control system 
is comprised of two basic elements: the central controller in the brain and sensors 
which gather information.
1.1.2 CENTRAL CONTROL
Pioneering work by Lumsden (1923) indicated that the periodic nature of inspiration 
and expiration is generated by three major respiratory centres within the brainstem, 
termed the medullary respiratory centre, the pneumotaxic centre and the apneustic 
centre.
1.1.2.1 Medullary respiratory centre
Respiratory units in the medulla are primarily concentrated into two major aggregates: 
the dorsal respiratory nucleus (DRN) and the ventral respiratory nucleus (VRN). The 
DRN is believed to contain predominantly (Vibert et al., 1976) or exclusively (von 
Baumgarten et al., 1957; von Baumgarten & Kanzow, 1958; von Euler et al., 1973) 
inspiratory units, whereas the VRN contains both inspiratory and expiratory units 
(Bianchi, 1971; Mitchell & Berger, 1975). Inspiratory units are nerve cells having a 
phasic discharge pattern linked to the inspiratory phase and provide excitatory drive to 
motoneurones innervating inspiratory muscles such as the diaphragm and the external 
intercostals. In expiratory units, the phasic discharge occurs during expiration and 
excitates motoneurones innervating expiratory muscles such as the internal intercostals 
and the abdominals.
Lumsden (1923) and others (Tenney & Ou, 1977) demonstrated that removing all but 
the medulla and the pons does not markedly alter the pattern of ventilation, indicating 
that some intrinsic pattern generator exists within these sites. A subregion of the VRN 
known as the preBotzinger complex is now thought to be the site of the respiratory 
rhythm generator (Smith et a l, 1991; Connelly et a l, 1992). Rhythmogenesis is still a 
poorly understood phenomenon, however, with models including pacemaker neurones
25(Feldman & Cleland, 1982), interconnected networks of platonic cells (Llinas, 1988) 
and hybrids between the two (Ogilvie et al, 1992).
1.1.2.2 Pneumotaxic centre
Stimulation of precise areas in the upper pons provokes a "phase-switch" in the 
respiratory cycle (Bertrand & Hugelin, 1971; Cohen, 1971), indicating that this is the 
site of the pneumotaxic centre. This area appears to terminate or inhibit inspiration and 
thus regulate ventilation. The role of this centre may be fine-tuning of the respiratory 
rhythm since normal respiration can exist in the absence of this centre.
1.1.2.3 Apneustic Centre
When a precise area in the lower pons of experimental animals is isolated by 
transection (Lumsden, 1923) or electrically stimulated (Ngai & Wang, 1957), the 
pattern of respiration is characterised by prolonged inspiratory gasps (apneuses) 
interrupted by transient expirations. Destroying this centre suppresses tidal volume but 
increases the frequency of ventilation (St. John & Wang, 1976), suggesting that the 
apneustic centre is primarily involved in controlling tidal volume. Tidal volume, 
however, is a complex process involving interaction between each of the brainstem 
respiratory centres, indeed, the apneustic centre's role in the control of normal human 
respiration is questionable.
1.1.2.4 Cortical Control
Breathing in humans is, to a considerable extent, under voluntary control, allowing the 
respiratory centres in the brainstem to be temporarily overridden. The cortical 
mechanisms involved in this are largely unknown (for review, see Davenport & Reep, 
1995).
1.1.3 SENSORS
The respiratory centres mentioned above receive sensory input from various receptors, 
the most important of which are chemoreceptors and mechanoreceptors.
1.1.3.1 Chemoreceptors
Since the purpose of respiration is to supply O2 to and remove CO2 from the blood, it is
unsurprising to find that the pattern of ventilation is exquisitely sensitive to feedback 
from receptors which respond to variations in blood O2 and CO2 levels.
1.1.3.1.1 Peripheral Chemoreceptors
The principal O2 sensors are the so-called peripheral chemoreceptors, localised in the 
carotid and aortic bodies (Duffin, 1971; Sorensen, 1971), which signal the brain via 
afferent pathways in the glossopharyngeal and vagus nerves, respectively. These
9 f \chemoreceptors increase their discharge as O2 levels are decreased, with steep increases
below ~50mmHg and this increased discharge stimulates breathing. Both carotid and 
aortic bodies are stimulated by a fall in Pao2> although the response of the aortic body
is much smaller (Lahiri et a l, 1981). Unlike the carotid body, the aortic body is 
stimulated by reductions in arterial O2 content which occur in carboxyhemoglobinemia,
anemia and hypotension (Lahiri, 1980; Lahiri et al., 1980), suggesting that the aortic 
body is more sensitive to total O2 delivery whereas the carotid body is primarily 
responsive to changes in Pao2 (Lahiri, 1991). Under normal conditions, O2 sensors
account for only a small part of the chemoreceptor drive to breathe, since removal of 
their sensory input by breathing pure O2 reduces minute ventilation by only about 15%
in awake mammals (for review, see Fidone & Gonzales, 1986).
1.1.3.1.2 Central Chemoreceptors
Although the peripheral chemoreceptors are also responsive to alterations in Paco2, the 
principle detectors for Paco2 changes are the central chemoreceptors, which have been
localised to the ventrolateral surface of the medulla (Mitchell et al., 1963; Loeschke et 
al., 1963; Schlaefke et al., 1970). A very small increase in Paco2 increases the activity 
of these chemoreceptors which in turn stimulate ventilation, therefore Paco2 acting on 
the central chemoreceptors is the principle respiratory stimulus.
It has been debated for many years whether CO2 activates peripheral and central
chemoreceptors exclusively via its acidifying action or via some pH-independent effect. 
Several studies indicate that differences exist in the ventilatory response to CO2 versus
H+ (Fukuda, 1983; Eldridge et a l, 1985; Harada et al., 1985; Neubauer et al., 1991), 
however, it is generally accepted that CO2 stimulates chemoreceptors via intracellular
acidification (Fidone & Gonzalez, 1986; Hanson et al., 1981; Rocher et al., 1991).
Thus, variations in Paco2 are detected by both the peripheral and central 
chemoreceptors, whereas changes in Pao2 are detected by the peripheral 
chemoreceptors only. Indeed, hypoxia exerts a depressive effect on central respiratory 
centres (Grunstein et al., 1981; Easton et al., 1986), presumably via a direct attenuation 
of neuronal excitability (Fowler, 1989; Doll et a l, 1991; Cummins et al., 1993).
1.1.3.2 Mechanoreceptors
Feedback from mechanoreceptors in the lungs is vital for the precise control of 
respiratory muscle activity. At least three types of mechanoreceptors exist in the lungs 
and all have afferent pathways travelling via the vagus nerve (Richardson & Ferguson, 
1979).
1.1.3.2.1 Slowly Adapting Receptors
Also known as "stretch receptors" these receptors are myelinated nerve terminals 
localised mainly to the smooth muscle of conducting airways (Guz & Trenchard, 1971) 
and are stimulated by changes in tension across the airway wall. They are responsible 
for the Hering-Breuer reflex which inhibits sustained inspiratory activity to avoid over 
inflation of the lung (Bartoli et a l, 1973). Slowly adapting receptors probably have 
little influence on the breathing pattern of normal people at rest (Clark & von Euler, 
1972), but they may play a role in the control of breathing in patients with chronic 
obstructive pulmonary disease who breath at high lung volumes (Bartoli et al., 1973).
1.1.3.2.2 Rapidly Adapting Receptors
These receptors are also myelinated nerve terminals, but differ from slowly adapting 
receptors in that they adapt more quickly and fire irregularly. In addition to mechanical 
stimuli, they are activated by chemical stimuli such as ammonia, ozone, histamine and 
prostaglandins (Sampson & Vidruk, 1975) and are therefore known as "irritant 
receptors." These receptors are situated below the epithelium and between epithelial 
cells (Das et a l, 1978; Laitinen, 1985) and when stimulated, evoke bronchoconstriction 
by a reflex increase in vagal efferent activity (see section 1.4.1.1). The role of these 
receptors is unclear but they may act to limit penetration of potentially harmful 
substances into the lung and thereby prevent these substances from reacting with the 
gas exchanging surfaces of the alveoli.
1.1.3.2.3 C-fibre Receptors
Nonmyelinated nerve endings, termed C-fibres, are also found in the airways, usually 
within the airway epithelium (Rhodin, 1966; Laitinen, 1985). Unmyelinated nerves are 
also occasionally seen in alveolar walls (Fox et a l, 1980) and these are thought to 
correspond to J-receptors, which are closely associated with pulmonary capillaries. 
Activation of these receptors, by lung deflation and certain chemical stimuli such as 
capsaicin (Coleridge et a l, 1965) and bradykinin (Kaufman et a l, 1980), leads to the 
development of rapid, shallow breathing.
1.1.3.2.4 Other Receptors
While the chemoreceptors and mechanoreceptors mentioned above are the principal 
receptors involved in controlling respiration, the central respiratory controller receives 
feedback from a number of other sources. Receptors in the upper airways of the nose, 
pharynx and larynx are involved in airway reflexes such as sneezing, while input from 
joint and muscle receptors are believed to be an important part of the stimulus to 
ventilation during exercise.
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1.2.1 INTRODUCTION
The airways consist of a series of branching tubes which become narrower and more 
numerous as they penetrate deeper. The upper respiratory tract, comprising the nose, 
paranasal sinuses and the nasopharynx, is principally involved in filtering, humidifying 
and adjusting the temperature of inspired air, whereas the function of the lower 
respiratory tract, which begins at the trachea and continues down through the bronchi 
and bronchioles to the alveolar sacs, is to conduct inspired air to the gas exchanging 
regions of the lungs. The lower respiratory tract can be conceptually divided into three 
zones:
1. The conducting zone, comprising the trachea, bronchi and bronchioles which have no 
gas exchanging surfaces (alveoli).
2. The transitional zone, which both conducts air and exchanges gas. These consist of 
respiratory bronchioles which have both gas exchanging and non-gas exchanging 
epithelium in their walls.
3. The gas exchanging zone which consists of the alveolated airways (alveolar ducts 
and sacs).
1.2.2 AIRWAY STRUCTURE
Although the conducting airways share a common plan - muscular tubes lined by a 
ciliated epithelium - they differ in detail depending on size (Hayward & Reid, 1952; 
Horsefield, 1974). The walls of airways approximately 1mm or more in diameter are 
reinforced by cartilage and are called bronchi, whereas conducting airways without 
cartilage are termed bronchioles.
1.2.2.1 Bronchial level
The trachea divides into left and right primary bronchi which supply each lung. Each 
primary bronchus gives rise to secondary bronchi supplying the lobes of the lung before 
dividing again to form tertiary bronchi which supply the segments of each lobe. Within 
the lung, the bronchi branch asymmetrically, giving rise to progressively smaller 
vessels. The bronchi are lined by a pseudostratified ciliated columnar epithelium resting 
on a basement membrane (McCarter & Vazquez, 1966), beneath which is the lamina 
propria, composed predominantly of longitudinal elastic fibres (Miller, 1947). The 
smooth muscle of the bronchial wall lies just beneath the elastic fibres and is arranged 
in discrete bundles which wind down the airway wall in a spiral pattern (Von Hayek, 
1960; Nagaishi et al., 1972). Loose connective tissue and bronchial glands occupy the 
space between the muscle and the outermost layer of the bronchi, which consists of
29heavy, circumferential bundles of collagen fibres and cartilage. The form taken by the 
cartilage varies between regions in the respiratory tract; in the trachea and 
extrapulmonary bronchi, the cartilage appears as U-shaped rings which are open 
dorsally, whereas the intrapulmonary bronchi have irregularly shaped islands of 
cartilage (Hayward & Reid, 1952).
The epithelium lining the bronchi fulfils a number of roles, including synthesis and 
release of various chemical factors (see section 1.4.3) as well as their degradation, but 
its principle function is the production and propulsion of mucus (Breeze & Wheeldon, 
1977). Glands in the submucosa also contribute significantly to the production of 
mucus (Meyrick et a l, 1969). These glands decrease in number distally, ultimately 
disappearing at the same level as the cartilage.
1.2.2.2 Bronchiolar level
The walls of airways less than 1mm in diameter lack cartilage and consist mainly of 
smooth muscle enclosed in a thin connective tissue space. The proportion of the airway 
wall occupied by smooth muscle increases as the airway diameter decreases, reaching 
maximal prominence in the terminal bronchioles (Von Hayek, 1960; Nagaishi et al., 
1972). The epithelium is classified as simple, columnar, containing only two cell types; 
ciliated cells and non-ciliated secretory cells, known as Clara cells (Clara, 1937). 
Mucus producing cells are not normally found, but may be present in a number of 
disease states or after chronic exposure to tobacco smoke (Ebert & Terracio, 1975). In 
respiratory bronchioles, the proportion of ciliated cells decreases and in distal 
respiratory bronchioles often disappear completely, while the non-ciliated cells become 
cuboidal in shape (Basset et a l, 1971).
1.2.2.3 Respiratory Zone level
The respiratory zone of the lung comprises functional units termed acini which are 
supplied by a single terminal bronchiole. All the structures comprising an acinus 
(respiratory bronchioles, alveolar ducts and alveolar sacs) partake to some extent in gas 
exchange, since they all have alveoli. Respiratory bronchioles are vessels composed in 
part of muscular bronchial wall covered with cuboidal epithelium and in part by alveoli. 
Alveolar ducts are conducting structures lined entirely by alveoli and lead to a final 
generation of blind-ending, alveolus-lined spaces known as alveolar sacs. Airway 
smooth muscle and elastic fibres penetrate down to the level of the alveolar ducts 
(Whimster, 1975; Young et a l, 1980), whereas the alveolar walls are composed of 
alveolar epithelium, pulmonary endothelium and interstitial cells (Crapo et a l, 1982). 
The capillaries of the pulmonary vasculature are arranged as a tight mesh (Miller, 1947; 
Sobin et a l, 1970) around the alveoli to maximise diffusion of gases.
1.2.2.4 Overview
Each section of the respiratory tract has its own characteristic structural feature, but 
there is a gradual rather than abrupt, transition from one type of airway to the next. The 
principal variations in architecture which occur along the respiratory tree are as 
follows:
(a) The respiratory epithelium undergoes progressive transition from a tall, 
pseudostratified, columnar, ciliated form in the larynx and trachea to a simple, 
cuboidal, non-ciliated form in the smallest airways. Mucus producing cells are 
numerous in the trachea but decrease in number and are absent in the terminal 
bronchioles.
(b) A layer of smooth muscle lies deep to the mucosa (except in the trachea) and 
becomes increasingly prominent as the airway diameter decreases, reaching its greatest 
prominence in the terminal bronchioles.
(c) Submucosal connective tissue underlies the smooth muscle layer and contains 
mucus glands which become progressively less numerous in the narrower airways and 
are not present beyond the tertiary bronchi.
(d) Cartilage lies outside the submucosa and diminishes in prominence as the calibre of 
the airway decreases.
Figure 1.1
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Figure 1.1
Idealization of the human lower respiratory tract. The first 16 generations (Z) make up 
the conducting airways and the. last 7 the respiratory and transitional zones. BR; 
bronchus, BL; bronchiole, TBL; terminal bronchiole, RBL; respiratory bronchiole, 
AD; alveolar duct, AS; alveolar sac.
Adapted from Levitsky, 1995.
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1.3.1 INTRODUCTION
As stated above, the airways can be thought of as a series of branching tubes 
responsible for the conduction of air in and out of the gas-exchanging regions of the 
lungs. Contraction of airway smooth muscle is one of the main determinants of airway 
diameter and therefore of the resistance to airflow (Pedley et al., 1970). According to 
Poiseuille's law, resistance is related to the fourth power of the radius, therefore small 
changes in airway smooth muscle tone can have a marked effect on airway resistance.
Poiseuille's Equation: Resistance = 8nl where:
1.3.2 PHYSIOLOGY OF AIRWAY SMOOTH MUSCLE
1.3.2.1 Structure
All smooth muscle cells contain the contractile proteins actin, myosin, tropomyosin and 
caldesmon (Stull, 1980; Kamm & Stull, 1985a; Kamm & Stull, 1989). They function 
by forming into parallel filaments which slide past each other. Actin represents the 
major contractile protein of smooth muscle, being 10-20 times more abundant than 
myosin. Actin filaments are composed of two linear polymers of a 42-kilodalton (kDa) 
globular protein wrapped together in a helical configuration. Myosin filaments are thick, 
bipolar and arranged asymmetrically in a hexameric structure. Myosin comprises one 
pair of heavy chains (each of 200kDa) and two pairs of light chains (one pair of 17kDa 
known as the "essential light chain" and the other of 20kDa referred to as the 
"regulatory light chain"). The myosin molecule can be divided into the long 'tail' 
section and the globular 'head.' The globular head section of myosin contains the 
binding sites for attachment to actin as well as the enzymatic (ATPase) sites which 
cleave ATP to provide the energy necessary for the binding reactions to take place 
(Adelstein & Eisenberg, 1980). The two sets of myosin light chains are also located at 
the head of the myosin molecule and are considered to be essential in the regulation of 
the contractile process.
1.3.2.2 Regulation of Myosin by Ca2 +
When the concentration of free intracellular calcium ([Ca2+]i) is elevated from basal 
levels to between 0.5 and 1.0|im, the free Ca2+ binds to calmodulin, a low molecular 
weight binding protein with a high degree of specificity for Ca2+ (Cheung, 1980;
rcr4
tu/8 = constant of proportionality 
1 = length of the tube
r = radius of the tube 
r| = viscosity of the fluid
Manalan & Klee, 1984). Each calmodulin molecule has the capacity to bind up to a 
maximum of four molecules of Ca2+ and it is generally accepted that at least three 
binding sites must be occupied for activation to occur. The activated calcium-calmodulin 
complex stimulates myosin light chain kinase (MLCK), which in turn phosphorylates 
the 20kDa light chains of myosin on a specific serine residue. This phosphorylation 
step is regarded as a prerequisite for the activation of actin-dependent myosin ATPase 
and hence, the initiation of contraction (Stull, 1980; DeLanerolle & Stull, 1980; 
DeLanerolle et al., 1982). Decreases in cytosolic [Ca2+]i result in the dissociation of 
calmodulin from MLCK and conversion of the kinase to the inactive state in which it 
normally exists in resting smooth muscle cells (Dabrowska et al., 1977). With MLCK 
inactivation, myosin light chain is dephosphorylated by a myosin light chain 
phosphatase (MLCP) localized to the contractile elements (Kamm & Stull, 1985b; 
Shimizu et al., 1994; Shirazi et al., 1994). Thus, the net extent of regulatory light chain 
phosphorylation, and hence the magnitude of smooth muscle contraction, is determined 
by the relative activities of MLCK and MLCP (see Kamm & Grange, 1996).
In addition to MLCK, myosin light chain can also be phosphorylated by protein kinase 
C (PKC) and cyclic AMP-dependent protein kinase A (PKA). Like MLCK, PKC is 
Ca2+ dependent, but its affinity for Ca2+ is enhanced by diacylglycerol (DAG, 
generated by agonist-activated receptors, as described below) such that it is fully active 
at basal levels of Ca2+ (Nishizuka, 1986; Collins et al.t 1992). Phosphorylation of 
myosin light chain by PKA occurs at such a slow rate that this mechanism is thought to 
be physiologically irrelevant with respect to mediating contraction (Walsh et al., 1981), 
therefore, MLCK is accepted as being the primary regulatory mechanism in initiating 
smooth muscle contraction (Kamm & Stull, 1989)
1.3.2.3 Actin-Myosin interaction
The generation of contraction by actin and myosin is achieved by the cyclic attachment 
of the globular heads of the myosin molecules to actin (so-called crossbridge 
formation), a flexing change in the configuration of the myosin head with respect to 
actin, detachment of myosin from actin followed by subsequent re-attachment at another 
site further down the actin molecule. This rapid '’crossbridge cycling" is responsible for 
the active force development in smooth muscle and is fuelled by the breakdown of ATP 
by actin-activated myosin ATPase. In the absence of ATP hydrolysis, i.e. when 
[Ca2+]0 is low and no activation of MLCK can occur, the orientation of the globular 
myosin heads is such that crossbridge formation with actin is prohibited. Thus, at rest, 
actin and myosin molecules can freely slide past each other and no active tension is 
developed.
1.3.2.4 Calcium Homeostasis
Given that contraction of airway smooth muscle (ASM) is inherently dependent upon 
the [ C a 2 + ] i  within the cytoplasm of the cell, the regulation of [ C a 2 + ] i  is a  tightly
controlled process. Sodium-calcium ion ( N a + - C a 2 + )  exchangers (Bullock et al., 1981) 
and Ca2+ efflux pumps (Bryson & Rodger, 1987) in the ASM cell membrane actively 
extrude Ca2+ from the cell, while a Ca2+ uptake mechanism in the sarcoplasmic 
reticulum sequesters intracellular Ca2+. This results in a [ C a 2 + ] i  of between 0.05- 
0 . 2 5 j l i M  in relaxed airway smooth muscle compared with a concentration of C a 2 +  in the 
extracellular fluid of between l-2mM. Since the cell membrane effectively partitions 
the intra- and extracellular environments, extracellular Ca2+ can only gain entry into 
the cell by the opening of C a 2 +  channels in the plasmalemma, allowing C a 2 +  to flow 
down the electrochemical and concentration gradient into the cell. Two types of C a 2 +  
channel have been proposed to exist in smooth muscle (a) voltage-dependent and (b) 
receptor-operated (Bolton, 1979).
1.3.2.4.1 Voltage-dependent Ca2+ Channels
These channels, referred to as "L-type Ca2+ channels" possess a Ca2+ conductance that 
is directly proportional to the potential difference that exists across the plasma 
membrane and are opened by membrane depolarization (Kotlikoff, 1988; Marthan et 
al., 1989). Voltage-operated Ca2+ channels have been shown to exist in airway smooth 
muscle (Rodger, 1985; Giembycz & Rodger, 1987; Worley & Kotlikoff, 1990) and are 
responsible for generating the contractions evoked by potassium chloride (Kirkpatrick, 
1975; Farley & Mills, 1977; Foster et al., 1983). In addition, these channels are 
involved in mediating the effects of agents which activate or inhibit potassium (K+) 
channels. K+ channels are a heterologus family of membrane channels which are 
activated by various stimuli (Small et al., 1991; Morley, 1994). Opening of K+ 
channels allows K+ to leave the cell, resulting in membrane hyperpolarization. This 
hyperpolarization tends to inactivate the L-type Ca2+ channels, leading to a fall in 
[Ca2+]i and hence a reduction in smooth muscle contractility. Agents which stimulate 
K+ channels, including the so-called K+ channel openers and P2 adrenoceptor agonists,
therefore tend to induce relaxation of smooth muscle.
1.3.2.4.2 Receptor-operated Ca2+ channels
Ion channels opened by a receptor for a particular ligand have been described in certain 
types of smooth muscle, including airway smooth muscle (Bolton, 1979; Murray & 
Kotlikoff, 1991; Murray et al., 1993). Murray and Kotlikoff (1991) studied canine 
tracheal smooth muscle cells and demonstrated increases in cytosolic Ca2+ with 
histamine or bradykinin that were insensitive to dihydropyridines (antagonists such as 
nifedipine and verapamil which block L-type Ca2+ channels). Further evidence of 
dihydropryridine-insensitive Ca2+ pathways channels in airway smooth muscle has
34been supplied (Croxton et a l, 1994; Vannier et a l, 1995), but the physiological role of 
these receptor-operated channels in airway smooth muscle remains to be established.
1.3.2.5 Excitation-contraction (E/C) Coupling
Essentially two forms of E/C coupling (electromechanical and pharmacomechanical) 
are recognized; electromechanical coupling depends either upon electrical 
depolarization of the plasmalemma, which opens voltage-operated Ca2+ channels, or on 
a voltage dependent release of Ca2+ from intracellular stores. In each case, the rise in 
[Ca2+]i is due to depolarization of the plasma membrane, whereas pharmacomechanical 
coupling mechanisms are voltage-independent. The latter may involve influx of 
extracellular Ca2+ via receptor-operated Ca2+ channels, release of Ca2+ from 
intracellular stores, or an increased sensitivity of the contractile proteins to Ca2+.
The Ca2+ needed for smooth muscle contraction can come from extracellular sources or 
from internal stores such as the sarcoplasmic reticulum and the relative importance of 
each source depends upon the agent used to induce tone. Receptor stimulation by 
pharmacological agonists such as cholinomimetics, histamine etc., initiate contraction 
of airway smooth muscle via the release of Ca2+ from intracellular stores (Cobum,
1977). Entry of extracellular Ca2+ is required, however, for the maintenance of force in 
the continued presence of the agonist (Bourreau et a l, 1991; Murray & Kotlikoff,
1991). In contrast, the entry of extracellular Ca2+ is essential for both the initiation of 
the contraction and the maintenance of force induced by depolarizing agents such as 
potassium chloride (Cobum, 1977; Bourreau et a l, 1991). Thus, pharmacological 
agonists binding to specific cell surface receptors induce contraction of airway smooth 
muscle by liberating Ca2+ from intracellular stores. This has led to huge interest in the 
so-called "second-messengers" which transduce the signal from the stimulated receptor 
in the plasma membrane to the intracellular organelles involved in the contractile 
process.
1.3.3 SIGNAL TRANSDUCTION PATHWAYS INVOLVED IN MEDIATING35 
CONTRACTION OF AIRWAY SMOOTH MUSCLE
1.3.3.1 Receptor-G protein interactions
For the majority of physiological contractile agonists, activation of guanine nucleotide 
regulatory proteins (G proteins) is a critical intermediate step in the coupling of 
receptor-activation to second-messenger generation (for review see Raymond, 1995; 
Exton, 1997). G proteins are heterotrimers consisting of an a-subunit that binds 
guanine nucleotides and possesses intrinsic GTPase activity, and tightly associated p- 
and y-subunits that anchor the a  subunit to the cytoplasmic surface of the cell 
membrane (Neer & Clapham, 1988). In the resting state, G proteins exist as an apy 
holomer, with guanine diphosphate (GDP) bound to the a  subunit (see Figure 1.2). 
Association of an agonist to its receptor promotes exchange of GDP for guanine 
triphosphate (GTP) in the a-subunit, which triggers the dissociation of the apy complex 
from the receptor and separation of a-GTP from the py-complex. The "active" a-GTP 
subunit is then able to interact with a particular effector mechanism to modulate 
second-messenger production or ion exchange. Hydrolysis of the bound GTP by an 
intrinsic GTPase activity in the a-subunit terminates its interaction with the effector 
and the a-GDP reassociates with the py-complex to form a heterotrimer ready for 
activation by another receptor molecule (Stemweis & Smrcka, 1992). There is 
considerable heterogeneity in the G proteins involved in signal transduction due to the 
existence of different forms of the a, p and y subunits, although specificity of receptor- 
effector action is largely determined by structural and functional differences in the a- 
subunits. The G protein a  subunits which are of most relevance to airway smooth 
muscle contractility are the subtypes Gas, Gai (which stimulate and inhibit adenylyl 
cyclase, respectively) and Gaq which stimulates phospholipase C.
Figure 1.2 The G protein cycle
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Figure 1.2
Diagrammatic representation of the G protein/GTP/GDP cycle that is 
regarded as critical in the receptor-mediated signal transduction process
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1.3.3.2 Phosphatidylinositol 4,5-biphosphate (PIP2) hydrolysis
The majority of agonists which evoke contraction of airway smooth muscle are 
believed to act via stimulation of phospholipase C (PLC). Stimulation of PLC results in 
the rapid breakdown of the membrane phospholipid, phosphatidylinositol 4,5- 
biphosphate (PIP2), resulting in the generation of the second messengers inositol 1,4,5- 
trisphosphate (IP3) and diacylglycerol (DAG).
1.3.3.2.1 Inositol 1.4.5-trisphosphate flPV)
Following the hypothesis of Berridge and Irvine (1984) that IP3 is the "missing link"
between plasma membrane receptors and internal Ca2+ stores, several papers 
demonstrated that IP3 acts by mobilizing Ca2+ from intracellular pools (Berridge and
Irvine; 1989; Carsten & Miller, 1990; Cobum & Baron, 1990; Somlyo & Somlyo,
1992). Reports that IP3 is rapidly generated in airway smooth muscle after contractile
agonist stimulation (Chilvers et a l, 1989; Langlands et al., 1989; Chilvers et al., 1991) 
and the findings that IP3 accumulation correlates directly with airway smooth muscle 
contraction (Meurs et al., 1988; Meurs et al., 1989) are compelling evidence that IP3 
production is directly linked to the initiation of airway smooth muscle contraction.
1.3.3.2.2 Diacvlglvcerol (DAG)
By contrast, DAG is not implicated in the intracellular Ca2+ release process, and hence 
the initial generation of contraction. Instead, it has been suggested that DAG may be 
more intimately involved in the maintenance of smooth muscle contraction via 
stimulation of protein kinase C (PKC, Park & Rasmussen, 1986a; Rasmussen et al.,
1987).
PKC represents a family of related kinases which are of central importance in 
intracellular signalling pathways. At least 11 distinct isozymes of PKC have been 
described, several of which exist in airway smooth muscle (Webb et a l, 1997). 
Stimulation of PKC by phorbol esters generally produces slowly developing, sustained 
contraction of airway smooth muscle, in some cases without raising [Ca2+]i (Dale &
Obianime, 1987; Park & Rasmussen, 1986a; Obianime et al., 1988).
It is thought that DAG increases the sensitivity of PKC to Ca2+ such that the kinase 
becomes active at [Ca2+]i which are normally below the threshold required to induce
contraction (Nishizuka, 1984; Nishizuka, 1986; Collins et al., 1992). The precise 
mechanism by which PKC evokes contraction remain elusive, but it is proposed that 
they increase the sensitivity of the contractile elements to Ca2+, either by 
phosphorylating MLCK directly (Nishikawa et a l, 1983; Singer & Baker, 1987; 
Fulginiti et a l, 1993) or by phosphorylating an intermediate kinase such as mitogen 
activated protein (MAP) kinase (see Singer, 1996).
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1.3.3.3 Tyrosine kinase pathways
The role of tyrosine kinase-linked signal transduction pathways has been examined 
largely in the context of long-term responses such as cell proliferation (see section 1.5). 
Given that tyrosine kinase activity is frequently associated with elevations in [Ca2+]i, it
has recently been suggested that this pathway may play an important role in regulating 
smooth muscle contraction (see Hollenberg, 1994; Di Salvo et al., 1996). Growth 
factors such as epidermal growth factor and platelet-derived growth factor, which 
activate membrane receptor tyrosine kinase, have been shown to evoke contraction of 
various smooth muscle preparations, including airway smooth muscle (Nasuhara et al., 
1996). Furthermore, contractions evoked by angiotensin II and thrombin in gastric 
smooth muscle can be blocked by tyrosine kinase inhibitors (Yang et al., 1993; 
Hollenberg et al., 1993), suggesting that these G protein-coupled receptor agonists may 
act via tyrosine kinase activation rather than the generally accepted IP3/DAG pathway
(Griendling & Alexander, 1990). It should be apparent, however, that considerably 
more work must be conducted in this area before tyrosine kinase activation can be 
accepted as being an important component of the signal transduction pathways leading 
to smooth muscle contraction.
1.3.3.4 Mediator release
A number of agents induce contraction or relaxation of airway smooth muscle via the 
secondary release of mediators such as histamine, cyclo-oxygenase metabolites and 
leukotrienes (see section 1.4.3).
1.3.3.5 Phospholipase D activation
It has recently been suggested that activation of phospholipase D (PLD) may be a novel 
signal transduction pathway leading to contraction of airway smooth muscle. This 
enzyme hydrolyses phosphatidylcholine, forming phosphatidic acid (PA), which is 
believed to lead to the formation of DAG (Exton, 1990). A number of agonists, both G 
protein-coupled receptor agonists and tyrosine kinase receptor agonists, have been 
shown to stimulate PLD (Liscovitch et al., 1993; Plevin et al., 1994), however the 
mode of coupling between agonist receptors and PLD activation is poorly understood. 
It is generally accepted that PKC plays a pivotal role both as a mediator and as a 
modulator of PLD activity (for review see Exton, 1990; Kiss, 1990), although the 
precise pathways remain to be elucidated.
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Figure 1.3 Mechanisms involved in excitation-contraction  
coupling in airway smooth muscle
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Figure 1.3
Diagrammatic summary of the sequence of events thought to be involved in contraction 
of airway smooth muscle. The cell membrane contains the sodium-calcium exchange 
system, the sodium pump (Na-K ATPase), the Ca2+ efflux pump (Ca-Mg ATPase), 
PKC (C-kinase) and a receptor complex coupled to the phosphatidylinositol (PI) 
system. Agonist-stimulation of the receptor activates, via G protein linkage, 
phospholipase C, resulting in the formation of IP3 and DAG. The former evokes 
release of Ca2+ from the sarcoplasmic reticulum (SR), which then activates the myosin 
light chain kinase pathway.
Adapted from Leff, 1988.
1.3.4 SIGNAL TRANSDUCTION PATHWAYS INVOLVED IN MEDIATING40 
RELAXATION OF AIRWAY SMOOTH MUSCLE
The predominant second messengers involved in agonist-induced relaxation of airway 
smooth muscle are the cyclic nucleotides adenosine 3', 5'-cyclic monophosphate 
(cAMP) and guanosine 3', 5'-cyclic monophosphate (cGMP), which are formed by the 
activities of adenylyl cyclase and guanylyl cyclase, respectively.
1.3.4.1 Adenosine 3', 5'-cyclic monophosphate (cAMP) generation
Elevation of intracellular cAMP levels is closely correlated with relaxation of airway 
smooth muscle (Niewoehner et al., 1979), indeed, exogenously administered cell- 
permeable analogues of cAMP induce bronchial smooth muscle relaxation (Triner et 
al., 1977). Intracellular cAMP levels may be elevated by a number of mechanisms:
(a)An increase in the activity of adenylyl cyclase following stimulation of membrane 
receptors (for example, p-adrenoceptors, Katsuki & Murad, 1977; Lau & Lum, 1983; 
Rinard et al., 1983) linked to G proteins of the Gs class.
(b)Direct activation of adenylyl cyclase via a receptor-independent mechanism, for 
example by forskolin (Seamon et al., 1981; Insel et al., 1982)
(c)Inhibition of phosphodiesterases (PDEs), which are responsible for the rapid 
hydrolysis of cAMP (Cortijo et al., 1993).
1.3.4.2 Guanosine 3', 5'-cycIic monophosphate (cGMP) generation
Guanylyl cyclase exists in two forms, a soluble form (GCs) found in the cytosol and a 
particulate form (GCm) located in the plasma membrane. GCs is activated by nitric 
oxide (NO) and NO donors (Gruetter et al., 1989; Ignarro et al., 1981; Feelisch & 
Novak, 1987), whereas GCm is a plasma membrane receptor for the natriuretic peptides 
and related hormones (Ishii & Murad, 1989; Wong & Garbers, 1992). Like cAMP, 
cGMP is inactivated by phosphodiesterases (Torphy & Undem, 1991).
1.3.4.3 Mechanisms underlying cyclic nucleotide-mediated relaxation
Agents which elevate cAMP, such as p2 adrenoceptor agonists and phosphodiesterase
inhibitors, are the most commonly used bronchodilators in the treatment of asthma. 
Despite this, the signalling pathways involved in the mediation of cyclic nucleotide 
responses are still unclear. It was originally believed that cAMP produced relaxation by 
stimulating cyclic AMP-dependent protein kinase, which then phosphorylated MLCK 
and subsequently inhibited the binding of calmodulin (Conti & Adelstein, 1981). It is 
now proposed that both cAMP and cGMP may induce smooth muscle relaxation via 
stimulation of cyclic GMP-dependent protein kinase (PKG, Francis et a l, 1988; 
Lincoln et al., 1990).
Given that contraction of smooth muscle is associated with an increase in [Ca2+]i, it^* 
was proposed that PKG evoked a lowering of [Ca2+]i to induce relaxation. This may 
occur through a number of mechanisms:
1.3.4.3.1 Sequestration of intracellular Ca2+
Early studies showed that cGMP could activate Ca2+ pumps in vascular smooth muscle, 
leading to a fall in [Ca2+]i (Lincoln et al., 1988; Furakawa and Nakamura, 1984; Vrolix
et al., 1988). It was subsequently found that PKG phosphorylated the Ca2+ uptake 
mechanism which exists in the sarcoplasmic reticulum of smooth muscle (Huggins et 
al., 1989; Cornwell et a l, 1991; Karczewski et al., 1992). This mechanism could 
therefore attenuate the contractions evoked either by entry of extracellular Ca2+ 
(through VOC) or by mobilization of intracellular Ca2+ (via IP3 generation).
1.3.4.3.2 Activation of Ca2+-activated K+ channels
Large-conductance, calcium-activated potassium (BK) channels are found in virtually 
every type of smooth muscle (Nelson, 1993; Nelson & Quayle, 1995). In vascular 
smooth muscle, cGMP increases the activity of these channels (Tare et al., 1990; Chen 
& Rembold, 1992) leading to membrane hyperpolarization and hence, relaxation. PKG 
is known to increase the opening probability of BK channels (Robertson et a l, 1993; 
Archer et al., 1994), however, the role of these channels in PKG-mediated relaxation 
remains controversial, since many studies indicate that PKG can induce relaxation via 
mechanisms independent of BK channel opening (Hamaguchi et a l, 1991; Bolotina et 
al., 1994).
1.3.4.3.3 Inhibition of PLC and IP^
Several studies suggest that cGMP and PKG inhibit agonist-evoked PLC stimulation, 
leading to a fall in IP3 production (Rapoport, 1986; Hirata et al., 1990; Ruth et al.,
1993). Alternatively, more recent studies indicate that PKG may inhibit the ability of 
IP3 to release Ca2+ from intracellular stores (Koga et al., 1994; Komalavilas & Lincoln,
1994).
Thus, it would appear that cAMP and cGMP, acting via PKG, may regulate, 
simultaneously, various mechanisms involved in the reduction of [Ca2+]i within the
smooth muscle cell.
While it is now believed that both cAMP and cGMP act via PKG, it has also been 
suggested that high concentrations of cGMP may be capable of stimulating, and acting 
via, PKA (Francis et al., 1988; Cornwell et al., 1994), indicating that some "cross-over" 
exists between the cyclic nucleotides.
1.3.5 Overview
Given that elevation of cyclic nucleotide levels is associated with decreases in [Ca2+]i
and smooth muscle relaxation, it is unsurprising that many contractile agents such as 
0C2-adrenergic agonists, platelet-activating factor and various prostaglandins are
associated with producing reductions in cyclic nucleotide levels, particularly cAMP. 
Indeed, in airway smooth muscle, activation of muscarinic M2 receptors can produce
contraction via inhibition of adenylyl cyclase (Candell et al., 1990). Stimulation of PLC 
remains the predominant mechanism by which agents produce contraction of airway 
smooth muscle however, with inhibition of adenylyl cyclase thought to be responsible 
for modulation of relaxant activity rather than initiation of contraction per se (see Eglen 
et al., 1994).
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While it is generally accepted that the initiation of smooth muscle contraction is due to 
the Ca2+-calmodulin-dependent phosphorylation of myosin light chains (as outlined 
above), there is still considerable debate regarding the mechanisms involved in the 
sustained phase of contraction. This is largely based on the finding that myosin 
phosphorylation may actually decline while developed contractions are maintained 
(Gerthoffer & Murphy, 1982; Kamm & Stull, 1985b). Two hypotheses, although not 
mutually exclusive, have been proposed to account for this; firstly the "latch-bridge" 
model and secondly, that PKC regulates the sustained phase of contraction.
1.3.6.1 The Latch-bridge theory
This model proposes that after the initiation of contraction, the rapidly cycling actin- 
myosin cross bridges are replaced by dephosphorylated myosin cross bridges which 
cycle slowly or not at all (Aksoy et al., 1982; Hai & Murphy, 1989). This model 
accounts for the fact that during maintenance of contraction, energy consumption is 
much lower than during tension development. The maintenance of these latchbridges is 
Ca2+ dependent, suggesting that during the tonic phase of contraction, when [Ca2+]j is
low, there must be some mechanism in operation which increases the sensitivity of the 
contractile apparatus to Ca2+. Precisely how this is achieved is unknown although a 
possible role for PKC has been proposed.
1.3.6.2 PKC activation
One of the strongest pieces of evidence in support of PKC being involved in 
maintaining tone is the finding that, during the sustained phase of agonist-induced and 
phorbol ester (which stimulate PKC)-induced contractions, the changes in patterns of 
protein phosphorylation are very similar (Park & Rasmussen, 1986b; Takuwa et a l,
1988). PKC is believed to increase the sensitivity to Ca2+ by phosphorylating specific 
residues on certain contractile proteins (Rasmussen & Barret, 1984; Rodger, 1986).
Thus there appear to be two separate, although in all likelihood interdependent, 
pathways which control contraction of airway smooth muscle. The first, a 
calmodulin/myosin light chain kinase pathway is thought to be responsible for the 
initial rapid phase of contraction. The second pathway, via PKC-mediated 
phosphorylations is postulated to adapt the cell to accommodate sustained muscle 
contraction with a minimum energy expenditure.
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1.4.1 NEURAL CONTROL
As early as the 17th century it was recognised that the airways are innervated 
(Bartholinus, 1663). Physiological experiments subsequently demonstrated that 
stimulation of the vagus nerve caused bronchoconstriction in dogs, an effect which 
could be blocked by the cholinergic receptor antagonist, atropine (Roy & Brown, 
1885). Although the dominant role of airway innervation is believed to be direct control 
of airway smooth muscle contractility, the autonomic nervous system controls many 
other aspects of airway function. Indeed, the innervation of submucusal secretory cells, 
the pulmonary vascular bed, the epithelium, mast cells and other inflammatory cells 
may influence airway smooth muscle tone indirectly. Human airways are innervated by 
three distinct neural pathways; two of these pathways, the cholinergic and the 
adrenergic have been established for some time (Larsell & Dow, 1933; Gaylor, 1934). 
The third, termed nonadrenergic, noncholinergic (NANC) is more poorly understood 
due to lack of knowledge of the neurotransmitter(s) involved (Richardson, 1979; 
Richardson, 1981).
1.4.1.1 Cholinergic Innervation
The parasympathetic nervous system is the dominant neural control mechanisms in all 
mammals, including humans. In many animal species, section of the vagus nerve or 
administration of atropine causes a marked bronchodilation, indicating that cholinergic 
innervation contributes significantly to resting bronchomotor tone. While it is more 
difficult to study cholinergic nerve function in human airways, the bronchodilator 
response to atropine and other anticholinergic drugs in normal subjects does suggest a 
degree of resting vagal tone in human airways (Vincent et al., 1970; de Troyer et al., 
1979). In addition, inhalation of the cholinesterase inhibitor edrophonium causes 
bronchoconstriction in normal subjects, confirming tonic release of acetylcholine in the 
airways (Quigley etal., 1985).
Cholinergic efferent nerves arise in the vagal nuclei of the brainstem and pass down the 
vagus nerve to synapse in ganglia situated in the airway wall. Short, postganglionic 
fibres proceed from the ganglia to airway smooth muscle cells where they release the 
excitatory neurotransmitter acetylcholine from axon varicosities. Histochemical 
staining for acetylcholinesterase indicates that cholinergic nerve fibres innervate human 
airway smooth muscle from the trachea to the terminal bronchioles (Partanen et al., 
1982; Sheppard et al., 1983). As is the case in many other species, the density of 
cholinergic innervation is believed to decrease in smaller airways, so that there are very 
few cholinergic fibres in terminal bronchioles and none in the alveolar walls. In 
contrast, a study by Daniel and co-workers in human airways (1986a) found that the 
smooth muscle of smaller bronchi (4th-7th order) was ten times more densely
innervated than trachealis muscle. Results from physiological and pharmacological 
studies, however, would suggest that cholinergic innervation does indeed decline in 
peripheral airways. For example, vagal stimulation in dogs causes marked 
bronchospasm in intermediate sized bronchi (l-5mm resting diameter), with relatively 
little effect in bronchioles with a resting diameter less than 0.5mm (Nadel et al., 1971). 
In humans, the bronchodilator effects of anticholinergic drugs are greater in large 
compared to small airways (Ingram et a l, 1977; Hensley et a l, 1977), while in isolated 
human airways, the cholinergic effects are less pronounced in bronchioles than bronchi 
(Palmer et a l, 1986). It is possible, therefore, that cholinergic innervation increases 
descending from the trachea to the intermediate bronchi and then decreases from the 
bronchi to the bronchioles. Alternatively, the apparent disparity between the study by 
Daniel et al and other workers in this field may reflect differences in methodology, 
since Daniel and co-workers assumed that the nerves being studied were cholinergic on 
the basis of the varicosities containing small agranular vesicles. Unfortunately there is 
no direct method to show that these vesicles actually contain acetylcholine and some 
may contain other mediators such as neuropeptides.
1.4.1.1.1 Cholinergic Receptors
Acetylcholine released from preganglionic vagal fibres activates nicotinic cholinergic 
receptors in airway ganglia, whereas postganglionic neurotransmission is mediated via 
muscarine-sensitive cholinergic receptors. At least four subtypes of muscarinic 
acetylcholine receptors have now been cloned which vary in their tissue locations and 
pharmacological effect (for review, see Eglen et a l, 1994). Mi-receptors, which are
excitatory, are present in airway parasympathetic ganglia of many animal species. Their 
function remains uncertain, but they may be involved in filtering the signal passing 
through the ganglia. Similar receptors may occur in humans since the Mi receptor
antagonist, pirenzepine, inhibits vagally-mediated bronchoconstriction at doses that do 
not inhibit the direct effect of cholinergic agonists on airway smooth muscle (Lammers 
et a l,  1989). The cholinergic receptors which mediate bronchoconstriction are located 
post-junctionally on airway smooth cells and are thought to be of the M3 subtype (see
Eglen et a l, 1994). Activation of these receptors evokes, via G proteins of the Gq class, 
stimulation of phosphoinositide turnover and generation of IP3 and DAG (Caulfield,
1993). As is the case with many other types of smooth muscle, airway smooth muscle 
appears to co-express both M2 and M3 receptor subtypes postjunctionally (Chilvers et 
a l, 1990; Challiss et a l, 1993; Thomas et a l, 1993). Activation of M2 receptors may
also lead to contraction, via inhibition of adenylyl cyclase (Candell et a l, 1990), 
although the role of M2 receptors appears to be modulation of p-adrenoceptor-mediated 
relaxation. Consistent with this hypothesis is the finding that M2 receptor antagonists 
augment the relaxant effect of the p-adrenoceptor agonist isoprenaline in isolated 
airways from guinea-pig (Watson & Eglen, 1994), dog (Fernandes et a l, 1992) and 
rabbit (Schramm et a l, 1995). Furthermore, in the absence of prevailing relaxant tone,
Af\M2 receptor activation appears to have little or no effect (Thomas et al., 1993). The
physiological implications of these findings remain unclear, but it would appear that the 
M3 receptors are the dominant subtype in terms of vagally-induced 
bronchoconstriction, whereas the M2 receptors may become more important under 
conditions of high sympathetic activity.
In addition to excitatory M2 receptors located postjunctionally, there are also 
prejunctional M2 receptors which act to inhibit release of acetylcholine from the nerve 
endings. These inhibitory ‘autoreceptors’ appear to be responsible for feed-back 
inhibition and may serve to limit vagal bronchoconstriction (Figure 1). Such receptors 
have been demonstrated in human bronchi in vitro (Minette & Barnes, 1988) and in 
vivo (Ind et al., 1989).
1.4.1.1.2 Cholinergic Innervation in Airwav Disease
Anticholinergic drugs have been shown to have significant therapeutic benefit in the 
treatment of acute severe asthma (Ward et al., 1981) and nocturnal asthma (Coe & 
Barnes, 1986). There is, however, no direct evidence that cholinergic mechanisms 
contribute to the airway hyperresponsiveness which is characteristic of asthma. 
Cholinergic mechanisms may play a role, however, in chronic obstructive pulmonary 
disease (COPD) and cystic fibrosis, indeed, anticholinergics are the most effective 
bronchodilators in the treatment of COPD (Crompton, 1968; Klock et al., 1975).
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Figure 1.4
Acetylcholine (ACh) released from preganglionic nerves binds to and stimulates 
nicotinic cholinergic receptors (DN) in the parasympathetic ganglion. ACh released 
from postganglionic nerves evokes contraction of airway smooth muscle 
predominantly via activation of muscarinic M3 receptors but also via M2 receptors.
M3 receptors are coupled by G-proteins of the Gq class to phospholipase C and hence 
to production of inositol trisphosphate (IP3) and diacylglycerol (DAG). Stimulation of 
M2 receptors inhibits, via G-proteins of the Gi class, adenylate cyclase, leading to a fall 
in cellular cyclic AMP (cAMP) levels. Activation of prejunctional M2 "autoreceptors" 
inhibits the release of ACh from the postganglionic nerve. (See text for more detail).
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1.4.1.2 Adrenergic Innervation
Catecholamine-containing nerve endings have been found in human airways although, 
in contrast to the dense parasympathetic nerve supply, sympathetic innervation is 
generally sparse (El-Bermani, 1978; Partanen et al., 1982). Adrenergic nerve fibres 
have been found in close association with submucosal glands (Partanen et a l,  1982) 
and bronchial arteries (Doidge & Satchell, 1982), but very few have been shown to 
innervate airway smooth muscle (Richardson & Beland, 1976; Sheppard et al., 1983). 
Stimulation of sympathetic nerves in guinea pigs evokes a marked bronchodilation 
(Ainsworth et a l, 1981), despite there being no direct sympathetic innervation of 
airway smooth muscle in this species (O’Donnell et al., 1978). This suggests that 
adrenergic nerves may influence bronchomotor tone indirectly. In dogs, stimulation of 
the sympathetic nerves also causes bronchodilation, but the magnitude of this effect is 
dependent on the degree of pre-existing vagal tone (Cabezas et al., 1971). Furthermore, 
the demonstration of adrenergic nerves within parasympathetic ganglia (Richardson & 
Ferguson, 1979) indicates that the sympathetic nerves may play a role in modulating 
cholinergic neurotransmission at the ganglionic level.
1.4.1.2.1 Adrenoceptor subtvpes
Noradrenaline released from sympathetic nerve endings activates a  and p-adrenoceptors 
on target cells in the airways (Barnes, 1984a). The sympathetically-induced 
bronchodilation mentioned above in guinea pigs and dogs can be abolished by p- 
adrenoceptor antagonists (Doidge & Satchell, 1982; Cabezas et al., 1971), indicating 
that activation of p-receptors leads to relaxation of airway smooth muscle, a- 
adrenoceptor-mediated contraction of airway smooth muscle has been demonstrated in 
a number of species including man (Simonsson et al., 1972; Kneussl & Richardson,
1978), although only under certain experimental conditions. For example, a- 
adrenoceptor-mediated contraction can only be shown in canine airways if there is a 
high degree of p-adrenoceptor blockade (Leff et al., 1986), or after pretreatment with 
histamine or serotonin (Kneussl & Richardson, 1978; Barnes et al., 1983). In humans, 
no a-adrenergic-induced contraction is found in normal airways, however, in certain 
disease states (chronic bronchitis, bronchopneumonia or after exposure to endotoxin), 
a-adrenoceptor contractile responses may be exhibited (Simonsson et al., 1972; 
Kneussl & Richardson, 1978). Since there appears to be no direct sympathetic 
innervation of human airway smooth muscle, it is likely that a-adrenoceptor activation 
induces bronchoconstriction indirectly. Interestingly, a-adrenoceptor agonists have 
been shown to facilitate histamine release from human lung fragments in vitro, 
suggesting the presence of a-receptors on lung mast cells (Kaliner et al., 1972), 
although this remains to be confirmed.
1.4.1.2.2 Adrenergic Innervation In Disease States
(i-adrenoceptor antagonists have no effect on resting bronchomotor in normal humans, 
indicating an absence of any tonic sympathetic bronchodilator tone (Zaid & Beall, 
1966; Tattersfield et a l, 1973). In contrast, asthmatic subjects develop 
bronchoconstriction after administration of p-blockers, suggesting an increased 
adrenergic drive to the airways in asthma (McNeill, 1964; McNeill & Ingram, 1966). 
The finding that a-adrenoceptor responses may be “uncovered” by inflammatory 
mediators in vitro supports the idea that there may be enhanced a-adrenergic activity in 
asthma (Reed, 1974; Szentivanyi, 1968). For example, the density of a-adrenoceptors is 
greater in lungs from patients with airway obstruction than from normal subjects 
(Barnes et al., 1980a). In addition, asthmatic subjects bronchoconstrict with inhaled cx- 
adrenoceptor agonists (Snashall et al., 1978), even in the absence of p-blockade (Black 
et al., 1982), whereas normal subjects are unaffected. In general, however, current 
research suggests that sympathetic mechanisms are involved to a limited degree in 
controlling airway tone in health and disease states.
1.4.1.3 Nonadrenergic-noncholinergic Innervation
In addition to the classical sympathetic and parasympathetic innervation of the airways, 
neural mechanisms that are neither adrenergic nor cholinergic have been described 
(Richardson, 1981; Barnes, 1984b). NANC mechanisms are responsible for several 
different responses within the airways, including bronchoconstriction, bronchodilation 
and mucus secretion. It is generally believed that more than one neurotransmitter may 
be involved.
1.4.1.3.1 Inhibitory NANC nerves
Relaxation of airway smooth muscle by inhibitory NANC nerves has been 
demonstrated in vitro in a number of species, including humans (Richardson & Beland, 
1976; Taylor et al., 1984). In human airway smooth muscle, this nerve system is the 
only direct neural bronchodilator pathway, since there is no functional sympathetic 
innervation. NANC inhibitory nerves have also been demonstrated in vivo in feline 
airways by electrical stimulation of the vagus nerve after cholinergic and adrenergic 
blockade (Diamond & O'Donnell, 1980). Determination of the neurotransmitter(s) 
responsible for inhibitory NANC responses has proved difficult, although evidence 
favours neuropeptides, particularly vasoactive intestinal peptide (VIP).
This peptide produces a prolonged and potent relaxation of airway smooth muscle in 
vitro which is unaffected by adrenergic or cholinergic blockers (Ito & Takeda, 1982; 
Cameron et al., 1983; Altiere & Diamond, 1984). Nerve terminals staining for VIP 
(Laitenen et al., 1985) and VIP receptors (Palmer et al., 1986) are present in large and 
intermediate bronchi but not bronchioles, which is consistent with the finding that 
NANC bronchodilation is predominantly seen in large, but not peripheral airways 
(Matsumoto et al., 1985). Activation of VIP receptors on airway smooth muscle
stimulates adenylyl cyclase and hence increases cellular cAMP levels (Lazarus et al., ^  
1986), indicating that VIP could have a direct effect on airway smooth muscle. VIP 
nerves are often distributed with cholinergic nerves and VIP may coexist in the same 
nerve terminals as acetylcholine, suggesting that VIP may be cotransmitted with ACh 
(Laitenen etal., 1985).
In addition to VIP, there is some evidence to suggest that nitric oxide mediates a 
component of the inhibitory NANC response in porcine (Kannan & Johnson, 1992), 
guinea pig (Li & Rand, 1991) and human airways (Belvisi et al., 1992; Bai & Bramley,
1993).
1.4.1.3.2 Excitatory NANC nerves
Electrical stimulation of guinea pig bronchi and trachea in vitro produces a contractile 
component which is not blocked by atropine (Anderson & Grundstrom, 1983). A 
similar NANC response has been reported in human isolated airways, but is 
inconsistent and non-reproducible (Lundberg et al., 1983). As with the inhibitory 
NANC response, the neurotransmitter involved in the excitatory response is thought to 
be a neuropeptide. Substance P (SP) remains a possible candidate since the in vitro 
excitatory NANC responses can be mimicked by SP and inhibited by SP antagonists.
SP contracts human airway smooth muscle in vitro (Lundberg et al., 1983) and 
produces bronchoconstriction in animals in vivo (Andersson & Persson, 1977) but has 
little effect on human airways in vivo (Fuller et al., 1986). Autoradiographic studies in 
guinea pig and human lungs indicate that SP-receptors are found in high density in 
airway smooth muscle from the trachea to the peripheral bronchioles (Carstairs & 
Barnes, 1986), however, the role of SP as the excitatory NANC neurotransmitter 
remains to be confirmed.
1.4.1.3.3 NANC Responses In Disease States
It remains to be established whether abnormalities in NANC neurotransmission 
contribute to airway diseases. In a cat model of asthma there is a reduced inhibitory 
NANC response (Miura et al., 1990) and post-mortem examination of asthmatic lungs 
revealed an apparent lack of VIP innervation (Ollerenshaw et al., 1989). While this 
would suggests that impaired inhibitory NANC responses may contribute to asthma, 
there is no evidence of a reduced NANC bronchodilator effect in patients with mild 
asthma (Lammers et al., 1989).
Despite considerable interest in the possibility that NANC abnormalities contribute to 
airway disease, there remains a lack of understanding regarding the role of 
neuropeptides in the control of airway smooth muscle tone. This is probably due to the 
large number of postulated neurotransmitters and the lack of specific agonists and 
antagonists which can be given safely to man.
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Many blood-borne mediators have the potential to influence airway smooth muscle 
tone, the most notable being catecholamines, natriuretic peptides and “classical” 
hormones.
1.4.2.1 Catecholamines
Human airway smooth muscle is potently relaxed by (3-adrenoceptor agonists in vitro 
and in vivo (Davis et al., 1980; Davis et al., 1982; Goldie et al., 1986; van Koppen et 
al., 1989). The apparent absence of direct functional adrenergic innervation (see section 
1.4.1.2) suggests that circulating catecholamines might be important in regulating 
airway tone, indeed, adrenaline has been used in the treatment of asthma since 1900. 
Noradrenaline in the plasma is derived almost entirely from overspill of sympathetic 
nerve activity (Brown et al., 1981), whereas adrenaline is secreted by the adrenal 
medulla and functions as a circulating hormone (Cryer, 1980). Infusion of 
noradrenaline within its physiological concentration range has no significant effect on 
airway function in normal or asthmatic subjects (Berkin et al., 1985; Larssen et al., 
1986). In contrast, adrenaline is a potent bronchodilator in normal (Warren & Dalton, 
1983) and asthmatic subjects (Barnes et al., 1982a) and protects against histamine- 
induced bronchoconstriction in non-asthmatics (Warren et al., 1984).
The lack of a bronchoconstrictor effect of (3-adrenoceptor antagonists in normal 
subjects suggests that basal concentrations of circulating adrenaline are probably not 
important in the regulation of resting bronchomotor tone (Tattersfield et al., 1973). In 
some asthmatics, however, (3-blockers evoke a bronchoconstriction (McNeil, 1964; 
Richardson & Sterling, 1969) and may increase bronchial hyperresponsiveness 
(Townley et al., 1976), indicating that circulating adrenaline may reduce airway tone in 
asthma. Strenuous exercise induces an increase in adrenaline levels to concentrations 
(Berkin et al., 1988) that can cause bronchodilation in normal and asthmatic subjects 
(Barnes et al., 1980b; Berkin et al., 1985; Warren & Dalton, 1983), however, basal 
catecholamine levels are no higher in asthmatics than in normal subjects, nor is there 
any relationship between plasma catecholamine levels and the severity of 
bronchoconstriction (Barnes et al., 1982b). Even during acute asthmatic attacks, there 
is no elevation in plasma adrenaline levels (Ind et al., 1985), indicating that normal 
circulating levels of adrenaline may be sufficient to protect asthmatics against 
bronchoconstrictor influences.
It is not fully understood how adrenaline can exert this protective effect at the low 
concentrations found in plasma, since these concentrations of adrenaline exert little 
effect on airway smooth muscle directly. It is possible that adrenaline may influence 
airway mast cells, since it has an inhibitory effect on IgE-induced histamine release
from human lung fragments (Butchers et al., 1980). Alternatively, anticholinergic drugs 
have been shown to prevent and reverse (3-blocker-induced bronchoconstriction (Grieco
52& Pierson, 1971), suggesting that adrenaline may exert an inhibitory effect on 
cholinergic ganglia.
1.4.2.2 Natriuretic Peptides
The natriuretic peptides; atrial natriuretic peptide (ANP), brain natriuretic peptide 
(BNP), C-type natriuretic peptide (CNP) and urodilatin are produced primarily in the 
heart but are also released from other tissues such as the central nervous system and the 
lungs (Gutkowska & Nemer, 1989). Autoradiographic studies indicate that ANP 
receptors are present in the lungs, notably on airway smooth muscle cells (Van 
Schroeder et a l, 1985). ANP relaxes isolated airways from a number of species, 
including man, and provides varying degrees of protection against subsequent agonist 
challenge (O’Donnell et al., 1985; Angus et al., 1994; Nally et al., 1994). Intravenous 
infusion of ANP produces a significant bronchodilator response in normal and 
asthmatic subjects (Hulks et al., 1989; Hulks et al., 1990) and attenuates the 
bronchoconstrictor response to inhaled histamine (Hulks et al., 1991) and to fog 
challenge (McAlpine et al., 1992). The relaxant effects of ANP appear to be mediated 
by stimulation of particulate guanylyl cyclase and subsequent generation of cGMP 
(Ishii & Murad, 1989), although a more recent study indicated that the opening of 
membrane-bound potassium channels may also be involved (Nally et al., 1995). In 
addition to a direct effect on airway smooth muscle, there is evidence that ANP 
performs a neuromodulatory role on the autonomic nervous system, which may alter 
airway tone indirectly. For example, Robichaud and colleagues (1993) found that ANP 
enhanced cholinergic nerve transmission and attenuated sympathetic nerve transmission 
in rabbit airways, which, in contrast to its relaxatory action on airway smooth muscle, 
would be expected to increase bronchomotor tone.
While it appears unlikely that physiological concentrations of circulating ANP 
contribute to basal bronchomotor tone in normal humans (Hulks et al., 1990), it is 
possible that ANP produced and released within the lungs may exert a local autocrine 
or paracrine effect on the airways.
1.4.2.3 “Classical Hormones,,
1.4.2.3.1 Cortisol
Corticosteroids are widely used in the treatment of asthma and administration of 
inhaled or oral corticosteroids results in a significant reversal of airflow obstruction and 
improvement in lung function in this disease. The mechanisms by which corticosteroids 
act are incompletely understood, but their therapeutic success in asthma is ascribed to 
their anti-inflammatory actions. In normal humans, however, pharmacological doses of 
intravenous cortisol have no short term effects on airway calibre (Ramsdell et al., 
1983), indicating that endogenous cortisol is unlikely to have an important effect on 
airway tone under normal conditions. In asthmatics, the role of physiological 
concentrations of circulating cortisol is unclear. Some groups have postulated that
reduced plasma cortisol may contribute to nocturnal asthma since the lowest point on ‘ 
its circadian cycle occurs four hours before maximal bronchoconstriction (Reinberg et 
al., 1963; Soutar et a l, 1975). Infusion of hydrocortisone to eliminate the fall in plasma 
cortisone at night however, does not prevent the nocturnal airway obstruction (Soutar et 
a l, 1975), indicating that the circulating cortisol is not the only factor in determining 
nocturnal asthma.
1.4.2.3.2 Thyroid Hormones
The relationship between asthma and thyroid disease provides indirect evidence for a 
role for thyroid hormones in maintaining airway function. Asthmatics who develop 
hyperthyroidism frequently undergo a deterioration in clinical condition, but 
subsequently improve after treatment of the thyrotoxicosis (Elliot, 1929; Ayers & 
Clark, 1981; Lipworth et a l, 1988). Conversely, the occurrence of hypothyroidism in 
asthma may be associated with an improvement in the clinical management of asthma 
which relapses following subsequent thyroxine replacement (Bush et al., 1977).
It is unclear how thyroid hormones may influence airway smooth muscle tone and 
responsiveness, although a number of mechanisms have been postulated. Firstly, p 
adrenergic airway responsiveness has been reported to be inversely related to thyroxine 
levels both in vitro in guinea pig trachea (Taylor, 1983) and in vivo in non-asthmatic 
subjects (Harrison & Tattersfield, 1984). Following treatment of hyperthyroidism, 
airway p responses return to normal levels (Harrison & Tattersfield, 1984). It is 
unlikely that alterations in p adrenergic activity are due to changes in circulating 
catecholamine levels (Coulombe et al., 1976) or p adrenergic receptor numbers 
(Scarpace & Abrass, 1981), but it is possible that thyroxine acts at a postreceptor site 
within the smooth muscle. Alternatively, thyroxine may alter the metabolism of 
arachidonic acid since prostaglandin breakdown has been shown to be reduced in 
hyperthyroid rats (Hoult & Moore, 1978).
1.4.2.3.3 Sex Hormones
It has been postulated that progesterone may influence airway smooth muscle tone, 
either by potentiating the effect of catecholamines (Foster et al., 1983) or through its 
immunosuppressive properties. Progesterone levels and airway responsiveness do not 
show a clear relationship during either pregnancy or the menstrual cycle, although 
changes in the levels of other hormones may obscure an effect of progesterone on the 
airways (Juniper et al., 1978; Juniper et al., 1989). It is of interest that intramuscular 
progesterone has a beneficial effect in some women with severe premenstrual asthma 
(Beynon et al., 1988).
Oestrogen possesses both immunostimulatory and immunosuppressive properties and 
causes increased acetylcholine activity in animal lungs (Abdul-Karim et a l, 1970), 
which could result in an increase or decrease in airway responsiveness. A recent report 
suggested that oestrogen treatment may have steroid-sparing effects in postmenoposal
54asthmatics (Celedon et al., 1995) although, conversely, hormone replacement therapy 
has been associated with an increased risk of developing asthma (Troisi et al., 1995).
1.4.2.4 Summary
In conclusion, humoral factors appear to play a minor role in the physiological 
regulation of airway tone in normal individuals. Circulating adrenaline is the only 
hormone known to influence bronchomotor tone and it is only during strenuous 
exercise that concentrations are raised sufficiently to cause bronchodilation. Circulating 
hormones play a more important role in the regulation of airway tone in respiratory 
disease states such as asthma and possibly in other disorders such as congestive heart 
failure and thyroid diseases. For many hormones, however, little is known about their 
effects on airway tone or on other functions of the airways.
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It is now known that the epithelium is a metabolically active tissue system which, 
through release of various mediators, regulates and maintains a chemical homeostasis 
necessary for the functional integrity of the underlying airway smooth muscle. In 
addition to the epithelium, mediators may be released from a number of other cell types 
within the airways, notably the mast cells, macrophages, and eosinophils. Indeed, many 
factors are released by the airway smooth muscle cells themselves and act in an 
autocrine fashion to influence airway reactivity.
Mast cells and macrophages are widely distributed throughout the human respiratory 
tract and are found in large numbers in the walls of the alveoli and airways. Eosinophils 
are circulating cells which are normally found at relatively low concentrations within 
the airways. During an inflammatory reaction of the airways, however, eosinophils 
infiltrate the bronchial mucosa in great numbers and this rise in eosinophilia correlates 
closely to the severity of the reaction (Burrows et al., 1980; Honsinger et al., 1972). 
The array of different mediators secreted by these cells can stimulate or inhibit the 
surrounding airway smooth muscle cells, either directly or indirectly. Some of the more 
important mediators are listed below.
1.4.3.1 Eicosanoids
The release of arachidonic acid (AA) from cell membrane phospholipids, through the 
action of phospholipase A2, leads to the production of a wide variety of mediators
which may be relevant to airway smooth muscle function (see figure 1.5). The 
metabolism of AA by the enzyme cyclooxygenase produces the prostaglandins (PGD2, 
PGE2 and PGF20O, prostacyclin (PGI2) and the thromboxanes (TxA2 and TXB2), while 
the metabolism of AA by 5-lipooxygenase produces the leukotrienes (LTB4, LTC4, 
LTD4 and LTE4). These metabolites, collectively termed eicosanoids, appear to be 
synthesised de novo on demand, rather than being preformed and stored in resting cells. 
Experimental data generally shows that the prostaglandins PGD2 and PGF201, the
thromboxanes and the leukotrienes are all contractile agents for airway smooth muscle 
(Sweetman & Collier, 1968; Gardiner & Collier, 1980; Dahlen et al., 1980; Jones et al., 
1982), while PGE2 and PGI2 are both relaxatory (Sheard, 1968; Hutas et al., 1981).
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Figure 1.5
An overview of some of the eicosanoids produced as a consequence of 
arachidonic acid metabolism. The cyclooxygenase pathway leads to the 
production of the prostaglandins, the thromboxanes and prostacyclin. 
The 5-lipooxygenase pathway leads to formation of the leukotrienes, 
whereas the 15-lipoxygenase pathway produces the lipoxins
1.4.3.1.1 Prostanoids
Both PGD2 and PGF20C cause bronchoconstriction in human subjects, either through a
direct effect on airway smooth muscle receptors or indirectly through stimulation of 
cholinergic-nerves (Beasley et al., 1987). The activity profile of PGE2 and PGI2 is
varied, although in general they relax and inhibit the responsiveness of airway smooth 
muscle, possibly via inhibiting acetylcholine release from parasympathetic nerves 
(Walters et al., 1984). Interestingly, release of PGE2 and PGI2 may be responsible for
the tachyphylaxis (a decreased response to repeated stimulation) exhibited by histamine 
and acetylcholine in airway smooth muscle both in vitro (Anderson et al., 1977) and in 
vivo (Shore & Martin, 1985; Manning et al., 1987).
Inhibitors of prostanoid production, such as the cyclooxygenase inhibitor, 
indomethacin, relax basal tone in guinea pig isolated airways, indicating that locally 
produced prostanoids contribute to the maintenance of basal tone (Farmer et al., 1972). 
This finding may be unique to the guinea pig, however, since human airways produce 
prostanoids, yet do not relax in vitro when treated with cyclooxygenase inhibitors 
(Steel et al., 1979; Brink et al., 1980; Haye-Legrand et al., 1986). Indomethacin does 
not alter baseline lung function in healthy or asthmatic subjects and furthermore, does 
not alter airway responsiveness to histamine or methacholine (Smith, 1975; Ogilvy et 
al., 1981), therefore the involvement of cyclooxygenase metabolites in controlling 
airway function in humans is questionable.
1.4.3.1.2 Leukotrienes
The leukotrienes evoke a pronounced contraction in isolated airway smooth muscle 
(Dahlen et al., 1980) and a sustained bronchoconstriction in healthy (Holroyde et al., 
1981) and asthmatic patients (Griffin et al., 1983), being, on a molar basis, between 50 
and 1000 times as potent as histamine. As stated earlier, cyclooxygenase products 
appear to be responsible for generating basal tone in guinea-pig trachea (Farmer et al., 
1972). In human bronchi, however, spontaneous tone can be abolished by 
lipooxygenase inhibitors (Ito et al., 1985; Honda & Tomita, 1987; Watson et al., 1997), 
indicating that basal production of leukotrienes is at least partly responsible for the 
generation of spontaneous tone in human airways. Further investigation into the role of 
leukotrienes in airway function awaits the development of selective leukotriene 
receptor antagonists, although a “first-generation” LTD4 receptor antagonist
significantly improved lung function in asthmatic patients (Cloud et al., 1989). This 
clinical improvement took approximately 6 weeks to manifest, suggesting that in 
addition to their acute bronchoconstricting effect, the leukotrienes may have a chronic 
effect on the responsiveness of airway smooth muscle. This is supported by the findings 
that inhaled leukotrienes induce a prolonged hyperresponsiveness to the spasmogens 
methacholine and histamine in normal subjects (Kaye & Smith, 1990) and asthmatics 
(Arm et al., 1988), with the effects persisting for up to a week.
1.4.3.2 Histamine
Histamine is associated predominantly with degranulation of mast cells (Riley & West, 
1953), although it may also be released from basophils (Henderson, 1990) and nerve 
terminals (Ishikawa & Sperelakis, 1987). The direct effect of histamine on airway 
smooth muscle is dependent upon the prevailing pattern of histamine receptors which 
varies between species and even between different sites on the bronchial tree (Chakrin 
& Krell, 1980). In most species the predominance of "excitatory" Hi-receptors over 
"inhibitory" H2-receptors ensures that histamine induces bronchoconstriction, as is the 
case in man. In addition to its direct effects, histamine may also influence airway tone 
indirectly by stimulating or inhibiting cholinergic nerves (White et al., 1987), 
increasing epithelial permeability (Braude et al., 1984), or by modulating mucus 
production (Shelhamer et al., 1980).
1.4.3.3 Nitric oxide
The endothelial cells of the vasculature produce and release a substance which relaxes 
the vascular smooth muscle and acts as a functional antagonist for vasoconstrictor 
agents. This endothelial-derived relaxant factor (EDRF) was subsequently identified by 
Palmer et al. (1987a) and Ignarro et al. (1987) as being nitric oxide (NO). The enzyme 
responsible for the production of NO, nitric oxide synthase, is present in great 
abundance in the airway epithelium of a number of species, including humans (Shaul et 
al., 1994; Asano et al., 1994). Thus, NO may be the putative epithelial-derived relaxant 
factor (EpDRF), thought to be the equivalent of EDRF in blood vessels, although this 
remains unresolved.
Inhaled NO has a significant bronchodilator effect in guinea pigs in vivo (Dupuy et al., 
1992), indeed, NO donors have been used in the treatment of bronchospasm for more 
than a century. NO is also released from a number of inflammatory cells and there is 
compelling evidence that inhibitory NANC responses in guinea pig (Tucker et al, 
1990) and human (Belvisi et al., 1992; Bai & Bramley, 1993) airways are mediated, at 
least partly, by release of NO from nerve terminals (see section 1.4.1.3.1).
1.4.3.4 Endothelin
The endothelins (ET-1, ET-2 and ET-3) are a family of structurally related peptides 
originally isolated from vascular endothelial cells (Yanagisawa et al., 1988), but 
subsequently shown to be synthesised and released by a number of cell types within the 
airways, including the epithelium, macrophages and neuroendocrine cells (Mattoli et 
al., 1990; Ehrenreich et al., 1990; Seldeslagh & Lauweryns, 1993). The endothelins act 
as autocrine and paracrine factors in the airways, evoking responses such as increased 
epithelial secretion (Tamaoki et al., 1991), histamine release from mast cells (Uchida et 
al., 1992), contraction of airway smooth muscle (Advenier et al., 1990), modulation of 
cholinergic nerve transmission (Henry & Goldie, 1995; Henry et al., 1996) and
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(Glassberg et al., 1994).
Two distinct endothelin receptors, termed ETa and ETb , have been cloned and
characterised (Hosoda et a l, 1992; Arai et al., 1993) although many reports suggest the 
existence of further subtypes. The ETb receptor is the predominant subtype in human 
airway smooth muscle, with the ratio of ETa t0 ETb being approximately 15:85
(Goldie et a l, 1995). The contractile effect of the endothelins in airway smooth muscle 
is due, at least in humans, mainly to activation of ETb receptors (Hay et a l,  1993), 
whereas their mitogenic actions appear to be mediated by ETa receptors (Panettieri et
a l, 1996). In a number of animal species, endothelin-induced bronchoconstriction is 
mediated to a large extent by the release of eicosanoids and indeed, activation of ETa
receptors in human airways induces the release of prostaglandins (Hay et a l,  1993). 
Current studies, however, indicate that, in humans, secondary-release of 
cyclooxygenase products does not contribute to the bronchoconstrictor effect of the 
endothelins and that contraction of human airway smooth muscle is due to a direct 
effect of ET receptor activation (McKay et a l, 1991; Hay et a l, 1993).
Activation of ET receptors can stimulate various signal transduction pathways, such as 
phospholipase A2 or phospholipase C activation, adenylyl cyclase stimulation or
inhibition, activation of tyrosine and threonine kinases and modulation of ion 
exchangers (for review, see Pollock et a l, 1995). In airway smooth muscle, endothelin- 
induced contraction is most commonly mediated by phospholipase C activation, 
leading to an elevation in intracellular free [Ca2+] via production of the second- 
messengers IP3 and DAG. Through their numerous and widespread effects, the
endothelins may contribute not only to the normal homeostasis of the airways but also 
to several lung diseases, including asthma, pulmonary fibrosis and pulmonary 
hypertension (see Michael & Markewitz, 1996, for review).
1.4.3.5 Summary
It is clear that a number of locally produced factors contribute to airway smooth muscle 
contractility under both basal and stimulated conditions. The precise role performed by 
each of these mediators is poorly understood and is further complicated by the finding 
that certain factors, such as the endothelins, the leukotrienes and histamine, may evoke 
their responses by inducing the secondary-release of other mediators.
A number of other mediators present within the lungs have the potential to modulate 
airway smooth muscle function, for example eosinophils and other inflammatory cells 
release various cytokines including the interleukines, eosinophil cationic protein and 
platelet-activating factor. The acute and chronic effect of these mediators on airway 
smooth muscle responsiveness remains to be established, however.
Table 1.1
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Cell Type
Mediator Epithelium Macrophage Mast Cell Eosinophil
Prostaglandins / / / /
Thromboxanes / / /
Leukotrienes / / /
Histamine /
Nitric Oxide / / / /
Endothelins / / t
Table 1.1: Some of the mediators which may influence airway smooth muscle function 
and the cell types which synthesize and release them.
Certain mediators, for example nitric oxide and prostaglandins are released from a 
number of cell types within the airways. Others, such as histamine, originate from a 
specific cellular source, t  -denotes that endothelin has been shown to be released from 
murine mast cells (Ehrenreich et al., 1992), although it is not yet known if this applies 
to other species. Nitric oxide is produced by the enzyme nitric oxide synthase, of which 
constitutive NOS (cNOS) is the subtype expressed by epithelial cells, whereas inducible 
nitric oxide synthase (iNOS) is expressed by inflammatory cells such as eosinophils.
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1.5.1 INTRODUCTION
It is widely recognised that airway remodelling contributes significantly to the airflow 
obstruction and bronchial hyperreactivity of asthma. Pathological findings in post 
mortem tissues from asthmatic patients have shown a marked thickening of the airway 
wall, largely as a result of a significant increase in the mass of the airway smooth 
muscle layer (Dunnill et al., 1969; Hossain, 1973; Heard & Hossain, 1973). It has been 
proposed that there is sufficient thickening of the airway wall in asthmatic patients to 
explain the major part of the bronchial hyperresponsiveness characteristic of this 
disease (James et al., 1989; Wiggs et al., 1992). This suggestion is based on a 
modelling of the relationship between resistance and radius, in that the same degree of 
smooth muscle shortening in a thickened airway wall and a normal airway wall results 
in amplification of airway narrowing in the thickened airway (James et al., 1989; 
Wiggs et al., 1992; Pare, 1993).
This increase in the mass of airway smooth muscle may be due to an increase in either 
the size (hypertrophy) or the number (hyperplasia) of individual smooth muscle cells 
(Heard & Hossain, 1973; Ebina et a l, 1993; Pare, 1993), although such adaptive 
responses are not mutually exclusive and often occur simultaneously (Taubman et a l, 
1989; Gabella, 1979).
The mechanisms involved in the control of airway smooth muscle proliferation are still 
poorly understood (Hirst & Twort, 1992; Stewart et al., 1993; Stewart et al., 1995a), 
although several factors with mitogenic properties have been implicated in the 
remodelling process. Smooth muscle cell mitogens fall into three broad categories: (1) 
growth factors linked to activation of receptors with intrinsic tyrosine kinase activity; 
(2) contractile agonists which mediate their effects through receptors coupled to G 
protein and (3) cytokines released from inflammatory cells.
The intracellular signal transduction pathways leading to cell proliferation are complex 
and incompletely defined. A number of events may be involved in the signalling 
process, including activation of phospholipase C (PLC), stimulation of protein kinase C 
(PKC) and the phospholipases D and A2 and activation and elevation of intracellular
Ca2+ (Huang & Ives, 1987; Rozengurt, 1989; Pouyssegur & Seuwen, 1992; Stewart et 
al., 1995a). These and other signals lead to activation of immediate early response 
genes such as c-fos, c-myc and c-jun (Curran & Franza, 1988; Nambi et al., 1989; 
Simons et al., 1992). The protein products of these proto-oncogenes play a critical role 
in transducing growth signals from the cell surface to the nucleus and in regulating 
gene transcription. More recently, the central role of mitogen-activated protein (MAP) 
kinase has been described (Meloche et a l, 1992; Whelchel et a l, 1997). This enzyme 
phosphorylates c-jun and other targets and its on-going activation appears to be 
required for cell division (Lenormond et al., 1993).
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1.5.2.1 Extracellular Receptors
1.5.2.1.1 Growth factors receptors with intrinsic receptor tvrosine kinase activity 
Growth factors are defined as polypeptides that stimulate cell proliferation through 
binding to specific high-affinity cell membrane receptors (Paris & Pouyssegur, 1993) 
and are thought to play a central role in the regulatory mechanisms controlling cell 
growth. In smooth muscle, epidermal growth factor (EGF), platelet derived growth 
factor (PDGF) and insulin-like growth factor (IGF) induce proliferation by binding to 
receptors with intrinsic tyrosine kinase (RTK) activity (Ross et al., 1974; King et al., 
1985; Banskota et al., 1989; Bomfeldt et al., 1990). Indeed, these growth factors are 
among the most potent smooth muscle mitogens.
Several sub-classes of RTK exist, but all share a similar molecular structure consisting 
of a large extracellular ligand-binding region, a single hydrophobic transmembrane 
segment, a cytoplasmic portion containing the tyrosine kinase catalytic domain and 
lastly, a carboxy-terminal regulatory region (see Cardenn & Gill, 1992; Panettieri, 
1996). Activation of the RTK is necessary for transduction of the growth factor- 
mediated response. Although the precise mechanisms by which the ligand activates the 
RTK is unknown, studies suggest that the ligand binding to the receptor may induce 
oligomerization of receptor monomers or may form a receptor-ligand complex which is 
then internalized (see Cardenn & Gill, 1992). The next step, autophosphorylation of 
tyrosine residues on the receptor, is critically important in transducing the extracellular 
signal into activation of an intracellular pathway. Autophosphorylation of the receptor 
removes inhibitory substrates and creates high-affinity sites containing phosphotyrosine 
residues. The substrates that bind to these autophosphorylated tyrosine residues contain 
particular binding sites, termed SH2 domains.
Substrates with SH2 domains are responsible for coupling activated growth factor 
receptors to intracellular pathways involved in the control of a variety of cellular 
functions such as proliferation and gene expression. Proteins with one or more SH2 
domains include phospholipase C, phosphatidylinositol 3-kinase (PI 3-kinase), Ras and 
other cytoplasmic kinases (Carpenter, 1992). Many of the proteins that posses SH2 
domains also contain a distinct sequence of approximately 50 amino acid residues 
termed the SH3 domain. Recent studies suggest that SH3 domains may modulate 
protein-protein interactions through the recognition of short peptide sequences that do 
not require phosphorylation. Signalling complexes based on the formation of SH2/SH3 
interactions are then followed by activation of downstream effector proteins which 
involve, for example, nonreceptor tyrosine kinases and MAP kinases (Satoh & Kaziro, 
1992; L'Allemain et al., 1991; Meloche et al., 1992).
1.5.2.1.2 Receptors coupled to G proteins
It is now recognised that several agonists which evoke contraction of airway smooth 
muscle can also induce myocyte proliferation. Contractile agonists typically bind to 
receptors coupled to G proteins, which are in turn coupled to various signal 
transduction pathways. G proteins are composed of three distinct subunits (see section 
1.3.3.1). Initially, the a  subunits were considered to be the most important component 
in mediating down-stream signalling events, however, recent studies suggest that the py 
complex is involved in activating various signal transduction cascades.
1.5.2.1.3 Cvtokine receptors
Cytokine receptors differ from RTKs in that the receptor is not a tyrosine kinase itself, 
but rather, upon activation, stimulates an associated protein, a Janus kinase (JAK), to 
phosphorylate tyrosine residues on both itself and the receptor. This provides docking 
sites for various proteins including signal transducers and activators of transcription 
(STATs) and other signalling molecules such as phospholipase C and PI3 kinase (see 
Denhardt, 1996).
1.5.2.2 Intracellular signal transduction cascades involved in mitogenesis
1.5.2.2.1 Mitogen-activated protein (MAPI kinase pathway
Activation of the MAP kinase, also known as extracellular regulated kinase (ERK), 
pathway is believed to play an important role in cell growth and proliferation. MAP 
kinase is initially located within the cytoplasm (Northwood et al., 1991), however 
following activation, MAP kinase translocates to the nucleus (Chen et al., 1992; 
Sanghera et al., 1992) and initiates the activation of transcription factors such as c-jun 
(Pulverer et al., 1991) and c-myc (Seth et al., 1991). Thus, MAP kinase provides a 
physical link in the signal transduction pathway from the cytoplasm to the nucleus. 
Cloning studies indicate the existence of several isoforms of MAP kinase, a 42 and 44- 
kilodalton version encoded by the ERK1 and ERK2 genes, respectively, with a third, 
54-kilodalton version having approximately 50% sequence similarity with its 
counterparts (Boulton et a l, 1990; Boulton et a l, 1991). Expression of both the 42 and 
44-kilodalton isoforms appears to be essential for agonist-induced mitogenesis in 
various cell types (Pages et a l, 1993; Cowley et a l, 1994; Mansour et a l, 1994). The 
activation of MAP kinase requires phosphorylation of both tyrosine and threonine 
residues (Anderson et a l, 1990) by the dual specificity tyrosine/threonine kinase MAP 
kinase kinase, MEK1 (MacDonald et a l, 1993; Yan & Templeton, 1994). Raf-1 is 
currently thought to be the only physiologically relevant activator of MEK, although 
there is evidence for the existence of other MEK kinases (MAP kinase kinase kinases, 
Gupta et a l, 1992; Lange-Carter, 1993). Raf is in turn activated by the membrane- 
bound small guanine-nucleotide binding protein Ras (McCormick, 1993), which is
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(Bonfini et al., 1992; Bowtell et al., 1992; Egan et al., 1993).
The MAP kinase pathway has historically been associated with growth factor receptors 
which display intrinsic tyrosine kinase activity (Fantl et al., 1993; Egan et al., 1993), 
however it is now clear that signals from G protein-coupled receptors can also impact 
on the Ras/MAP kinase signal transduction cascade (DeVivo & Iyengar, 1994).
The intracellular pathways that link G protein-coupled receptors to MAP kinase 
activation are poorly understood, but for many agonists, stimulation of PKC appears to 
be a critical step (Granot et al., 1993; Bogoyevitch et al., 1994). Recent evidence, 
however, suggests that the py subunit complex from individual G proteins may be able 
to stimulate Ras (Faure et al., 1994; Crespo et al., 1994), thus leading to MAP kinase 
activation.
In airway smooth muscle cells, MAP kinase is activated by a number of mitogenic 
factors including the growth factors PDGF, EGF and IGF (Kelleher et al., 1995) and the 
G protein-coupled agonists bradykinin (Malarkey et al., 1995), thrombin, endothelin-1 
(Shapiro et al., 1996) and 5-hydroxytriptamine (Kelleher et al., 1995). As in other cell 
types, the duration of MAP kinase appears to be critical in evoking proliferation of 
airway smooth muscle. Sustained activation of MAP kinase is associated with 
mitogenesis of airway smooth muscle cells, whereas agonists which stimulate only a 
transient activation of MAP kinase failed to induce a proliferative response (Malarkey 
et al., 1995; Kelleher et al., 1995).
1.5.2.2.2 Protein Kinase C (PKC)
PKC is a family of multiple isoenzymes with different biochemical characteristics, 
substrates and co-factor requirements (Hug & Sarre, 1993). Activation of PKC by DAG 
is an important signalling event in the proliferation of many cell types (Adamo et al., 
1986). DAG is primarily produced by hydrolysis of PIP2 via the action of PLC. (In the 
case of G protein-coupled receptors, phosphoinositide-specific PLC, PLC-pi, is 
activated rather than PLC-y, which is activated by RTK-dependent receptors (Panettieri, 
1996). Furthermore, with G proteins of the Gq family, it is the a  subunits that activate 
PLC-pi, whereas with G proteins of the Gi class, activation is mediated through the py
subunits (Exton, 1996; Lee & Rhee, 1995)). Recent evidence, however, suggests that 
the production of DAG from the phospholipase D-mediated hydrolysis of 
phosphatidylcholine (Daniel et al., 1986b; Takuwa et al., 1987; Grillone et al., 1988; 
Griendling et al., 1986; Konishi et al., 1991) may contribute greatly to the regulation of 
PKC.
While RTK-mediated cell proliferation is both PKC-dependent and independent 
(Stumpo & Blackshear, 1983), agonist-induced mitogenesis is thought to be almost 
exclusively PKC-dependent. Indeed, activation of PKC is believed to be the primary 
mechanism by which signals from G protein-coupled receptors impinge on the MAP 
kinase pathway (Granot et al., 1993; Bogoyevitch et al., 1994). Recent evidence,
however, suggests that G protein-linked agonists may activate MAP kinase via a PKC- ^  
independent manner (van Corven et al., 1993; McLees et al., 1995; Malarkey et a l, 
1995), possibly via a Gi-type G protein-linked pathway.
While it is clear that PKC activation is an important constituent of many signalling 
pathways, the critical targets of the various PKC isoforms remain, for the most part, to 
be discovered.
1.5.2.2.3PI3 kinase
Phosphatidylinositol 3-kinase (PI3 kinase) is a dimer of an 85kDalton a  subunit, which 
contains an SH2 domain and therefore associates with growth factor RTKs, and a 
llOkDalton (3 subunit (Kazlauskas & Cooper, 1989; Escobedo et al., 1991). Growth 
factor-stimulated PI3 kinase activation, leading to the formation of phosphatidylinositol 
(3,4,5) trisphosphate, was originally demonstrated by Cantley and co-workers 
(Whitman et al., 1988). As with other tyrosine kinase pathways, G protein-coupled 
receptor agonists have also been shown to activate the PI3 kinase pathway (Kumagai et 
al., 1993; Stephens et al., 1993). PI3 kinase has been proposed to mediate a number of 
intracellular events involved in mitogenesis such as activation of PKC (Nakanishi et a l, 
1993; Liu, 1996), stimulation of a ribosomal kinase (rsk, Lane et al., 1993) and 
activation of the MAP kinase pathway (Rodriguez-Viciana et al., 1994).
1.5.2.2.4 PLD
Regulation of phospholipase D (PLD) has received considerable attention since 
hydrolysis of the membrane phospholipid, phosphatidylcholine, by this enzyme 
produces, phosphatidic acid, a potential second-messenger in many cell types (see 
Exton, 1994). The activity of PLD in a wide variety of cells is influenced by many 
hormones, neurotransmitters, growth factors and other agonists linked to heterotrimeric 
G proteins or tyrosine kinases (Exton, 1994; Exton, 1997). The mechanisms by which 
G protein-coupled receptors and RTK are linked to PLD are not well understood but 
PKC activation appears to play a major role in many cell types (Eldar et a l, 1993; 
Balboa et al., 1994). Since the majority of agonists that promote PLD activation also 
stimulate PLC, a logical mechanism is that PLD activation is secondary to PKC 
stimulation due to production of DAG from PIP2 (Exton, 1997). At present, the
mechanism(s) by which PKC activates PLD is undefined, indeed the role for PLD in 
early mitogenic signalling is controversial, with both supporting and conflicting 
evidence (see Boarder, 1994).
1.5.2.2.5 PLAo
The hydrolysis of phosphatidylcholine by phospholipase A2 (PLA2) was one of the 
earliest phospholipase pathways to be described. The "classical" role of PLA2 
activation is to generate arachidonic acid, which is the rate limiting precursor of 
prostaglandin and leukotriene biosynthesis (see section 1.4.3.1). It is probable that in 
inflammatory states this is the major function of arachidonate, however in mitogenic 
signal transduction, other pathways may be important. These alternative pathways 
include the activation of certain isoforms of PKC (Asaoka et al., 1992) as well as PLD 
stimulation (Wang et al., 1992). Although PLA2 is activated by many agonists linked to
heterotrimeric G proteins, there is no compelling evidence that G proteins interact 
directly with this enzyme (Clark et al., 1995). RTK growth factors such as PDGF and 
EGF can stimulate PLA2 activity (Goldberg et al., 1990), indeed it has been 
demonstrated that PLA2 can be phosphorylated and activated by MAP kinase (Lin et 
a l, 1993). Since growth factors and contractile agonists can both stimulate MAP 
kinase, it is possible that both RTK-linked growth factors and G protein-coupled 
receptor agonists control the activity of PLA2 through MAP kinase activation.
In rabbit airway smooth muscle, endothelin-1 induces cell proliferation by activating 
PLA2, leading to the generation of thromboxane A2 and leukotriene D4 (Noveral et al.,
1992; Panettieri et al., 1991a).
1.5.2.2.6 SAP kinases
As their name suggests, stress activated protein kinases (SAP kinases) are activated by 
agents which induce cellular stress, such as UV light and the cytokines, tumour 
necrosis factor a  and interleukin-1 (Kolesnick & Goldie, 1994). The SAP kinases 
include additional members of the MAP kinase family (a 38-kilodalton isoform, Han et 
al., 1994) and the c-jun N-terminal kinases (Jun kinases) which are distant relatives of 
the MAP kinases (Kyriakis et al., 1994), but are thought to exist in signal transduction 
cascades distinct from MAP kinase. There is evidence, however, for the existence of 
cross-talk between the two pathways since RTK-linked growth factors (Minden et al., 
1994) and G protein-coupled receptor agonists (Dalton & Treisman, 1992) can also 
activate the SAP kinases. A recent study in airway smooth muscle cells showed that Jun 
kinase was activated by the G protein-linked receptor agonists endothelin-1 and 
thrombin (Shapiro et al., 1996), indicating that contractile agonists may induce 
proliferation of airway smooth muscle via both the MAP kinase and SAP kinase 
pathways.
1.5.2.2.7 Jak STATS
One of the most recently identified tyrosine kinase signalling cascades involves the 
activation of a novel class of tyrosine kinases, comprising Janus kinase (JAK) and the 
tyrosine phosphorylation of cytoplasmic proteins called signal transducers and 
activators of transcription (STATs). As stated earlier (see section 1.5.2.1.3), this 
pathway is activated primarily by cytokines such as interferons (Schindler et al., 1992; 
Shuai et al., 1992), interleukin-3 (Silvennoinen et al., 1993) and growth hormone 
(Winston & Hunter, 1995). JAKs do not contain SH2 or SH3 domains, but cytokine 
stimulation leads to the association of these kinases with the receptor and their 
subsequent tyrosine phosphorylation and activation (Velazquez et al., 1992). Recently, 
RTK-linked growth factors (Fu & Zhang, 1993) and G protein-coupled receptors 
(Marrero et al., 1995) have been shown to activate components of this cascade and may 
represent an additional pathway through which these agents can induce mitogenesis.
1.5.2.3 Intracellular signal transduction cascades involved in inhibiting 
mitogenesis
Recognition that airway smooth muscle proliferation is important in the pathogenesis of 
asthma has focused attention on identifying cellular and molecular mechanisms that 
inhibit smooth muscle cell growth. An understanding of these mechanisms is not only 
critical in preventing cell growth, but also in addressing whether the loss of inhibitory 
signals may induce proliferation.
Cytokines, activation of cyclic nucleotides and alterations in extracellular matrix 
proteins have all been reported to inhibit myocyte proliferation (Stewart et al., 1995b; 
Panettieri, 1996).
1.5.2.3.1 Alterations in extracellular matrix proteins
Heparin and related molecules, which are components of the extracellular matrix, 
potently inhibit proliferation of vascular smooth muscle (Clowes & Kamovsky, 1977), 
although the molecular mechanisms underlying this inhibition are unresolved. Pukac et 
al (1992) suggest that specific receptor signals transduce the antiproliferative effects of 
heparin, whereas others propose that the antiproliferative effect is mediated by its 
intracellular action (Castellot et al., 1985). After binding to high affinity surface 
receptors, the heparin-receptor complex is internalized and then localizes near the 
perinuclear membrane where it may interact with proteins or proto-oncogenes that 
modulate gene transcription (Castellot et al., 1985).
In cultured airway smooth muscle cells, growth factor-induced mitogenesis is inhibited 
by heparin (Page, 1991; Johnson et al., 1994), but not by chondroitin sulphate, another 
extracellular matrix protein (Panettieri et a l, 1990). Furthermore, although extracellular 
matrix proteins have been shown to inhibit proliferation, these proteins may prevent 
degradation of certain growth factors and thereby potentiate mitogenesis (Border et a l,
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other matrix proteins may modulate smooth muscle cell growth in a complex manner.
1.5.2.3.2 Cvtokines
Smooth muscle cells stimulated by growth factors have been shown to release 
cytokines which modulate myocyte proliferation in an autocrine manner (Hajjar et al.,
1992). Transforming growth factor (3 (TGF |3), a cytokine secreted by many cell types 
including smooth muscle, may either enhance (Majack et al., 1990) or inhibit (Majack 
et al., 1987) growth factor-induced mitogenesis of vascular smooth muscle cells.
The inflammatory cytokine tumour necrosis factor-a (TNFa) has been detected in 
increased levels in broncheoalveolar lavage from symptomatic asthmatic patients 
(Broide et al., 1992) and alveolar macrophages cultured from asthmatic subjects 
produce higher levels of TNFa (Gosset et al., 1991). TNFa inhibits the mitogenic 
effect of agents such as thrombin and EGF in airway smooth muscle cells, but at very 
low concentrations, TNFa has a small stimulatory effect on these cells (Stewart et al., 
1995b). The signalling pathways which transduce the cellular effects of cytokines are 
largely unknown.
1.5.2.3.3 Cyclic nucleotides
cyclic Adenosine Monophosphate (cAMP)
Several studies now support the idea that elevation of intracellular cAMP levels inhibits 
the proliferation of airway smooth muscle cells (Panettieri et al., 1990; Tomlinson et 
al., 1994; Tomlinson et al., 1995). There is circumstantial evidence, however, that 
transient elevation of cAMP may be a mitogenic stimulus (Lew et al., 1992). Elevation 
of cAMP activates cAMP-dependent protein kinase A (PKA, see section 1.3.4), which 
inhibits agonist-induced cell growth (Panettieri et al., 1991b; Panettieri et al., 1993; 
Shapiro et al., 1996). Interestingly, PKA activation appears to selectively inhibit 
mitogens which induce airway smooth muscle cell growth through PKC-dependent 
pathways, whereas mitogenesis induced by RTK-activating growth factors are less 
sensitive to PKA-mediated inhibition (Panettieri et al., 1991b; Panettieri et al., 1993).
The mechanism by which PKA inhibits mitogenesis remain unclear, but in various cell 
lines PKA has been shown to block activation of Raf by Ras and thereby inhibit the 
MAP kinase cascade (Cook & McCormick, 1993; Wu et al., 1993).
cyclic Guanosine Monophosphate (cGMP)
It has also been reported that pretreating cells with cGMP-producing vasodilators, such 
as atrial natriuretic peptide, or with cGMP analogues inhibits proliferation of vascular 
smooth muscle cells (Garg & Hassid, 1989; Itoh et al., 1990). As with cAMP, the 
intracellular mechanisms by which cGMP inhibit mitogenesis are poorly understood, 
but, as mentioned earlier (see section 1.3.4.3), under certain conditions, cGMP appears 
to be able to stimulate PKA.
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1.5.2.3.4 Other inhibitory mechanisms
Anti-inflammatory steroids do reduce airway smooth muscle cell proliferation directly, 
but the magnitude of the effect is dependent on the stimulant - EGF and the 
thromboxane A2 mimetic U46619 are relatively insensitive, whereas the effects of
thrombin are almost abolished by dexamethasone (Stewart et al., 1995a).
1.5.3 SUMMARY
When a receptor is activated, a number of signalling pathways is typically stimulated to 
a varying degree. The fact that some of the proteins in a pathway become multiply 
phosphorylated raises the possibility that more than one signal may be transmitted 
simultaneously via the same pathway. If this phenomenon, known as multiplex 
signalling (Denhardt, 1996), exists, it adds another layer of complexity to the signalling 
processrinvolved in mitogenesis.
The relationship between the extent of the airway remodelling and the severity of the 
asthmatic condition (Kuwano et al., 1993) suggests that this is a progressive feature of 
the disease. As such, early intervention with appropriate agents may arrest or reverse 
the development of these structural changes. Identification of the critical cellular and 
nuclear mechanisms by which airway smooth muscle proliferation is controlled is 
therefore of obvious clinical importance.
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1.6.1. INTRODUCTION
1.6.1.1 Historical perspective
It has long been recognised that air is essential for life. In the 17th century, Robert 
Boyle noted that neither a flame nor an animal would survive in a confined chamber 
(Boyle, 1668). Although oxygen was first discovered in the early 1770s by Priestley, it 
was an essay by Lavoisier in 1775, entitled "Experiments on the respiration of animals 
and on the changes affecting air in its passage through the lungs," which gave rise to 
the concept that metabolic processes of the body are dependent upon a constant supply 
of oxygen (see Fishman & Richards, 1964).
1.6.1.2 Classifications of hypoxia
Hypoxia is a physiological term for the condition in which the oxygen supply to cells, 
tissues, organs or whole animals is insufficient to maintain a normal function. The 
physiological classifications of hypoxia are based on the original description by 
Barcroft (1920), in which he divided anoxaemia into three types: low oxygen in the 
blood (anoxic hypoxia), reduced functional haemoglobin (anaemic hypoxia) and an 
insufficient blood supply to tissues (stagnant hypoxia). The classification was expanded 
by Peters and van Slyke (1932) to include a fourth class (histotoxic hypoxia) caused by 
exposure to poisons that retard the oxidation process.
More recently, anoxic and anaemic hypoxia have been grouped under the term "simple 
hypoxia," in which the major change is a decrease in the oxygen concentration of the 
blood (Silver, 1977; Jones, 1986). In contrast to stagnant hypoxia, simple hypoxia 
occurs without blood flow-dependent limitations in nutrient supply and removal of 
waste products. Stagnant hypoxia occurs in acute ischaemia, caused by cardiac 
insufficiencies, blood vessel occlusion or blood stasis, whereas simple hypoxia results 
from anaemia, low inspired oxygen or respiratory disorders involving impaired 
ventilation or alveolar gas exchange.
The focus of this chapter is the effect of hypoxia on airway smooth muscle function. In 
vivo, airway smooth muscle could be subjected to hypoxia classified as simple, stagnant 
or even histotoxic hypoxia. From the following sections, however, it should become 
clear that the term 'hypoxia' in this case refers to alveolar hypoxia and would therefore 
be classified as 'simple-hypoxia'.
1.6.1.3 The hypoxic ventilatory response
Considerable attention has been focused on the ventilatory response to hypoxia. In 
several mammalian species, including humans, the hypoxic ventilatory response is 
described as biphasic and consists of an initial increase in ventilation followed by a 
decline that may return to or below the control level (see Fisher et al., 1987). The
71increase in ventilation is thought to be due to an increase in the respiratory rate rather 
than in tidal volume (Haldane et al., 19l9; Rebuck et a l, 1976).
Although most authors agree that the initial ventilatory rise is due to the hypoxic 
activation of the peripheral chemoreceptors, the mechanisms behind the subsequent 
decline in ventilation have been, and continue to be, the object of many publications. 
The most obvious hypothesis is that rapid adaptation of the peripheral chemoreceptors 
or central filtering of the chemoreceptors input occurs, although experimental evidence 
appears to suggest otherwise (Eldridge & Millhom, 1986; Vizek et al., 1987). 
Alternatively, the initial increase in ventilation may lead to hypocapnia, which would 
therefore lead to a reduction in ventilatory drive. Maintaining CO2 levels, however,
does not significantly change the biphasic ventilatory response (Easton & Anthonisen, 
1988). Indeed, even a modest hypercapnia does not eliminate the secondary decline in 
ventilation (Georgopoulos et al., 1989). Further studies indicate that hypoxia-induced 
elevations in airway resistance are not likely to be responsible for the ventilatory 
decline (Fisher et al., 1987).
In short, acute hypoxia evokes an initial increase, followed by a decline, in ventilation 
although the mechanisms underlying^ffle subsequent fall remain unknown.
1.6.1.4 Introducing the effects of hypoxia on the airways
Alveolar hypoxia, and subsequent hypoxaemia, can often occur in respiratory diseases 
such as acute severe asthma, chronic obstructive airway disease, and bronchial 
dysplasia. Despite this the effects of hypoxia on airway smooth muscle function are 
controversial and poorly understood. In isolated airway preparations, reducing the 
oxygen tension generally impairs contractile responses (Stephens & Chui, 1970; 
Stephens & Kroeger, 1970; Paterson et al., 1988) and reverses induced tone (Twort & 
Cameron, 1986; Gao & Vanhoutte, 1989; Fernandes et al., 1993), whereas in vivo, 
hypoxia has been reported to induce bronchoconstriction (Nadal & Widdicome, 1962; 
Sterling, 1968; Saunders et al., 1977; Teague et a l,  1988), bronchodilation (Wetzel et 
al.i 1992; Julia-Serda et al., 1993) or have no effect (Goldstein et al., 1979; Tam et al., 
1985). The conflicting results among the various reports may reflect variations in the 
design of the studies, since differences in the species studied, the intensity and duration 
of the hypoxic stimulus, the method used to measure changes in airway tone and the 
anaesthetic technique employed may all have important effects on the resulting 
response. A key point in the methodology is the control, or otherwise, of other relevant 
stimuli, such as carbon dioxide levels, which are known to have potent effects on 
airway tone. Since hypercapnia is commonly associated with hypoxia in many 
physiologicaPand pathophysiologicalconditions, combined hypoxia/hypercapnia would 
thus provide a more relevant characterization of the effects of hypoxia on the 
respiratory system. Unfortunately, it also limits the general applicability of the results 
from each study and makes the task of synthesizing the data more difficult.
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As stated above, the general response of airway smooth muscle to hypoxia in vitro is an 
impairment of contraction. Hypoxia-induced pulmonary vasoconstriction plays a major 
role in the crucial physiological function of ventilation (V) /perfusion (Q) matching by 
diverting blood flow away from hypoxic areas of the lung (Sylvester et al., 1986). 
Theoretically, hypoxia-induced bronchodilation could improve V-Q matching by 
decreasing airway resistance and facilitating gas flow to the hypoxic regions of the 
lungs.
In contrast to the extensive study of hypoxic pulmonary vasoconstriction, there is a 
paucity of data regarding the mechanisms of hypoxia-induced impairment of contractile 
responses in airway smooth muscle.
1.6.2.1 Postulated mechanisms of hypoxia-induced relaxation
1.6.2.1 .4 Depletion of ATP levels
Early work by Stephens and co-workers (Stephens & Chui, 1970) proposed that the 
impairment of airway smooth muscle tone during hypoxia was due to depletion of the 
energy stores needed for phosphorylation of myosin. During moderately severe 
hypoxia, however, intracellular ATP concentrations are in the millimolar range (Zhou 
et al., 1991), whereas the amount of ATP required by smooth muscle to maintain 
contraction is in the micromolar range (Paul, 1980).
1.6.2.1.2 Release of inhibitory factors
Others have postulated that hypoxic relaxation is secondary to the release of inhibitory 
agents within the airways. A likely source of relaxant factors is the airway epithelium 
and indeed, Gao and Vanhoutte (1989) found that hypoxia-induced relaxation of canine 
bronchi was dependent upon the presence of the epithelial layer. In contrast, however, a 
more recent study in porcine bronchi found that removing the epithelium did not alter 
the ability of hypoxia to induce relaxation (Fernandes et al., 1993). Furthermore, 
indomethacin, methylene blue and propranolol each failed to inhibit the hypoxic 
response, indicating that cyclooxygenase products, cGMP or p-adrenergic agonists are 
unlikely to mediate hypoxic relaxation of airway smooth muscle (Fernandes et a l,
1993).
Alternatively, several groups have postulated that cells known as pulmonary 
neuroendocrine cells (PNEC) act as airway receptors involved in controlling 
bronchomotor tone in response to hypoxia. Groups of PNEC, termed neuroepithelial 
bodies (Lauweryns & Peuskens, 1972), are found in the epithelial layer and mucosa 
throughout the respiratory tract (Hung, 1984). PNEC are known to secrete a number of 
bioactive molecules such as serotonin (Lauweryns et a l, 1973), bombesin/gastrin
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Rather than secreting their products into the airway lumen, their polarity of secretion is 
directed towards structures underlying the basement membrane such as nerve fibres, 
pulmonary blood vessels and airway smooth muscle cells (Hung, 1984). The 
association of PNEC with nerve fibres has long suggested a "receptor" role for these 
cells (Lauweryns & Peuskens, 1972), indeed, acute airway hypoxia or hypercapnia both 
cause release of secretory products from these cells (Lauweryns et al., 1978; Keith & 
Will, 1982), implying a role as 'intra-airway oxygen sensors'. Interestingly though, the 
products secreted by these cells are all reported as inducing contraction of airway 
smooth muscle (Zucker & Comish, 1980; Palmer et al., 1987b; Belvisi et al., 1991), 
therefore one would expect hypoxia to evoke a contractile response in the airways. The 
disparity between this and the hypoxia-induced reversal of tone in isolated airways may 
be due to the fact that PNEC are concentrated in smaller conducting airways whereas 
the preparations used for in vitro studies tend to be tracheal or upper bronchus. Many 
authors now propose that the primary role of PNEC is in regulating airway 
differentiation and lung development.
Thus, there is a lack of evidence supporting the hypothesis that hypoxic relaxation of 
airway smooth muscle is due to release of an inhibitory factor within the airways.
1.6.2.1.3 Inhibition of entry of extracellular Ca2+
More recent studies suggest that calcium availability may be the limiting factor during 
hypoxia. As mentioned in section 1.3.2, the calcium needed for smooth muscle 
contraction can come from extracellular sources or internal calcium stores. Fernandes et 
al (1993) showed that hypoxia did not inhibit the initial contractile response to 
carbachol, whereas the maintained phase of the carbachol-induced contraction was 
inhibited. In addition, both the initial and the sustained phase of contractions evoked by 
potassium chloride were impaired (Fernandes et a l, 1993). This strongly suggests that 
hypoxia attenuates the contractility of airway smooth muscle by inhibiting the entry of 
extracellular calcium, whereas the release of calcium from intracellular stores appears 
to be unaffected. Entry of extracellular calcium into airway smooth muscle cells occurs 
almost exclusively through voltage dependent Ca2+ channels, although there is indirect 
evidence for the existence of receptor-operated Ca2+ channels in this tissue (Croxton et 
al., 1994; Murray & Kotlikoff, 1991). Vannier et al (1995) recently showed that 
hypoxia limits entry of Ca2+ predominately via voltage operated channels, although a 
small component of the hypoxia-induced relaxation may be mediated by inhibition of 
receptor-operated Ca2+ channels.
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1.6.2.2 Postulated mechanisms of Ca2+ influx inhibition
1.6.2.2.1 K+ channel opening and membrane hvperpolarization
A possible mechanism by which hypoxia inhibits entry of extracellular Ca2+ is 
hyperpolarization of the cell membrane. Hyperpolarization would reduce the open-state 
probability of voltage-operated Ca2+ channels, leading to a decrease in Ca2+ entry, a 
decrease in free Ca2+ and a reduction in airway tone. Physiological hyperpolarization is 
often accomplished by opening potassium (K+) channels on the cell membrane, indeed, 
Lindeman et al (1994) demonstrated that opening of ATP sensitive K+ (Katp)
channels is involved in the relaxatory responses of airway smooth muscle to hypoxia. 
The mechanisms by which K a t p  channels are activated during hypoxia are not yet
known. Reductions in oxygen tension could (1) decrease availability of ATP required to 
directly inhibit the channels, (2) redistribute intracellular ATP required for K a t p
channel phosphorylation, or (3) reduce intracellular pH. Indeed, these factors could also 
affect VOC channels directly, without the involvement of K a t p  channels. For example,
VOC channel activity is inhibited b>r?eductions in the availability of ATP in vascular 
smooth muscle cells (Ohya & Sperelakis, 1989) and by intracellular acidosis in 
ventricular myocytes (Kalibara & Kameyama, 1989). The importance of these 
regulatory mechanisms on Ca2+ channel activity has not been established in airway 
smooth muscle, however a recent study, outlined below, by Croxton et al (1995) 
investigated the role of intracellular pH changes in the relaxatory response of isolated 
airway smooth muscle to hypoxia.
1.6.2.2.2 Intracellular pH changes
Given that both hypercapnia, which decreases active force generation in bronchial rings 
(Stephens et al., 1968) and relaxes precontracted airway smooth muscle (Duckies et al., 
1974; Twort & Cameron, 1986), and hypoxia evoke a fall in intracellular pH, it was 
postulated that hypoxia may inhibit VOC channel activity in airway smooth muscle 
cells via intracellular acidosis. It was found however, that while hypercapnia-induced 
relaxation was indeed associated with intracellular acidosis, hypoxia evoked substantial 
relaxation without altering intracellular pH (Croxton et a l , 1995). This demonstrates 
that changes in intracellular pH may be an important regulator of airway smooth muscle 
tone, but that intracellular acidosis does not mediate the rapid relaxatory response to 
hypoxia. The possibility remains that changes in intracellular pH may occur in airway 
smooth muscle during more prolonged hypoxia and that these changes may have 
additional effects on airway tone.
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1.6.2.3 Summary
In summary, in isolated airway preparations, hypoxia relaxes precontracted tissues and 
attenuates active tension generation. Inhibition of VOC channels appears to play a key 
role in the hypoxic response, but the cellular mechanisms underlying this remain 
elusive.
1.6.3 THE EFFECT OF HYPOXIA ON AIRWAY SMOOTH MUSCLE TONE In 
vivo
The effects of alveolar hypoxia on the mechanical function of the airways in vivo have 
been recognised since the report by Roy and Brown in 1885 that asphyxia can both 
increase and decrease bronchial tone in dogs (Roy and Brown, 1885). Einthoven 
extended the observation in 1892, showing that alveolar hypercapnia and hypoxia can 
each independently produce a bronchoconstrictive response in dogs (Einthoven, 1892). 
Since these early publications, a large number of investigators have approached the 
effects of hypoxia on the airways from various angles to reach conclusions that are not 
always uniform. Aside from the differences in methodology and study design, a likely 
explanation for such discrepancies is the fact that the response of the upper airways to 
hypoxia may differ from the response of the lower airways.
1.6.3.1 Response of the upper airways to hypoxia
There is little question that alveolar hypoxia stimulates the contraction of the muscles 
that dilate all three segments of the upper airway: the nose, pharynx and larynx (van 
Luteren, 1991). Breathing a hypoxic or hypercapnic gas mixture stimulates the alae nasi 
muscles (Strohl et al., 1982; Mezzanotte et al., 1992) resulting in nasal flaring, a classic 
sign of respiratory distress (Strohl et al., 1980). Activation of these muscles can reduce 
nasal resistance by nearly 25% (Maltais et al., 1991), a significant figure if one 
considers that the nose can contribute up to 40% of the total respiratory resistance in 
humans (Span & Hyatt, 1971). The pharyngeal (Martin et al., 1990; Okabe et al., 1993) 
and laryngeal (Bartlett, 1979; Wheatley et al., 1991) dilator muscles are also selectively 
recruited during alveolar hypoxia, resulting in a further decrease in resistance to airflow 
(Maltais et al., 1991).
1.6.3.2 Response of the lower airways to hypoxia
The idea that the smooth muscle of the trachea and the bronchi can respond to changes 
in the composition of the inspired gas has intrigued physiologists for over a century. In 
addition to the classic observations of Roy and Brown (1885) and Einthoven (1892), 
highlights in the quest to characterize this response include the demonstrations: by
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anaemic blood or oxygen-desaturated blood causes bronchoconstriction; by 
Loofbourrow et al (1957) that asphyxia, hypoxaemia and hypercapnia contract the 
trachealis muscle; and by Nadel and Widdicombe (1962) that either carotid denervation 
or vagotomy abolish the constrictive effects of alveolar hypoxia and hypercapnia on the 
trachea and bronchi.
While many subsequent studies confirm that hypoxia produces bronchoconstriction 
(Sterling, 1968; Saunders et al., 1977; Fisher et al., 1987), there are other showing that 
it has no measurable effect on the airways (Goldstein et al., 1979; Tam et al., 1985). 
Indeed, two separate groups have found a bronchodilatory response to hypoxia in vivo 
(Wetzel et al., 1992; Julia-Serda et al., 1993).
As stated earlier, the apparent confliction in results may be due to methodological 
reasons. While the trachealis muscle is accessible to direct force recordings, the 
bronchial smooth muscle cannot be studied conveniently without disturbing its 
innervation or its mechanical anchoring on the surrounding tissue. The traditional 
strategy is to rely on indirect measurements of airway calibre, such as by measuring 
flow-vdlume and pressure-flow relationships of the respiratory system on the 
assumption that they will reflect changes in airway diameter. Unfortunately, these 
measurements, or the total lung and respiratory resistances calculated from them do not 
provide a proportional representation of all airways. Moreover, they cannot easily 
distinguish the contributions of airways and lung or chest wall tissues to the flow- 
dependent properties of the system. Consequently, they may be influenced by changes 
unrelated to airway diameter, such as changes in lung volume. Furthermore, invasive 
procedures such as nasal and pharyngeal catheters or fibre-optic laryngoscope may 
stimulate upper airway reflexes and hence modify airway resistance. Interestingly, two 
of the more non-invasive techniques, computed tomography and acoustic reflection 
(Wetzel et al., 1992; Julia-Serda et al., 1993, respectively) recorded a bronchodilation 
during hypoxia.
After taking into account the methodological considerations outlined, the bulk of the 
existing information still points to a bronchoconstrictor response to hypoxia, a response 
which appears to be dependent on a reflex loop that includes the peripheral 
chemoreceptors and the parasympathetic motoneurones of the vagus nerve (Nadel & 
Widdicombe, 1962; Green & Widdicombe, 1966). The response is due to peripheral 
chemoreceptor stimulation and can be eliminated by section of either the 
glossopharyngeal nerves, which represent the afferent pathway of the reflex, or the 
vagus nerves-^diieh supply the afferent innervation to the airway smooth muscle (Nadel 
& Widdicombe, 1962). As mentioned in section 1.4.1.1, the parasympathetic nerves 
provide the dominant excitatory innervation of the airway smooth muscle. These 
neurones are connected with areas of the brain stem known to receive inputs from the 
peripheral and central chemoreceptors and lung receptors (Haxihiu et al., 1994) and are
77also functionally coordinated with the central respiratory generator (Mitchell et al., 
1985).
While a bronchoconstrictor response to hypoxia, leading to an increase in airflow 
resistance, may at first seem to be self-limiting, it is part of a homeostatic reflex and 
must be considered in conjunction with the overall ventilatory response to hypoxia (see 
section 1.6.1.3). The elevated expiratory efforts caused by hypoxia place increased 
transmural pressures on the central airways, thereby limiting flow by dynamic 
compression (Fry & Hyatt, 1960). Contraction of the airway smooth muscle makes the 
airways stiffer, thereby reducing the likelihood of deformation. Thus the balance 
between decreased airflow resistance and susceptibility to collapse tends to favour an 
increased stiffening of the lower airways in an effort to prevent deformation during the 
hypoxia-induced increase in ventilation.
1.6.3.3 Complicating factors
The effect of hypoxia on airways in vivo may be complicated by a number of factors. 
For example, the direct response of the airways to hypoxia may lead to alterations in 
lung volumes and CO2 levels or to activation of lung receptors, all of which may exert
a modulatory role on airway calibre.
1.6.3.3.1 Responses to COo in the airwavs
The effects of hypo- and hypercapnia on the bronchi are just as complex as those of 
hypoxia. The available information indicates that isolated arterial hypocapnia relaxes 
bronchial smooth muscle by decreasing cholinergic tone (Ingram, 1975). In contrast, 
isolated alveolar hypocapnia may evoke bronchoconstriction (Ingram, 1975), probably 
by a local action of CO2 on the muscle cells (Stephens et al., 1968). These apparently
contradictory effects may reflect the presence of two regulatory mechanisms: one 
triggered primarily by increases in arterial Pc02 and directed at limiting airway
deformation during periods of hyperpnea, and the other initiated by decreases in 
alveolar Pco2 and directed at limiting gas flow to regions of the lung where blood flow
is reduced.
As with hypoxia-induced bronchoconstriction, chemoreceptor stimulation by arterial 
hypercapnia evokes a bronchoconstrictor response via a reflex pathway involving 
stimulation of the efferent vagus nerve (Nadel & Widdicombe, 1962; Green & 
Widdicombe, 1966). In contrast to hypoxia, however, the response to hypercapnia 
remains intact after section of the glossopharyngeal nerves, indicating that the response 
to CO2 is mediated via central,. rather than peripheral chemoreceptors (Nadel &
Widdicombe, 1962; Green & Widdicombe, 1966). In addition, cooling of the ventral 
surface of the medulla, an area of presumed chemoreceptor function (see section 
1.1.3.1.2), blocks the cholinergically mediated constriction of the airways to 
hypercapnia (Deal et al., 1986).
This increase in bronchomotor tone during hypercapnia may represent, in a manner 
similar to the bronchoconstrictive response to hypoxia, a protective mechanism to 
reduce airway deformation during periods of increased ventilation.
1.6.3.3.2 SAR activation
Airway slowly adapting stretch receptors (SAR, see section 1.1.3.2.1) increase their 
activity during contraction of airway smooth muscle (Bartlett et a l, 1976), leading to a 
reflex bronchodilation (Widdicombe & Nadal, 1963). Since both hypoxia and 
hypercapnia evoke a bronchoconstriction, SAR activity would be expected to increase 
during inhalation of these gas mixtures. Indeed, in awake dogs, the increase in 
ventilation due to hypoxia stimulates SAR and produces a bronchodilation which can 
completely offset the hypoxia-induced bronchoconstriction (Sorkness & Vidruk, 1986). 
Fisher et al (1983) have proposed that the stimulation of SAR may be a physiological 
mechanism for limiting the bronchoconstriction induced by hypoxia and hypercapnia.
1.6.3.3.3 The effect of lung volumes
Alveolar hypoxia has been reported tcraffect the elastic recoil of the lungs and therefore 
to alter lung volumes (Green & Widdicombe, 1966; Saunders et al., 1977). This may 
have an important effect on airway calibre, indeed it has been postulated that the 
hypoxic-bronchoconstriction may be mediated in part via changes in lung volume 
(Watney et al., 1988). The majority of studies report an increased functional residual 
capacity and residual volume of the lungs in hypoxia. The mechanism may involve 
delayed lung emptying by the increase in airway resistance, or a decrease in the tone of 
the intercostal muscle (Saunders et al., 1977; Garfinkel & Fitzgerald, 1978). Perhaps 
more likely, however, is a reduction in the elastic recoil of the lungs, which has been 
reported to occur during acute hypoxia (Saunders et al., 1977; Gautier et al., 1982). 
This may be caused by relaxation of smooth muscle in the lung parenchyma, either due 
to a direct effect of hypoxia or an increase in circulating catecholamine concentrations 
(Saunders et al., 1977; Gautier et al., 1982). Considered in terms of its effects on the 
mechanical behaviour of the respiratory system, the increase in lung volume produced 
by hypoxia may counteract the contraction of the airway smooth muscle which, in 
isolation, would tend to increase lung recoil.
1.6.3.3.4 Hvpoxic depression of central ventilatory centres
Another factor which should be considered is the ability of hypoxia to depress the 
central neural systems that control ventilation (Lee & Milhom, 1975). If the 
bronchomotor-eentre, like the ventilatory control centre, is depressed by hypoxia, one 
would expect that, via this mechanism, hypoxia would reduce airway smooth muscle 
tone. Whether this effect occurs or not, or whether the level of the hypoxic stimulus in 
these studies is low enough to produce central depression, is unknown.
1.6.3.4 The effect of chronic hypoxia on airway smooth muscle tone in vivo 
The effects of chronic alveolar hypoxia on lung mechanics have not been well studied. 
Chronic hypoxia is associated with airflow limitation, possibly resulting from a 
structural encroachment of the airways by the thickened pulmonary arteries (Bancalari 
et al., 1977; De Troyer et al., 1977). Experimental studies, conducted almost 
exclusively in rats, have shown that sustained alveolar hypoxia during development 
causes an increase in the lung size, the number and size of alveolar spaces (Burri & 
Weibel, 1971; Mortola et al., 1986) and a decrease in total lung resistance (Okuba & 
Mortola, 1989). Furthermore, chronically hypoxic rats have more compliant lungs 
(Okuba & Mortola, 1989), possibly due to a decrease in elastic recoil generated by 
surface tension in the larger alveoli.
It is unclear how this relates to the response of humans to chronic hypoxia, since Brody 
et al (1977) found an increase in lung resistance in Andean natives. Furthermore, a 
more recent study in calves exposed to chronic hypoxia also found an increase in lung 
resistance (Inscore et a l, 1990), indicating that the effects of chronic hypoxia on lung 
mechanics remain to be established.
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1.6.4.1 Acute hypoxia
In addition to the rapid effect of hypoxia on airway tone, several authors have reported 
that hypoxia enhances bronchial reactivity to various spasmogens in vivo (Ahmed & 
Marchette, 1985; D'Brot & Ahmed, 1988; Vidruk & Sorkness, 1985). The mechanisms 
underlying this alteration in airway responsiveness are not well understood. For 
example, Vidruk and Sorkness (1985) demonstrated that histamine-induced reflex 
tracheal constriction in anaesthetized dogs was enhanced by hypoxia and that this 
response was abolished by denervation of the trachea. The authors proposed that the 
potentiating effect of hypoxia on reflex bronchoconstriction is caused by an interaction 
between lung sensory receptors (possibly rapidly adapting receptors or C-fibre 
receptors) and carotid body chemoreceptors (Vidruk & Sorkness, 1985). In contrast, 
Ahmed and co-workers suggest that hypoxia-induced bronchial hyperreactivity is due 
to local release of mediators which "prime" the airway smooth muscle. In support of 
this theory, sodium cromoglycate, a mast cell membrane-stabilizing agent, prevents 
hypoxia-induced degranulation of mast cells as well as enhancement of bronchial 
reactivity after hypoxia in awake sheep (Ahmed et al., 1982; Ahmed & Marchette, 
1985), suggesting a central role for mast cell mediators. Other studies implicate 
metabolites of arachidonic acid as being involved. For example, leukotriene C4
concentrations in broncheoalveolar lavage fluid have been shown to be elevated during 
alveolar hypoxia (Morganroth et al., 1984) and furthermore, a leukotriene antagonist 
abolishes hypoxia-induced airway hyperreactivity in sheep (D'Brot & Ahmed, 1988). A 
more recent study, however, showed that cyclooxygenase metabolites are not involved 
since indomethacin, a cyclooxygenase inhibitor, failed to attenuate the enhanced 
responsiveness (D'Brot & Ahmed, 1991). Thus it is possible that hypoxia stimulates the 
5-lipoxygenase-linked cascade without affecting the cyclooxygenase pathway. 
Interestingly, it appears that the hypoxic enhancement of airway reactivity is abolished 
by breathing a hyperoxic gas mixture. While hyperoxia per se has no effect on resting 
tone (Vidruk & Sorkness, 1985) or airway responsiveness (D'Brot & Ahmed, 1991), it 
attenuated the hypoxic-enhancement of reflex bronchoconstriction in dogs (Vidruk & 
Sorkness, 1985) and the hypoxic-enhancement of histamine and carbachol-mediated 
bronchoconstriction in sheep (D'Brot & Ahmed, 1991). The effect of hyperoxia on 
airway responsiveness in humans is unclear, with both an inhibition (Inoue et al., 1989) 
and lack of effect of hyperoxia on methacholine responsiveness being reported (Beckett 
& Wong, 1988).
1.6.4.2 Chronic hypoxia
To the best of my knowledge, only one study has examined the effect of chronic 
hypoxia on airway responsiveness. Inscore et al (1990) exposed neonatal calves to 14 
days of hypobaric hypoxia and subsequently measured airway responsiveness both in 
vivo and in vitro. Chronic hypoxia evoked a marked remodelling process in these 
animals, manifested as a significant increase in airway fibrous tissue and airway smooth 
muscle. Compared with control calves, however, responses to methacholine either in 
vivo or in vitro were not altered by chronic hypoxia, although contractility to potassium 
chloride was significantly increased in airways from hypoxic calves in vitro.
In contrast to the lack of study of chronic hypoxia on airway responsiveness, there are 
many reports, conducted almost exclusively on rats, concerning the effects of chronic 
hyperoxia on airway reactivity. Chronic exposure to hyperoxia results in airway 
hyperresponsiveness, both in vivo and in vitro, to contractile agents such as 5- 
hydroxytryptamine and methacholine (Szarek, 1989; Hershenson et al., 1992a and b). 
Most groups report that this increase in airway reactivity correlates closely with the 
thickening of the airway wall which develops in chronically hyperoxic rats (Hershenson 
et al., 1992a and b), indicating that airway remodelling is largely responsible for the 
airway hyperresponsiveness in these animals. More recently, however, Szarek et al 
(1995) showed that the development of airway hyperreactivity in chronically hyperoxic 
rats occurs before the remodelling process, suggesting that other mechanisms are also 
involved. Removal of the epithelial layer or treatment with indomethacin abolishes the 
hyperreactivity to acetylcholine in chronically hyperoxic rats (Hershenson et al., 1994), 
implying that epithelial-derived prostanoids may contribute to the hyperoxia-induced 
hyperresponsiveness in rats. In contrast, Burghardt et al (1996), found that a 5- 
lipoxygenase inhibitor prevented the development of airway hyperreactivity and airway 
remodelling in chronically hyperoxic rats, indicating a possible role for leukotrienes.
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1.6.5 SUMMARY
There is no doubt that the airways respond to acute and chronic changes in alveolar 
oxygen tension. The manner of the response is less well defined, partly due to the 
difficulty in interpreting the conflicting results from various studies. As stated above, it 
is technically very difficult to study the direct effect of hypoxia on airway function 
without altering other variables, for example CO2 levels, lung volumes, lung receptors
and airway reflexes, which may have a significant influence on the end response.
While there remains a fair amount of controversy among various groups, the majority 
of studies report that hypoxia inhibits contractility of airway smooth muscle in vitro, 
perhaps reflecting the direct effect of hypoxia on airway smooth muscle function, and 
dilates the upper airways in vivo. In contrast, hypoxia tends to induce 
bronchoconstriction in the lower airways, a response that would at first appear to be 
maladaptive in that it would increase resistance to airflow and hence, impair alveolar 
ventilation. This response, however, should be considered in terms of the overall 
response to hypoxia, an increase inrespiratory rate, which would elevate the airway 
transmural pressures. Thus, the bronchoconstrictor response to hypoxia is proposed to 
be an attempt to stiffen the airways and hence avoid dynamic compression.
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1.7 THE EFFECT OF HYPOXIA ON CELL PROLIFERATION
1.7.1 INTRODUCTION
As stated in section 1.5, excessive proliferation of airway smooth muscle cells leads to 
thickening of the airway wall and may contribute to airflow limitation. It is of obvious 
clinical relevance, therefore, to understand the physiological and pathophysiological 
factors which are involved in regulating mitogenesis. There is compelling evidence that 
the oxygen concentration in the surrounding environment has an important effect on 
cell proliferation.
Much of the work studying the effect of hypoxia on cell growth has been conducted 
upon pulmonary artery smooth muscle. This perhaps reflects the well defined response 
of the pulmonary arteries to hypoxia; namely an initial contraction followed by 
subsequent hypertrophy and hyperplasia (Hales, 1985). This remodelling process 
occurs in pulmonary hypertension, a clinical condition associated with sustained 
alveolar hypoxia.
Exposing animals, mainly rats or mice, to sustained hypoxia is the most commonly 
used model for pulmonary hypertension. Rats subjected to chronic hypoxia (either 
normobaric or hypobaric, see section 2.1.7.4) exhibit significant pulmonary 
hypertension and develop morphological changes in the pulmonary vascular bed that 
are similar to those observed in human pulmonary hypertension (Hislop & Reid, 1976; 
Rabinovitch et al., 1979).
1.7.2 THE EFFECT OF HYPOXIA ON THE MITOGENESIS OF PULMONARY 
CELLS
1.7.2.1 In vivo
The histological changes occurring in the pulmonary arterial wall in response to chronic 
hypoxia have been extensively described and several cell types appear to be involved. 
DNA synthesis by endothelial cells is detectable in the first 24 hours of hypoxic 
exposure (Meyrick & Reid, 1979), with hypertrophy and hyperplasia of these cells 
resulting in increased intimal thickness. In proximal pulmonary arteries, medial 
thickening caused by hypertrophy and hyperplasia of vascular smooth muscle occurs 
gradually and follows the early endothelial change (Meyrick & Reid, 1979), while in 
the distal pulmonary circulation, muscularization of previously nonmuscular vessels 
occurs. The ^ earliest and most dramatic hypoxic growth occurs in the adventitial 
fibroblasts, especially in resistance-sized vessels (Meyrick & Reid, 1979).
1.7.2.2 In vitro
In cultured endothelial cells, hypoxia induces the formation of several growth- 
promoting peptides (Shweiki et a l, 1992; Kourembanas et al., 1993), although 
proliferation of these cells has not been reported. In a similar manner, hypoxia does not 
stimulate proliferation of pulmonary vascular smooth muscle cells in vitro, indeed 
hypoxia may actually have an inhibitory effect in these cells (Dempsey et al., 1991). 
Only the fibroblast proliferates directly in response to hypoxia in vitro (Storch & 
Talley, 1988), indicating that the effects of hypoxia in vitro are cell type-specific.
1.7.2.3 Mechanisms by which hypoxia affects mitogenesis
While hypoxia induces proliferation of pulmonary vascular smooth muscle cells in 
vivo, it is apparently without effect in vitro. This suggests that hypoxia may alter 
proliferation of smooth muscle cells indirectly, possibly via removing inhibitory 
mechanisms, via effects on signal transduction pathways or via changes in growth 
factor expression.
1.7.2.3.1 Removal of inhibitory mechanisms
An elaborate network of proliferative and antiproliferative mechanisms is thought to 
exist for most cell types in vivo. Hypoxia may alter this balance by impairing 
mechanisms which attenuate proliferation. For example, vascular endothelial cells 
secrete heparin sulphates (Benitz et al., 1990) which directly inhibit smooth muscle and 
fibroblast growth (Castellot et al., 1989; Das et al., 1995). Release of this substance is 
attenuated by hypoxia (Benitz et al., 1990), therefore removal of this inhibitory 
influence may induce or facilitate proliferation.
1.7.2.3.2 Effects on signal transduction pathways
Many different effects of hypoxia on protein synthesis, transport mechanisms and 
signal transduction pathways have been described in vascular cells. These events do not 
lead directly to growth in isolated smooth muscle cells (Dempsey et al., 1991), but in 
other systems have been implicated in proliferative responses. For example, in 
pulmonary artery smooth muscle cells in vitro, hypoxia stimulates an increase in 
intracellular Ca2+ (Salvaterra & Goldman, 1993; Cornfield et al., 1994), stimulates 
translocation of PKC (Dempsey et al., 1996) and increases polyamine transport (Haven 
et al., 1992). Although none of these hypoxia-induced changes stimulate vascular cell 
growth directly, they may have indirect proliferative effects. Specifically, they may 
enhance responsiveness to other growth-promoting stimuli such as locally produced 
growth factors*
1.7.2.3.3 Changes in growth factor expression
Hypoxia has been shown to increase the expression of various growth factors, such as 
PDGF (Katayose et a l, 1993), insulin-like growth factor (Perkett et al., 1992) and ET-1 
(Stelzner et al., 1992), in whole lungs and also in isolated cells. To date, ET-1 is the 
mitogen most strongly implicated in the vascular remodelling found in chronic 
hypoxia-induced pulmonary hypertension (Bonvallet et al., 1994; Zamora et a l, 1993).
1.7.3 SYNERGY BETWEEN SIGNAL TRANSDUCTION PATHWAYS AND 
MITOGENS
Stimuli which activate complementary signalling pathways can combine to yield 
dramatically increased cell proliferation. In pulmonary artery smooth muscle cells, 
activation of PKC by basic fibroblast growth factor augments the mitogenic response to 
insulin-like growth factor (Dempsey et al., 1990). Furthermore, in human airway 
smooth muscle cells, epidermal growth factor-induced mitogenesis is potentiated by 
ET-1 (Panettieri etal., 1996). ^
Activated signalling pathways can also increase expression of growth factors that 
promote further growth (Shubeita et al., 1992). For example, ET-1 induces proliferation 
of rabbit airway smooth muscle by activating phospholipase A2 and thereby generating 
thromboxane A2 and LTD4 (Noveral et al., 1992; Panettieri et al., 1993). Similarly, 
prostaglandin mediators (thromboxane A2) and mitogens (angiotensin II) stimulate 
increased expression of specific complementary growth factors that lead to augmented 
growth (Ali et al., 1993; Delafontaine & Low, 1993). Synergy between signal 
transduction pathways and growth factors may be an important means of augmenting 
hypoxia-initiated cell growth.
1.7.4 THE EFFECT OF HYPOXIA ON THE PROLIFERATION OF AIRWAY 
SMOOTH MUSCLE CELLS
While the effect of chronic hypoxia on the proliferation of pulmonary vascular smooth 
muscle cells has been extensively studied, the effect on airway remodelling has 
received little attention. As stated in section 1.6.3.4, the mechanical airflow limitation 
associated with exposure to hypoxia has previously been assumed to be due to a 
structural encroachment of the airways by the thickened pulmonary arteries (Bancalari 
et a l, 1977r~Hordof et a l, 1977). Inscore et al (1990) showed that in neonatal calves 
exposed to chronic hypobaric hypoxia, the airway smooth muscle surrounding the 
terminal bronchioles and the large central airways was significantly thickened. This 
suggests that, in a manner similar to pulmonary arteries, chronic hypoxia induces
proliferation of airway smooth muscle in vivo, resulting in a remodelling process which 
may increase resistance to airflow.
1.7.5 THE EFFECT OF HYPEROXIA ON THE PROLIFERATION OF AIRWAY 
SMOOTH MUSCLE CELLS
In contrast to the paucity of data concerning the effect of chronic hypoxia on the 
proliferation of airway smooth muscle, there are many reports concerning the effects of 
chronic hyperoxia on this cellular response.
As stated in section 1.6.3.4, chronic alveolar hyperoxia induces remodelling of the 
respiratory tract in rats, characterized as a thickening of the airway smooth muscle and 
epithelial cell layers from the central conducting airways to the small peripheral 
airways (Hershenson et al., 1992). Hyperoxic exposure also causes airway constrictor 
hyperresponsiveness in these animals, the severity of which correlates with the severity 
of airway wall thickening (Hershenson et al., 1992). Thickening of the airway wall may 
theoretically arise from hyperplasiaf'hypertrophy or accumulation of collagen and 
elastin within the smooth muscle layer. Indeed, Hershenson et al (1994) have shown 
that hyperplasia of airway smooth muscle cells occurs in rats exposed to chronic 
hyperoxia and that this contributes to the remodelling process. In contrast, Absher et al 
(1994) found that hyperoxia inhibited proliferation of rat tracheal smooth muscle cells 
in culture, but induced a hypertrophic response in these cells.
1.7.5.1 Mechanisms underlying the effects of hyperoxia on airway smooth muscle
1.7.5.1.1 Growth factor release
The mechanisms underlying the potential effects of hyperoxia on airway remodelling 
have not been established, although several reports have implicated local release of 
growth factors such as PDGF. Chronic hyperoxia increases expression of PDGF B- 
chain mRNA in rat lungs (Fabisiak et al., 1989) and furthermore, Davis and colleagues 
(1983) found increased PDGF bioactivity in the broncheoalveolar lavage fluid from 
humans who inspired a hyperoxic gas mixture for up to 18 hours.
1.7.5.1.2 Reactive Oo species
Under hyperoxic conditions, reactive O2 species such as superoxide anion (O2"), 
hydrogen peroxide (H2O2) and hydroxyl radicals ( OH) are formed (Heffner & Repine,
1989). TheseTctive particles may* have potent effects on cell growth and have been 
reported to either inhibit (Libby et al., 1985) or to stimulate (Rao & Berk, 1992) 
proliferation in vascular smooth muscle. Delafontaine & Ku (1997) showed that 
reactive O2 species increase the synthesis and release of insulin-like growth factor I in 
cultured rat aortic smooth muscle cells, suggesting that O2 radicals may mediate their
cultured rat aortic smooth muscle cells, suggesting that O2 radicals may mediate their 
proliferative effects via the secondary release of mitogenic agents. A recent study, 
however, demonstrated that superoxide anion can mediate cell proliferation direcdy via 
activation of the ras/Raf-l/MEK/MAP kinase pathway (Bhunia et al., 1997).
1.7.6 THE EFFECT OF HYPOXIA ON GENE EXPRESSION
Within recent years, a number of genes have been identified that are regulated by 
oxygen tension. Most of our current understanding of the hypoxic regulation of gene 
control is derived from studies on erythropoietin (EPO). This protein hormone 
stimulates the production of red blood cells and is a crucial mechanism by which 
mammals respond to hypoxia. EPO mRNA and protein increase 10- to 100-fold in 
response to hypoxia (Goldberg et al., 1991), partly through increased transcription and 
partly through increased stability of mRNA (Rondon et al., 1991). A hypoxic 
responsive enhancer region exists in close proximity to the EPO gene (Semenza et al., 
199i f  and recent studies show that*a transcription factor, hypoxia-inducible factor 
(HIF-1), binds to this region (Semenza & Wang, 1992; Beck et al., 1993). Binding of 
HDF appears to be critical for activation of the enhancer region (Semenza et al., 1994), 
and hence gene transcription.
There are other nuclear transcriptional factors, such as AP-1 and NF-kB, which appear 
to be oxygen sensitive (Webster et al., 1994; Schenk et al., 1994), although 
involvement in hypoxia-induced gene expression is less well defined than HIF-1.
In spite of the wealth of information on the EPO gene, the initial steps in sensing 
oxygen tension and the intracellular elements that transduce the primary response to 
hypoxia remain unclear. At present, it is widely believed that the oxygen sensor is a 
haem-containing protein (Goldberg et al., 1988) that exists in two reversible 
conformational states, deoxy or oxy, depending upon the available oxygen tension. It is 
proposed that the haem-group might serve as a ligand that binds directly to transcription 
factors such as HIF-1, or alternatively, that haem may function as an oxygen sensor 
within the transcription factor itself (for review, see Pitt et al., 1996).
In addition to EPO, several other gene products, many involved in cell growth, have 
been shown to be elevated by hypoxia. Transcription of PDGF (Kourembanas et al.,
1990), ET-1 (Kourembanas et al., 1991), interleukin-8 (Karakurum et al., 1994), 
vascular endothelial cell growth factor (Shweiki et al., 1992) and transforming growth 
factor-pl (Falanga et al., 1991) is increased by hypoxia in various cell cultures. It is 
noteworthyThat several of these growth factors are increased in the lungs of hypoxic 
animals in situ (Elton et al., 1992; Katayose et al., 1993), suggesting that hypoxic- 
regulation of these, and other, gene products may contribute to the pathologies of 
various diseases associated with chronic hypoxia.
1.7.7 SUMMARY
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As stated in section 1.7.2, the reported effects of hypoxia on smooth muscle 
proliferation differ between in vitro and in vivo experiments. This is also the case for 
hyperoxia, with an inhibitory effect of hyperoxia on proliferation of rat airway smooth 
muscle cells in culture (Absher et al., 1994), compared to a stimulatory effect in vivo 
(Hershenson et al., 1994). This suggests that the effect of changes in gas composition 
on airway smooth muscle proliferation may be indirect and may involve other factors or 
cell types which cannot be mimicked by studying isolated airway smooth muscle cells 
in culture. This makes the task of elucidating the mechanisms of hypoxia- and 
hyperoxia-mediated airway remodelling all the more difficult
There appears to be a certain amount of confliction between the effects of hypoxia or 
hyperoxia on airway smooth muscle proliferation. On the one hand, hyperoxia induces 
proliferation of airway smooth muscle in rats in vivo, while chronic hypoxia also 
induces thickening of the airway smooth muscle layer, although in this case in calves 
(Inscore et al., 1990). The most obvious explanation is that this represents a species 
difference between rats and cows, although the findings that pulmonary hypertension 
can be induced in rats by either chronic hypoxia or hyperoxia (Coflesky et al., 1988), 
or that PDGF expression in rat lungs appears to be elevated by both hypoxia and 
hyperoxia is not consistent with this. It is possible therefore, that the two opposite ends 
of the spectrum, hypoxia and hyperoxia, produce the same end response, namely an 
increased proliferation of airway smooth muscle, although the mechanisms underlying 
this may be different in each case.
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1.5 AIMS OF PROJECT
The main points I wished to address with my research were to:
1) Study the effect of acute changes in oxygen tension on airway smooth muscle 
function. In the first instance, using bovine bronchial rings, I set out to examine the 
effect of changes in oxygen tension on the responsiveness of airway smooth muscle to 
contractile and relaxatory agonists.
2) Examine the effect of chronic exposure to hypoxia on airway smooth muscle 
responsiveness. I compared contractile and relaxatory responses using tracheal rings 
isolated from either control rats or rats exposed to chronic hypobaric hypoxia.
3) Compare and contrast endothelin receptor-mediated responses in tracheal rings from 
both chronically hypoxic and control rats and to characterise the endothelin receptor 
subtypes involved in mediating these-ffcsponses.
4) Examine the effect of hypoxia on the proliferation of cultured human airway smooth 
muscle cells and to determine if hypoxia alters the responsiveness of these cells to 
mitogenic agents.
5) Study the effect of changes in inspired oxygen tension on salbutamol-mediated 
bronchodilation and methacholine- and histamine-mediated bronchoconstriction in 
asthmatic patients in vivo.
6) Conduct a parallel study in vitro, examining the effect of changes in oxygen tension 
on salbutamol-, methacholine- and histamine-mediated response in human isolated 
bronchial rings.
CHAPTER 2
MATERIALS AND METHODS
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2.1 TECHNIQUES FOR STUDYING ISOLATED AIRWAYS
2.1.1 ORGAN BATH SET UP FOR STUDYING ISOLATED AIRWAY 
PREPARATIONS
Standard organ bath procedures were used for studying responses in isolated airway 
preparations in vitro. Figure 2.1 shows a schematic diagram of the organ bath set up. 
Rings of trachea or bronchus were suspended between two stainless steel wires. The 
lower wire was anchored to a glass tissue holder and the upper was connected by cotton 
to a force displacement transducer (Grass FT03T). Isometric contractions were recorded 
via a transducer connected to a 6-channel chart recorder (Linseis L2005). Each airway 
preparation was mounted in a 5 ml organ bath containing modified Krebs-Henseleit 
solution (see section 2.1.8 for composition). Appropriate tension was then placed on the 
vessels (see experimental chapters) and the Krebs-Henseleit solution was maintained at 
37± 0.5°C, by means of an insulating water jacket surrounding the bath. The Krebs- 
Henseleit solution was bubbled with an appropriate gas mixture (for exact gas details 
see section 2.1.5).
Pen recorder
bridge amplifier
isometric transducer
tissue holder cotton
thread
to water 
bath
ring segment o f tissue suspendended 
—  between two hooks
heated water to 37 C
heated Krebs Heinslet 
solution —
Figure 2.1.
Diagrammatic representation (not to scale) of the organ bath experimental apparatus used 
for studying larger diameter pulmonary arteries in vitro. Volume of the organ bath was 5 
ml, gas bubbling apparatus is not shown on diagram.
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2.1.2.1 Rat trachea
Rats were killed by overdose of sodium pentobarbitone (60 mg/kg i.p.) and the trachea 
removed and immediately placed in ice cold Krebs-Henseleit solution. The trachea was 
carefully cleaned of connective tissue using a dissecting microscope and cut into rings 
without damage to the epithelium. Each ring preparation was approximately 4mm long 
with an internal diameter (i.d.) of ~2mm. Each rat normally yielded 4 such tracheal ring 
preparations. Where appropriate, removal of the epithelium was achieved by gentle 
rubbing of the intimal surface. These vessels were then placed in a vial of ice cold 
Krebs-Henseleit solution in preparation for mounting in the organ baths (see section 
2 .1. 1).
2.1.2.2 Bovine bronchus
A lobe of bovine lung was placed on a dissecting tray with its visceral surface exposed. 
The main internal bronchus was identified and dissected free using large scissors. This 
exposed the branches of the next generation of bronchi. The branching pathway of this 
generation of bronchi was followed using fine scissors until an internal diameter of 
approximately 3-5mm was identified. This length of bronchus was then removed and 
cut into rings approximately 4mm long (i.d. 3-5mm) using sharp disposable blades. 
Each lobe of lung could yield more than 30 of these bronchial ring preparations. These 
bronchial rings were placed in a vial of ice cold Krebs-Henseleit solution. To avoid 
desiccation of the tissue during the course of the dissection, the tissue was regularly 
moistened with Krebs-Henseleit solution.
2.1.2.3 Human bronchus
The lung samples were placed in a petri dish containing Krebs-Henseleit solution. The 
size of the sample was very variable, but bronchi with internal diameters of 
approximately 3-5mm were identified and carefully dissected free using fine scissors or 
sharp disposable blades. The bronchus was cut into rings approximately 4mm long (i.d. 
3-5mm) and cleaned of surrounding connective tissue before being placed in a vial of 
ice cold Krebs-Henseleit solution.
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The transducers and chart recorders used in the organ bath set-up were calibrated daily 
using known weights (1 g wt). The temperature of the solution in the organ baths was 
routinely measured with a thermometer.
2.1.4 GENERAL PROCEDURE FOR ORGAN BATH EXPERIMENTS
The general procedure for in vitro organ bath studies is listed below, but varies between 
individual experiments. Exact procedures are therefore given in each experimental 
chapter.
1) After mounting the airway preparations in the organ bath and applying the 
appropriate degree of tone, vessels were allowed to equilibrate for 45 minutes. During 
this time, tension was reapplied where necessary.
2) The viability of the tissue was ascertained by the addition of a single concentration 
(10"4M) of methacholine to evoke P reference contractile response. Once the response 
reached a plateau, the vessels were than washed 3 times with fresh Krebs-Henseleit 
solution and allowed to return to baseline tensions.
3) Tension was adjusted if necessary and the vessels were left for a further 45 minutes 
before the addition of any drugs.
4) A cumulative concentration-response curve (CCRC) was then conducted to the 
required agonist covering a range of concentrations which ensured that the threshold 
response and the maximum response (if possible) were included.
5) For agonists which reversibly bind to their receptor, vessels were washed 3 times 
with fresh Krebs-Henseleit solution following the initial CCRC. Tissues were left for 
45 minutes to allow the tension to return to baseline levels and the antagonist/inhibitor 
was added and left for its required incubation period. Following this, a second CCRC to 
the agonist was conducted. On each experimental day, one tissue acted as a time control 
in that the second CCRC was conducted without the addition of the 
antagonist/inhibitor.
For agonists which irreversibly bind to their receptors, only one CCRC could be 
conducted in each preparation. In such cases, separate tissues were used to perform 
experiments using antagonists/inhibitors. In such experiments, the antagonist/inhibitor 
was added 45 minutes after the methacholine response and left for its required 
incubation period before the CCRC was performed.
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The standard gas mixture used for in vitro studies of isolated tissues is 95% 02/5% 
CO2. This hyperoxic gas mixture was originally chosen to prevent areas of the tissue 
becoming hypoxic. 5% CO2 is included to buffer the pH of the Krebs-Henseleit 
solution to 7.4. On certain experimental occasions, the O2 content of the perfusing gas 
mixture was reduced from 95% to 20% or 0% O2, by substituting N2 for O2. Bubbling
the Krebs-Henseleit solution in the organ baths with gas mixtures containing 95, 20 or 
0% O2 gave final bath O2 tensions of 520-525mm Hg, 142-145mmHg and 24- 
28mmHg, respectively. The O2 tension in each organ bath was measured by means of a 
Jencons O2 probe placed directly in the Krebs-Henseleit solution. In each of the 
experimental gas mixtures, 5% CO2 was included to buffer the pH to 7.4. The pH in 
each organ bath was measured using a Mettler pH meter and remained within ±0.1 of 
pH 7.4.
2.1.6 NOTES ON ET RECEPTOR AGONISTS
CCRCs conducted to the ET receptor agonists ET-1 and sarafotoxin S6c were normally 
taken to a maximum concentration of 3xl0 '7M. Addition of this final concentration, 
however, often produced a further contractile response and can therefore not strictly be 
considered "maximal." The two reasons for not increasing the concentrations of agonist 
further are that: (l)The relative solubility of the peptide yields a stock solution of 10' 
4M therefore a large volume of stock solution must be added to 5ml baths to give final 
concentrations of 10-6M and (2) ETrl and sarafotoxin S6c are extremely expensive and 
we therefore could not afford to use large volumes of stock solution.
2.1.7 ANIMAL MODELS USED IN THESE STUDIES
As human tissue was only available in limited amounts, it was necessary to use tissue 
from various animal models.
2.1.7.1 Bovine
Bovine bronchial rings were used in some experiments as this tissue is reported as 
being a good model for human bronchi (for example, see Nally et al., 1994b; Angus et 
al., 1994). Bovine lungs were obtained on the day of experimentation from the local 
abattoirs (either Duke St., Glasgow or Sandyford, Paisley). Lungs were removed from 
freshly slaughtered cattle and were transported to the laboratory in a container filled 
with chilled Krebs-Henseleit solution.
2.1.7.2 Human
Whenever possible, studies were carried out using human bronchial tissue. 
Macroscopically normal sections of human lung were obtained from patients 
undergoing thoracic surgery at the Western Infirmary, Glasgow for bronchial 
carcinoma. Samples were placed in chilled Krebs-Henseleit solution as soon as possible 
(normally less than 15 minutes after being removed from the patient) and taken to the 
laboratory for dissection (see section 2.1.2.3). Human tissue was normally utilised as 
soon as possible after dissection, but in some cases was stored overnight in Krebs- 
Henseleit solution at 4°C. Published data has shown that overnight storage of this tissue 
does not alter its reactivity to contractile and relaxant agonists (Brink et al., 1980; Nally 
et al., 1994a). Details of individual patient histories are not known.
2.1.7.3 "In House" adult Wistar rat.
The adult Wistar rat from the "In House" breeding stock of the University of Glasgow's 
Central Animal Facility was used in several studies. The Wistar rat was used to produce 
the chronically hypoxic rat model (see section 2.1.7.4) and also acted as controls for the 
chronically hypoxic rats. Animals v^re maintained on a twelve hour light/dark cycle 
and allowed free access to standard diet and water.
2.1.7.4 Chronic hypobaric hypoxic rat
2.1.7.4.1 Introduction
Hypoxic animal models (mainly rats and mice) have been used since the 1920's to study 
various environmental conditions and disease states. The animals were exposed to 
hypoxic environments by the use of environmental chambers (normobaric hypoxia; a 
decreased inspired O2 at normal atmospheric pressure, or hypobaric hypoxia; a 
decreased inspired O2 due to decreased atmospheric pressure) or by actual relocation of 
the animals to altitude where the inspired O2 levels are lower than at sea level (see
Campbell, 1927a,b,c; Timiras et al., 1957). These early investigations studied the 
acclimatisation of animals to altitude, or the O2 tensions which would be experienced at
altitude. Animals exposed to these hypoxic environments exhibited initial weight loss 
and alterations in certain internal organ weights (Campbell, 1935; Timiras et al., 1957). 
The basic principles of normobaric and hypobaric hypoxia are described below.
2.1.7.4.2 Normobaric versus Hypobaric hvpoxia 
Normobaric hypoxia
The normobaric method of chronic hypoxia used by most investigators has been 
adapted from a chamber described by Cryer and Bartley (1974). The O2 concentration
within the chamber is reduced from the normal 21% to -10% (160mm Hg to ~80mm 
Hg O2) by intermittent infusion of N2. To prevent the build up of CO2, humidity and
other gases, the air is circulated through specific chemical absorbers.
Hypobaric hypoxia
Hypobaric hypoxia reduces the inspired O2 content of the environment by reducing the 
atmospheric pressure within the chamber. This is the equivalent of taking the animals to 
high altitude. As the atmospheric pressure decreases, the partial pressure of the gaseous 
components of air decreases. Therefore, while the percentage of the gaseous 
components of the air remains the same (O2 -  21% and N2 -  78%), the effective partial 
pressure of inspired O2 declines. Hypobaric hypoxia is achieved by withdrawing air
from the chamber by use of a pump until the pressure within the chamber is equivalent 
to -0.5 atmospheres, which reduces the inspired O2 pressure from 160mm Hg to 80mm
Hg. The chamber is continuously flushed with room air to maintain conditions of low 
humidity and CO2.
While normobaric and hypobaric chambers are both commonly used (mainly for the 
study of pulmonary hypertension), the hypoxic hypobaric chamber has proved to be 
more economical and it is this type which was used in my studies. The Royal 
Hallamshire Hospital Sheffield designed and manufactured the hypoxic hypobaric 
chamber for Dr Margaret MacLean and her Pulmonary Research Group based in the 
Institute of Biomedical and Life Sciences at the University of Glasgow. The chamber 
conforms to the high safety standards required by the Home Office.
2.1.7.4.3 Chamber Design
The chamber is designed to hold two standard rat cages, with up to four rats in each 
cage. The structure of the chamber is made from transparent high resistance Plexiglass. 
Air is continually removed from the chamber by the pump. Air constantly flows 
through the chamber at 45L/minute, ensuring that moisture and CO2 do not build up.
Temperatures are similar both inside and outside of the chamber.
2.1.7.4.4 Maintenance of animals
The chamber was housed in a specially designed environmental room which maintains 
temperatureUt approximately 21°C, humidity at 55%, gives 20 changes of filtered air 
per hour and maintains a 12 hour on/12 hour off light cycle. Animals used in the 
experiments were obtained from credited commercial suppliers, Harlan UK Ltd. The 
rats supplied were male specific pathogen free and ordered in at age 28-30 days 
(approximately 60g weight). Animals were allowed to acclimatise within the
environmental chamber for five days before being split into two groups of four. One 
group of animals was placed in the chamber and the other group remained in normal 
atmospheric conditions to act as age matched controls.
2.1.7.4.5 Production and maintenance of chronic hvpoxic rats
(1) The chamber door was removed and the rat cage placed in the chamber with the 
food and water dispensers at the rear, thus allowing observation of the rats.
(2) The chamber door was replaced and the pump switched on.
(3) The chamber was taken down to the desired pressure (550mbar) in small steps by 
slowly closing the inlet valve and observing the pressure reading on the gauge. Once 
the stable experimental pressure was reached, rats were checked every 15 minutes for 
the following hour to ensure that the pressure remained stable and the animals were not 
in distress.
(4) The chamber could then be left to run for the experimental time required. Checks 
were made five times a day to ensure th a t:
(a) pressure readings were not fluctuating beyond desired levels
(b) temperature inside and outside th6 chamber remained between 20 and 23 °C
(c) animals were not showing signs of distress
(d) the pump was in good operating condition
(5) At weekends, the chamber was checked by a member of the Central Animal Facility 
staff, University of Glasgow.
(6) When the animals required fresh diet and water, usually every three days, the 
chamber was taken down to atmospheric pressure over two hours by opening the inlet 
valve. Once atmospheric pressure was reached, the pump was switched off and allowed 
to cool for half an hour while the rat cages were cleaned and animals given fresh food 
and water. Following this, the animals were placed back in the chamber, the pump 
switched on and the chamber taken back to 550mbar over a period of two hours.
(7) After 14 days in the chamber, two of the rats were removed and the remaining two 
rats were taken back to experimental pressure for a further two days. Of the two rats 
removed, one was immediately sacrificed and studied on that day along with an aged 
matched control. The second rat was left in room air to be studied no longer than 24 
hours after removal from the chamber. The same procedure occurred on day 16 for the 
remaining two rats.
2.1.8 MATERIALS AND SOLUTIONS
The composition of the Krebs-Henseleit solution was as follows: (mM) NaCl 118.4, 
KC1 4.7, CaCl2 2.5, M gS04 1.2, NaHCCb 24.9, KH2P 0 4 1.2 and glucose 11.1.
The following drugs and chemical reagents were used:
COMPOUND SUPPLIER
ANP Bachem
(a-human atrial natriuretic peptide 28 amino acid)
BQ-788 Peptide international
(4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-
(2-methoxy-phenoxy)-2,2I-bipyrimidin-4-yl]
-benzenesulphonamide)
Endothelin-1 Novabiochem
FR 139317 Neosystems
(N-CO-L-Leu-D-1 -Me-Trp-D-3 
(2-Pyridyl) Ala-OH
Histamine Sigma
Isosorbide dinitrate Schwarz Pharma Ltd.
("Isoket")
Indomethacin Sigma
L-NAME Sigma
(N^-nitro-L-arginine methylester)
methacholine chloride Sigma
Phosphoramidon Sigma
(N-(a-rhamnopyranosyloxyhydroxy
phosphinyl)-L-leucyl-L-tryptophan
potassium chloride BDH
salbutamol Sigma
Sarafotoxin S6c Sigma
SB 209670 Gift
(1 S,2R,3S^3-(2-carboxymethoxy-4- 
methoxyphenyl)-1 -(3,4-methyleudioxy-phenyl)
-5-(propyl- l-oxylindane-2-carboxylic acid)
sodium nitroprusside Sigma
2.1.9 DATA ANALYSIS
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2.1.9.1 Calculation of results
For measurements of isometric tension, data from preparations undergoing the same 
procedure were grouped together and expressed as the mean value ± the standard error 
of the mean (SEM). Data may be expressed as absolute contraction (mg wt), percentage 
of reference contraction to 10'4M methacholine or as a percentage of its own maximum 
response (see experimental chapters).
2.1.9.2 Measurement of agonist potency
Values are given as the pD2, the -log of the concentration of an agonist which produces 
50% of the maximum response to that agonist. In cases where a maximum response 
was not achieved, values for the pEC200mg or pEC400mg are given, the -log of the 
concentration of an agonist which produces a response of 200mg wt or 400mg wt, 
respectively.
2.1.9.3 Statistical Analysis
Statistical comparisons between data points was made using Students t-test for paired or 
unpaired data where appropriate. Comparisons between data sets was tested by two- 
way analysis of variance (ANOVA). A value of P<0.05 was considered to be 
statistically significant
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MUSCLE CELLS
2.2.1 PRIMARY CULTURE OF HUMAN AIRWAY SMOOTH MUSCLE CELLS
Human airway smooth muscle cells were harvested from bronchial segments obtained 
from thoracic surgery. Each segment was cleaned of adhering parenchyma, minced and 
resuspended in 10ml of serum free Dulbecco's Modified Eagle's Medium (DMEM, see 
section 2.2.6) containing 5mg/ml collagenase and 1 mg/ml elastase. Enzymatic 
dissociation of the tissue was performed for 120 minutes in a shaking water bath at 
37°C. Cells were collected by centrifugation (5 minutes, 200g, room temperature), 
washed in 10ml of DMEM supplemented with 20% foetal calf serum (FCS) and seeded 
in two 25 cm2 culture flasks (5ml into each flask). The flasks were labelled with the 
date and kept in a humidified LEEC incubator (model number GA 25N) under an 
atmosphere of 5% CO2 (to buffer the pH of the media to 7.4) and a temperature of
37°C.
Confluency (the cells covering the lower surface of the flask) normally occurred within 
7-10 days. At this stage, cells were passaged and reseeded in 75 cm2 culture flasks.
2.2.2 CELL PASSAGE
Under sterile conditions (within a Microflow laminar-flow hood, model number 
M25121/1), the media in each 25cm2 flask was aspirated off. The cells were washed 
twice with 2ml trypsin (0.25% trypsin (w/v) in phosphate buffered saline (see section 
2.2.6)) which was immediately aspirated off. The cells were incubated at 37°C for 3-4 
minutes until the cells were seen to have lifted off the bottom of the flask. The cells 
were suspended in 10ml of DMEM supplemented with 10% FCS and transferred to a 
75 cm2 flask. Thereafter, cells were harvested weekly and passaged at a ratio of 1:3 in 
75 cm2 culture flasks. Cells between passage 3 and 7 were used as published data 
shows that over these intervals, they retain their native contractile protein expression 
(Panettieri et al.t 1989).
102
2.2.3 IMMUNOCYTOCHEMISTRY
The identity of the bronchial smooth muscle cells was confirmed by 
immunocytochemical staining using a smooth muscle specific a-actin mouse 
monoclonal antibody (DAKOM635) detected using rabbit anti-mouse HRP-linked 
antibody and 3-amino 9-ethyl-carbazole (Sigma). Cells were subcultured into 8-well 
glass tissue culture chamber slides and grown to 100% confluency before being washed 
three times in phosphate buffered saline. The cells were permeabilized for 5 minutes 
with cold methanol (-20°C) and washed a further three times in phosphate buffered 
saline. This was followed by exposure to the primary antibody (a-actin mouse 
antibody) for 1 hour at room temperature and then the second antibody (anti-mouse 
antibody conjugated to fluorescein isothiocyanate) for 1 hour at room temperature. The 
staining of these cells was then observed by fluorescence microscopy. Each of the cell 
lines used in these studies showed uniform staining for smooth muscle specific a-actin.
2.2.4 ASSESSMENT OF CELL PROLIFERATION
2.2.4.1 Introduction
Cell proliferation is a process fundamental to growth, development, adaptation to 
disease and neoplasia. Assessing proliferation is often a pivotal investigation in 
biomedical science and a range of techniques have evolved to quantify the process, 
both directly and indirectly.
2.2.4.2 The cell cycle
The concept of the cell cycle is central to cell proliferation. Recognition of the synthetic
(S) phase, a period of intense DNA synthesis, combined with the mitotic (M) phase as 
two landmarks separated by two gaps led to the model of the cell cycle shown in Figure 
2.2. M phase is followed by Gi, the post-mitotic gap, and S phase is followed by the 
post-synthetic gap G2, which is in turn followed by a further M phase in progressively
proliferating tissue. Cells not actively proliferating can temporarily occupy a fifth phase 
(Gq) after M phase but, with appropriate stimuli, may be recruited to re-enter the cycle.
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Figure 2.2
Cell growth can be conceptualised as occurring in distinct phases; the mitotic M phase 
and the synthetic S phase, each divided by a Gap phase (G1 or G2). Cells may 
temporarily occupy an additional GO, or "resting phase."
2.2.4.3 Assessment of DNA synthesis
In general, these techniques measure the assimilation of radiolabelled nucleotides such 
as [3H] thymidine into newly synthesized DNA. Thymidine is commonly used as it is 
not incorporated into RNA. Most tissue cultures comprise cells at various stages of the 
cell cycle, so cells are typically growth-arrested in serum-free media. This synchronises 
cells to the Go/Gi phase of the cell cycle in which cells minimally incorporate [3H]
thymidine (Panettieri eta l., 1989).
There are a number of potential drawbacks in relating [3H] thymidine uptake to DNA 
synthesis: Firstly, although most DNA synthesis occurs during cell replication, some of 
the DNA synthesis may be for ungoing reparative processes rather than for 
proliferation,.Secondly, [3H] may. be incorporated into cellular macromolecules other 
than DNA, such as RNA and lipids. Despite these potential artefacts, measuring uptake 
of [3H] thymidine remains one of the best and most widely used methods for assessing 
cell proliferation.
2.2.4.4 [3H] Thymidine Incorporation Assay Used in Current Studies
Cells were grown to 60% confluency in 24 well plates and growth-arrested for 24 hours 
in serum free DMEM (see section 2.2.4.3). Cells were then stimulated with appropriate 
agonists and incubated for 24 hours, either in a normal CO2 incubator (5% CO2) or in a 
LEEC variable O2 flow incubator (model number GA 156). In the variable O2 flow 
incubator, the O2 content of the atmosphere was reduced from 21% to 2% by flooding 
with N2. Using a Jencons oxygen probe placed in the media inside the chamber, the O2 
tension of the culture medium under an environmental O2 tension of 2% was estimated 
to be between 26 and 32mm Hg. In both normoxic and hypoxic incubators, 5% CO2 
was included to buffer the pH of the media to 7.4. Using a Mettler pH probe, the media 
from both the normoxic and hypoxic incubators was measured and found to be pH 
7.4±0.1
For the remaining 4 hours of agonist stimulation (20 hours after addition of agonist), 
cells were labelled with [3H] thymidine (O.lpCi/ml) to give an indication of DNA 
synthesis and hence, cell proliferation. The reaction was stopped by washing the cells 
twice in phosphate buffered saline. Proteins were precipitated by washing three times in 
5% trichloroacetic acid and lipid fractions were solubilised by washing twice in 90% 
ethanol before the remaining cell contents were solubilised by a 30 min incubation in 
0.3M NaOH. The contents of each well were transferred to scintillation vials, to each of 
which was added 3mls of Ecosint A scintillation fluid. Vials were vortexed thoroughly 
before radioactive counts were measured by scintillation counter. Results are expressed 
as disintegrations per minute (DPM).
2.2.5 NOTE ON STERILITY
Since the conditions (warm, humid and nutrient rich) necessary for culturing the cells 
are an ideal environment for promoting fungal and bacterial growth, extreme caution 
must be taken to avoid contamination. All steps such as making up solutions, changing 
media etc must be conducted under sterile conditions, that is, within a clean, laminar 
flow hood. The laminar flow hood was dismantled and cleaned regularly and before use 
each day was sprayed liberally with 70% (w/v) ethanol. Anything taken inside the flow 
hood (i.e. pipettes and reagent bottles) was also sprayed with ethanol and sterile gloves 
were worn throughout: Pipette tips and distilled water were sterilised using a Prestige 
Medical "Omega" autoclave (model number 220140). To avoid bacterial or fungal 
contamination of the culture medium, the DMEM was supplemented with 
penicillin/streptomycin at concentrations of 400iu/ml and 400p.g/ml, respectively and 
2.5}ig/ml oHrmphotericine B. For the initial primary culture, these concentrations of 
penicillin/streptomycin and amphotericine B were doubled.
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2.2.6 MATERIALS AND SOLUTIONS
All general purpose compounds were purchased from Sigma (Poole, Dorset, UK). All 
tissue culture flasks and media were purchased from Gibco (Paisley, Renfrewshire, 
UK). Fetal calf serum was purchased from Imperial Laboratories (Andover, Hants, 
UK). Antibodies were purchased from Affiniti Research Products Ltd. (Nottingham). 
[3H] thymidine was purchased from DuPont (Stevenage, Hertfordshire, UK).
The cell culture media was composed of Dulbecco's Modified Eagles Medium 
(DMEM) supplemented with L-glutamine (27mg/ml), penicillin/streptomycin and 
amphotericine B (see section 2.2.5 for concentrations) and either 10 % or 20% fetal calf 
serum (see sections 2.2.1 and 2.2.2).
Phosphate buffered saline was composed of lOOmM NaCl and 20mM NaH2PC>4 and 
buffered to pH 7.4.
Drugs used in these cell culture experiments were:
BQ-123 Peptide International
(cyclo[D-Trp-D-Asp-L-Pro-D-Val-L-Leu])
BQ-788 Peptide International
(4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-
(2-methoxy-phenoxy)-2,2'-bipyrimidin-4-yl]
-benzenesulphonamide)
Endothelin-1 Novabiochem
Platelet-derived Growth Factor Sigma
Sarafotoxin S6c Sigma
Staurosporine Sigma
2.2.7 STATISTICS AND DATA ANALYSIS
Proliferation assays were carried out in quadruplicate and in three cell lines derived 
from lung specimens from three individual patients. Results are expressed as mean 
values ± s.e.means for n=3 cell lines. Statistical significance between individual data 
points was assessed using Student's t test, while comparisons between data sets 
(concentration-response curves) was assessed by two way analysis of variance
(ANOVA). In each case, a probability level of P<0.05 was considered to be statistically ^  
significant.
2.3 STUDIES CONDUCTED UPON HUMAN SUBJECTS IN  VIVO
2.3.1 RECRUITMENT
Asthmatic subjects were recruited into the study from databases held by the Asthma 
Research group, West Glasgow Hospitals University NHS Trust (see experimental 
chapters for precise details on group sizes, age range etc). The medical history of each 
patient was recorded, i.e smoker or non-smoker, bronchodilator therapy etc. All 
subjects gave informed written consent to the studies, which had the approval of the 
West ethics committee.
2.3.2 STUDY DESIGN
Protocols differed for the various studies (see experimental chapters), but a general 
protocol is listed below:
(1) At an initial screening visit, subjects performed baseline spirometry (see section 
2.3.3.2), and underwent a bronchial provocation test to measure the responsiveness of 
the airways to the appropriate agonist (i.e salbutamol, methacholine or histamine). If 
the patients displayed airway responses within certain predetermined limits they were 
deemed eligible for the study.
(2) On study days, subjects using bronchodilator therapies were asked to discontinue 
inhaled p2 agonists for 8 hours, salmeterol for 24 hours and oral theophyllines for 48
hours prior to attendance. Subjects using inhaled corticosteroids were asked to continue 
their medication as normal. All subjects were asked to refrain from caffeine containing 
products for 8 hours before each study.
(3) On study days, subjects were rested in a supine position for 30 minutes following 
which the patients were connected to closed breathing circuit. After a 10 minute period 
breathing air through the closed breathing circuit, baseline measurements of FEV i (see 
section 2.3.3.2), oxygen saturation (Sa02%), heart rate (HR), respiratory rate (RR), 
inspired oxygen and carbon dioxide levels (insp 02%, insp C02%) and end-tidal 
oxygen and carbon dioxide levels (pET02%, pETC02%) were made.
(4) Patients then received the study gas (Fi02 1.0, Fi02 0.21 or Fi02 0.15) for the 
remainder of the experimental protocol. All gases were administered in a randomised, 
double-blincTfashion by a second operator, fen  minutes after commencing the study 
gas for that day the measurements made at baseline were repeated. Subsequently at 
fifteen minute intervals, in a randomised double-blind fashion, patients received 
incremental doses of the appropriate agonist delivered via a nebuliser. Control subjects 
received nebulised saline. The MicroCirrus nebuliser was driven by the experimental
gas mixtures at a predetermined flow rate to produce a nebuliser output of 0.13 
mls/min. Measurements were repeated thirteen minutes after each nebulisation until 
completion of the study day.
2.3.3 MEASUREMENTS
2.3.3.1 Heart rate, SaC>2, inspired and expired O2 and CO2 levels
Heart rate and oxygen saturation were measured using a pulse oximetry probe (Datex 
Division of Instrumentarium Corp, Helsinki, Finland). A side port on the face mask 
allowed continuous sampling of the inspired and expired gases and monitoring of 
respiratory rate. The gases were continuously analysed using an OSCARoxy TM 
multigas monitor (Datex Instrumentarium Corp, Helsinki, Finland). Recordings were 
made every ten seconds for one minute and automatically printed by a Hewlett Packard 
Think Jet printer in a blind fashion. Results were analysed after completion of the 
study.
2.3.3.2TEVi ~=*
Due to the practical problems of measuring airway calibre in vivo, changes in airway 
radius are normally assessed indirectly, for example by measuring resistance to airflow. 
The physiological meaning of total airways resistance is obscured by the complexity of 
the branching system of the airways. The resistance to airflow is reported to be greatest 
in the upper airways of the nose and larynx, which accounts for approximately half of 
the airways resistance. The trachea and major bronchi are believed to contribute 30% of 
the total resistance, with only 20% being sited in airways smaller than 2mm in diameter 
(Macklem & Mead, 1967). These early estimates may be too low (Hoppin et al., 1978), 
but it is known that peripheral resistance is much higher in patients with chronic airflow 
obstruction (Hogg et al., 1968).
The most accurate measure of airways resistance is whole body plethysmography, but 
for reasons of cost, time and ease, the most widely used method for measuring airflow 
is spirometry. Simply, a patient exhales forcibly to residual volume after a full 
inspiration to total lung capacity. The ratio of the forced expiratory volume 1 (FEVi),
the volume expired in the first 1 second of forced expiration, to the vital capacity is an 
important indicator of airways obstruction. Comparison of these measurements to tables 
of predicted values gives an important indication as to whether the airways are patent or 
narrowed. The measurements of FEV1 and vital capacity are highly reproducible and
normally forrrrthe starting point for any investigation of lung function.
In our studies, FEVi was measured using a dry wedge spirometer (Vitalograph S,
Vitalograph, Buckingham, UK). The best of three attempts was taken for analysis.
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2.3.3.3 Plasma catecholamines
In some of the in vivo studies, plasma catecholamine levels were measured. Five 
millilitre aliquots of venous blood were collected into lithium heparin tubes, stored on 
ice and spun within 90 minutes. Adrenaline and noradrenaline were later measured by 
radioenzymatic assay (Goldstein et al., 1981) with both interassay and intra-assay 
variations of less than 10%.
2.3.4 OXYGEN BREATHING CIRCUIT
Study gases were generated by passing oxygen (G size cylinders 3400 litre capacity 
from British Oxygen Corporation, Medical Gases) and nitrogen (British Oxygen 
Corporation, Medical gases) contained in separate cylinders through a Quantiflex 
air/oxygen flowmixer (model A-O, Cyprane Ltd, Keighley, Yorkshire) which was 
connected via elephant tubing to a calibrated flow head and a five litre rebreathing bag. 
Elephant tubing then ran from the rebreathing bag to a two way breathing valve 
attached to an aircraft face mask (Thomas Respiratory Systems, London) from which 
the patient inspired the desired oxygen tension throughout the study day.
2.3.5 STATISTICAL ANALYSIS
For the in vivo studies, analysis of Variance (ANOVA) corrected for multiple 
comparisons was used to compare measurements made at baseline and following each 
dose of nebulised saline or agonist between study days.
2.3.6 DRUGS AND SOLUTIONS
The solutions of salbutamol, methacholine, histamine and saline were made up by the 
sterile unit of our pharmacy department, West Glasgow Hospitals University NHS 
Trust.
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CHAPTER 3
THE EFFECT OF ACUTE CHANGES IN OXYGEN 
TENSION ON THE RESPONSIVENESS OF BOVINE 
ISOLATED BRONCHI TO CONTRACTILE AND 
RELAXATORY AGONISTS
t
1
3.1 INTRODUCTION 110
As stated in section 1.6, acute hypoxia impairs active tension generation in isolated 
airway preparations (Fernandes et a l, 1993). In contrast, hypoxia appears to enhance 
bronchial reactivity to spasmogens in animals in vivo. For example, bronchoconstrictor 
responses to agonists such as histamine in dogs (Vidruk & Sorkness, 1985) and 
carbachol and histamine in sheep (Ahmed & Marchette, 1985; D'Brot & Ahmed, 1988) 
are enhanced after acute exposure to hypoxia. Less is known, however, regarding the 
effect of acute hypoxia on airway reactivity in vitro.
In this study, we measured, in bovine isolated bronchial ring preparations, responses 
evoked by the standard bronchoconstrictor methacholine, a stable analogue of 
acetylcholine. Responses were measured in three different oxygen tensions, generated 
by perfusing the bathing medium with gas mixtures containing oxygen concentrations 
of 95% (hyperoxia), 20% (approximately normoxia) and 0% (hypoxia).
While most interest has concentrated upon the effect of oxygen tension on spasmogen- 
evoked responses in airway smooth muscle, the effect on bronchodilators has not 
received sufficient study. When investigating the effectiveness of a bronchodilator, two 
aspects of its performance are important: (l)the ability to relax tissue pre-constricted by 
a spasmogen and (2)the ability to protect against subsequent challenge with a 
bronchoconstrictor.
In this study, we compared the ability of four drugs to reverse methacholine-induced 
tone and also to confer protection against subsequent challenge with this agonist in 
hyperoxia, normoxia and hypoxia. The drugs used; salbutamol, atrial natriuretic 
peptide, sodium nitroprusside and isosorbide dinitrate were selected on the basis of 
their postulated mechanisms of action. Salbutamol, a 62-adrenoceptor agonist, is
thought to act via stimulation of adenylyl cyclase leading to elevation of cAMP (Rinard 
et al., 1983) as well as via K+ channel opening (Miura et al., 1992), while atrial 
natriuretic peptide evokes a rise in cyclic guanosine monophosphate (cGMP) via 
stimulation of particulate guanylyl cyclase (Ishii & Murad, 1989). Sodium nitroprusside 
and isosorbide dinitrate also induce an elevation in cGMP levels, in this case via 
stimulation of soluble guanylyl cyclase (Ignarro & Kadowitz, 1985; Feelisch & Novak, 
1987).
We therefore sought to examine if changes in oxygen tension altered the effectiveness 
of the drugs used in this study and if each of the drugs was affected to a similar degree.
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3.2.1 Tissue Collection And Preparation
Rings of bovine bronchi were prepared and mounted in vertical organ baths as 
described in section 2.1.1.
3.2.2 Measurement Of Isometric Responses
Initial experiments (see section 3.3.1) indicated that the optimal level of applied tension 
in this tissue was 2g wt. In all subsequent experiments using bovine bronchial rings, 
therefore, a resting tension of 2g wt was applied. Tissues were allowed to equilibrate 
for 45 minutes, during which time tension was reapplied where necessary. The 
concentration of O2 in the gas mixture was reduced from 95% to 20% or 0% by 
substituting O2 with nitrogen. The oxygen tension of the solution was measured 
directly using a Jencons oxygen probe placed in the organ bath. Concentrations of O2
reached steady state in the organ baths within 2-3 minutes. Gas mixtures containing 
95%, 20% and 0% O2, produced O2 tensions of 524, 147 and 26 mm Hg, respectively. 
The pH was buffered to 7.4 by the inclusion of 5% CO2. A Mettler pH meter was used 
to measure the pH of the solution in the organ baths. Lowering the oxygen tension from 
95% to either 20 or 0% evoked a marked reduction in applied tension. Tension was 
reapplied until a stable baseline of approximately 2.0g wt was achieved.
3.23 Experimental protocol
3.2.3.1 Optimisation of applied resting tension
Under hyperoxic conditions, an initial resting tension of 0.5g wt was applied to each 
bronchial ring. Tissues were allowed to equilibrate for 15 minutes before addition of a 
single concentration of methacholine (10“4M). This concentration was chosen as it 
evoked a near maximal contractile response. When the contraction had reached a 
plateau, the tissues were washed three times with fresh Krebs-Henseleit solution over a 
15 min period, or until the tension returned to baseline. Tension was then removed 
before increasing the degree of initial tension to the next increment (l.Og wt).
3.2.3.2 Contractile responses to methacholine
Cumulative concentration-response curves to methacholine (10_9-3xl0_4M) were 
constructed in each of the O2 tensions. Results are expressed both as a % of the 
maximum response in 95% O2 arid also in absolute terms (mg wt).
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3.2.3.3 Reversal of methacholine-induced tone
To study the effect of O2 tension on responses evoked by the bronchodilators, tissues 
were preconstricted with methacholine (3xlO"6M, approximately the EC50 for 
methacholine in this tissue). In separate tissues, cumulative-concentration response 
curves were then constructed to salbutamol (10~8-3xl0‘6M), atrial natriuretic peptide 
(10_9-10~6M), sodium nitroprusside (10"8-10"5M) and isosorbide dinitrate (10-7-3xl0“ 
5M). Results are expressed in terms of the mean maximal inhibition. Whenever atrial 
natriuretic peptide was used, the neutral endopeptidase inhibitor, phosphoramidon 
( 3 . 7 x 1 0 ' 5 M ) ,  was included to prevent its rapid breakdown (Angus et a l., 1994a). 
Experiments were also conducted to ascertain if phosphoramidon altered methacholine- 
induced tone. In each case, one tissue acted as a time control to establish that the 
methacholine contraction was sustained.
3.2.3.4 Protection against subsequent methacholine challenge
Cumulative concentration-response curves to methacholine (10"9-3xl0 '4M) were 
constructed in each of the O2 tensions, first in the absence then the presence of each
dilator. Three concentrations of each dilator were used; ANP (10-7, 3xl0-7 and 10_6M), 
salbutamol (10~7, 3xl0"7 and 10’6M), SNP (10 6, 3xl0’6 and 10'5) and ISDN (10 5, 
3xlO-5 and 10_4M). These concentrations were based on the ability of each drug to 
reverse methacholine-induced tone in the experiments mentioned above, in which the 
approximate IC50 (the concentration which evoked 50% of the mean maximal 
inhibition) for each drug was: ANP; 10~7M, salbutamol; 10_7M, SNP; 10_6M and ISDN; 
10'5M.
As stated earlier, phosphoramidon (3.7x10_5M) was included to prevent the rapid 
breakdown of ANP by neutral endopeptidases. Experiments were also conducted to 
ascertain if phosphoramidon had any effect on methacholine-induced responses. In each 
experiment, one tissue acted as a time control to establish that the methacholine 
contractions did not vary with time. Results are expressed as a % of the maximum 
response in the initial concentration-response curve to methacholine.
The sensitivity of the tissue to methacholine is expressed in terms of the pD2 (the
negative log of the concentration of methacholine which evokes 50% of the maximum 
response).
3.2.4 Materials
The following chemicals were used; atrial natriuretic peptide, isosorbide dinitrate, 
methacholine*~salbutamol and sodium nitroprusside. See section 2.1.8 for a list of full 
chemical and suppliers names.
113
3.2.5 Analysis of Results
Number of observations (n) refers to the number of individual animals from which 
tissue was obtained (n=6 in each case, unless otherwise stated). Statistical analysis was 
performed using the Minitab package. Two-way analysis of variance was used for the 
different data sets generated by concentration response curves. Significance between 
data points was calculated by Student's t test. Results are expressed as a percentage ± 
standard error of the mean (s.e.m.). A probability of P<0.05 was considered to be 
statistically significant.
3.3 RESULTS
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3.3.1 Optimisation Of Initial Resting Tension
Changing the degree of applied (passive) tension significantly altered the contractile 
(active) response evoked by a near maximal concentration of methacholine (10“4M). 
The measured contractile response increased as the applied tension was increased from 
0.5g wt to 2.0g wt, reaching a maximum contraction at 2.0g wt. When the applied 
tension was increased beyond 2.0g wt, there was no significant change in the 
contractile response to 10"4M methacholine. The maximum response to methacholine, 
at a resting tension of 2.0g wt, 2561.6±435.9mg wt, was significantly greater (P<0.05 
for data points) than the response to methacholine at a resting tension of 1.5g wt, 
1728.6±242.8 mg wt. Number of observations (n) =6 in each case.
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Figure 3.1
The effect of changing the degree of initial resting tension on contractile responses. 
Contractions evoked by a single concentration (KHM) of methacholine were measured 
in bovine bronchial rings in hyperoxia. Responses are expressed in milligrams weight 
(mg wt). Contractile responses were significantly (P<0.05 for data points) greater at a 
resting tension of 2.0g wt than at a resting tension of 1.5 g wt. Number of observations 
(n) = 6 in each case.
responses to methacholine were significantly altered throughout the concentration- 
response curve, changes in O2 tension did not alter the sensitivity of the tissue to 
methacholine (methacholine pD2 values: in 95%; 5.11±0.10, n=8, in 20%; 5.17±0.09, 
n=8 and in 0%; 5.24±0.12, n=8).
Expressing the results as either % of the maximum response in hyperoxia (Figure 
3.3A), or in mg wt (Figure 3.3B) did not alter the pattern of responses. Furthermore, 
expressing the results in mg wt did not significantly alter the estimations of 
methacholine pD2 values (methacholine pD2 values from results expressed in absolute
terms: in 95%; 5.34±0.21, n=8, in 20%; 5.43±0.32, n=8 and in 0%; 5.49±0.36, n=8).
- 1 g wt 10 mins
Figure 3.2
Representative trace depicting contractile responses evoked by methacholine in 
bovine bronchial rings. Methacholine was added cumulatively to give final bath 
concentrations of 10~9M - 3xlO"4M. Consecutive concentrations were added after the 
previous response had reached a plateau.
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Figure 3.3
Cumulative concentration response curves to methacholine in bovine bronchi in 
hyperoxia^®), normoxia (□) and hypoxia (O). Responses are expressed as (A) % of 
the maximum response in hyperoxia and (B) in mg wt. Both normoxia and hypoxia 
significantly (P<0.001) potentiate methacholine responses compared to hyperoxia. 
There was no significant difference between responses in normoxia and hypoxia. 
Expressing the results as either % of the maximum response in hyperoxia or in absolute 
terms did not significantly alter the estimation of EC50 values. Number of observations 
(n) = 8 in each case
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3.3.3 Reversal Of Methacholine-induced Tone
Responses to the single concentration (3x1 O^M) of methacholine were dependent upon 
the O2 tension used (Figure 3.4): in 95% O2, a contraction of 1.20±0.16g wt was 
produced, whereas in 20 and 0%, the responses were significantly (P<0.001 for data 
set, n=12) greater (2.37±0.31 and 2.19±0.31g wt, respectively). Again, there was no 
difference between responses in 20 and 0% O2.
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Figure 3.4
Responses evoked by a single concentration (3xl0 '6M) of methacholine in bovine 
bronchi in hyperoxia (open column), normoxia (stippled column) and hypoxia (striped 
column). Responses are expressed in milligrams weight (mg wt). Both normoxia and 
hypoxia significantly (P<0.001) potentiate methacholine responses compared to 
hyperoxia. Number of observations (n) = 12 in each case.
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Figure 3.5
Representative trace depicting relaxtory responses evoked by salbutamol in.bovine 
bronchial rings. After a stable contraction to methacholine was achieved, salbutamol 
was added cumulatively to give final bath concentrations of 10'8M - 3xl0“5M. 
Consecutive concentrations were added after the previous response had reached a 
plateau.
The ability of the drugs to relax preconstricted tissue was dependent upon the oxygen 
tension used (Table 3.1). Salbutamol was more effective in normoxia than hypoxia, 
whereas the other dilators were either equipotent (isosorbide dinitrate) or more 
effective (atrial natriuretic peptide) in 0% than 20% O2. In contrast, sodium
nitroprusside was more effective in hyperoxia than normoxia.
For salbutamol (10"8-3xl0_6M) (Figure 3.4), there was no difference between 
responses in 95 and 20% O2 (mean maximal inhibitions, at the 3xl0“6M level; 77.09± 
11.47% and 98.01± 7.31%, respectively, n=6), or 95 and 0% O2 (mean maximal 
inhibitions, at the 3xlO_6M level; 77.09± 11.47% and 70.87± 7.31%, respectively), 
however, salbutamol was significantly P<0.001 for data set, n=6) more effective at 
reversing tone in 20% than in 0% O2 (mean maximal inhibitions, at the 3xlO‘6M
level; 98.01± 7.31% and 70.87± 7.31%, respectively, P<0.05 for the data points ). 
Atrial natriuretic peptide (10"9t10"6M) showed a different pattern of results from 
salbutamol (Figure 3.5). There was no difference between responses in 95 and 20% 
O2 (mean maximal inhibitions, at the 10"6M level; 36.08± 12.38% and 33.03± 7.59%, 
respectively, n=6). In this case, however, responses in 0% were significantly (P<0.05 
for data set, n=6) enhanced compared to 20% O2, albeit with no change in the mean 
maximum inhibition (mean maximal inhibition, at the 10'6M level; 50.30± 8.50%).
Figure 3.6
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Figure 3.6
The ability of salbutamol to reverse methacholine induced tone in bovine bronchi in 
95% (■), 20% (□) and 0% O2 (O). Salbutamol was added cumulatively to give final 
bath concentrations of (lO^-SxlO^M). Responses are expressed as a % reversal of the 
methacholine contraction. Salbutamol was significantly (P<0.001) more effective in 
20% O2 than in 0%, however there was no difference between responses in 95 and 
20%, or between 95 and 0%. Number of observations (n) = 6 in each case.
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Figure 3.7
The ability of atrial natriuretic peptide (ANP) to reverse methacholine induced tone in 
bovine bronchi in 95% (■), 20% (□) and 0% O2 (O). ANP was added cumulatively 
to give final bath concentrations of (10~9-10'6M). Responses are expressed as a % 
reversal of the methacholine contraction. ANP was significantly (P<0.05) more 
effective in 0% O2 when compared with both 95 and 20%. All experiments involving 
atrial natriuretic peptide were conducted in the presence of phosphoramidon to prevent 
rapid hydrolysis by neutral endopeptidases. Number of observations (n) = 6 in each 
case.
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For sodium nitroprusside (Figure 3.8), responses throughout the whole curve (10"8-10" 
5M) were significantly (P<0.01 for data set) greater in 95% compared to 20% C>2, 
although there was no significant difference between the maximum responses (mean 
maximal inhibitions, at the 10'5M level; 83.74±11.21 % and 77.77±9.27%, in 95 and 
20%, respectively). Responses in hypoxia (mean maximal inhibition; 90.19± 11.51%) 
were not significantly different from those in either 95 or 20%.
Figure 3.8
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Figure 3.8
The ability of sodium nitroprusside to reverse methacholine induced tone in bovine 
bronchi in 95% (■), 20% (□) and 0% O2 (O). SNP was added cumulatively to give 
final bath concentrations of (10'8-10_5M). Responses are expressed as a % reversal of 
the methacholine contraction. Sodium nitroprusside was significantly (P<0.01) more 
effective in 95% O2 than 20% O2. Responses in 0% O2 were not significantly different 
than either 95% or 20% O2. Number of observations (n) = 6 in each case.
Isosorbide dinitrate (10_7-3 x l0 '5M) (Figure 3.9), evoked significantly greater 
relaxations in 20% O2 than 95% (P<0.01 for data set, n=6, mean maximal inhibition at 
the 3x10_5M level; 64.51±10.08% and 33.42±5.90%, respectively, P<0.05 for data 
points). Responses to isosorbide in 0% O2 were also significantly enhanced (P<0.001 
for data set, n=6, mean maximal inhibition at the 3xlO_5M level; 80.37±5.32%, 
P<0.001 for data points) compared to 95% O2, although there was no significant 
difference between responses in 20% and 0% O2.
Figure 3.9
ao
ua«-
BOo
<ua
5 0 -J3
<L>
E
H -o
7 5 -u<u><uQC
100
4 .5 4- 7 .5 66 .5 5 .5 57
lo g [ is o s o rb id e  d in i t r a te ] ( M )
Figure 3.9
The ability of isosorbide dinitrate to reverse methacholine induced tone in bovine 
bronchi in 95% (■), 20% (□) and 0% O2 (O). Isosorbide was added cumulatively to 
give final bath concentrations of (10'7-3xl0*5M). Responses are expressed as a % 
reversal of the methacholine contraction. Isosorbide was significandy more effective in 
0% and 20% O2 (P<0.001 and P<0.01, respectively) than in 95%. Number of 
observation£j(n) = 6 in each case.
Table 3.1: Reversal of methacholine-induced contraction
Bronchodilator Oxygen tension Maximum
(±s.e.m)
2-way ANOVA
Salbutamol 95% 77.09(11.47)
( 1 0 - 8 - 3 x 1 0 - 6 M )
20% 98.01 (7.31)+
0% 70.87 (7.31) 20% > 0%
(p<0.001)
ANP 95% 36.08 (12.38)
(10-9-10-6M)
20% 33.03 (7.59)
0% 50.30 (8.50) 0% > 95%, 20%
(p<0.05)
SNP 95% 83.7(11.2) 95% > 20%
(10-8-10-5M) (p<0.01)
20% 77.8 (9.3)
0% 90.2(11.5)
ISDN 95% 33.42 (5.90)
( 1 0 - 7 - 3 x 1 0 - 5 M )
*
20% 64.51 (10.08)* 20% > 95% (p<0.01)
0% 80.37 (5.32)*** 0% > 95% (p<0.001)
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Table 3.1 displays the mean maximum reversal of methacholine-induced tone for each 
bronchodilator in the three oxygen tensions: 95, 20 and 0%. Values are expressed as the 
mean (± s.e.m.) % reversal of the induced tone. Statistical significance between mean 
maximum responses was determined using Student's t-test, while differences between 
the data sets from each concentration response curve were calculated using 2-way 
analysis of variance (ANOVA). The concentration of methacholine used was 3xl0_6M. 
Number of observations (n) = 6 in each case. Abbreviations: ANP, atrial natriuretic 
peptide, SNP, sodium nitroprusside, ISDN, isosorbide dinitrate. Statistical significance 
for mean maximal inhibition: + P<0.05 for salbutamol in 20% compared with 0% O2, * 
P<0.05 for isosorbide dinitrate in 20% compared with 95% O2 and *** P<0.001 for 
isosorbide dinitrate in 0% compared with 95% O2.
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Contractile responses to methacholine
Methacholine evoked concentration-dependent contractions in the bovine isolated 
bronchial rings, with the threshold concentration for contraction being between 3x10- 
8M and 3xl0*7M. In each of the experiments, there was no difference between two 
consecutive concentration-response curves to methacholine alone (data not shown), 
indicating that methacholine-induced responses did not alter with time.
As stated in section 3.3.1, we have shown that lowering the oxygen tension from 
hyperoxia to normoxia or hypoxia significantly enhances methacholine-induced 
contractions in bovine bronchial rings. Our results from these present experiments are 
in agreement with this, and again, changing the oxygen tension did not alter the 
sensitivity of the tissue to methacholine (methacholine pD2 values: in 524mm Hg;
5.04±0.09, n=72, in 147mm Hg; 5.15±0.07, n=72 and in 26mm Hg; 5.18±0.09, n=72). 
There was no difference between two consecutive methacholine concentration-response 
curves conducted in the same oxygen tension, indicating that any change between the 
two cufves was due to the effect of the bronchodilator.
Atrial natriuretic peptide
In hyperoxia, pre-incubation of ANP, in the presence of phosphoramidon, attenuated 
methacholine-induced responses in a concentration-dependent manner. At a 
concentration of 10-7M, ANP did not alter the contractions evoked by methacholine 
(methacholine p02 values; control for ANP 10_7M; 5.01 ±0.09, n=6, methacholine plus
ANP 10'7M; 5.14±0.12, Figure 3.10A). Pre-incubation of ANP at concentrations of 
3xl0_7M and 10_6M (Figure 3.10 B and C, respectively) significantly (P<0.05 and 
PcO.001 for data sets, respectively) attenuated the methacholine concentration-response 
curve compared to control responses. This attenuation was not manifested as a change 
in the sensitivity of the tissue (methacholine pD2 values; control for ANP 3xl0_7M;
5 11±0.11, n=6, plus ANP 3xlO-7M; 4.94±0.14. Control for ANP 106M; 5.39±0.12, 
n=6, plus ANP 10_6M; 5.20±0.12. In each case P>0.05 for data points, compared to 
control.).
The ability of higher concentrations (3x10 7M and 10’6M) of ANP to protect against 
challenge with methacholine in 95% O2 was lost when the oxygen tension in the gas
mixture was reduced to 20%. At concentrations of 10 7M, 3xl0-7M and 10*6M, ANP 
did not alter subsequent responses to methacholine (methacholine pD2 values; control
for ANP 10_7M; 5.20±0.18, methacholine plus ANP 10'7M; 5.25±0.16, control for ANP 
3xlO’7M; 5.12±0.12, methacholine plus ANP 3xl0_7M; 5.07±0.12 and control for ANP 
10_6M; 4.87±0.14, methacholine plus ANP 10'6M; 4.94±0.16 (Figures 3.11 A, B and C, 
respectively). In each case there was no significant (P>0.05) difference between 
corresponding data points and controls).
Under hypoxic conditions, ANP actually enhanced responses to methacholine in a ‘ 
concentration-dependent manner. At a concentration of 10_7M, pre-incubation of ANP 
did not alter contractions evoked by methacholine (methacholine pD2 values; control
for ANP 10-7M; 5.08±0.12, n=6, methacholine plus ANP 107M; 5.18±0.08, Figure 
3.12A). After pre-incubation of either 3xlO'7M or 10'6M ANP, the methacholine 
concentration-response curve was significantly (PcO.Ol and P<0.001, respectively) 
enhanced compared to control responses, albeit with no change in the sensitivity of the 
tissue (methacholine pD2 values; control for ANP 3x10‘7M; 5.12±0.12, n=6,
methacholine plus ANP 3xlO'7M; 5.10±0.11. Control for ANP 10_6M; 5.01±0.13, n=6, 
methacholine plus ANP 10_6M; 4.85±0.15 (Figure 3.12B and C, respectively). In each 
case there was no significant (P>0.05) difference between corresponding data points 
and controls).
Phosphoramidon (3.7xlO~5M) alone did not alter contractile responses to methacholine 
in any of the oxygen tensions studied (results not shown).
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Figure 3.10
In hyperoxia (95%  O 2 ), cum ulative concentration response curves evoked by 
m ethacholine (M Ch, 10‘9-3 x l(H M ) were constructed in bovine bronchial rings in the 
absence (■ ) and in the presence o f atrial natriuretic peptide (ANP) at concentrations o f 
10_7M (A), 3x10 7M (B) and 10'6M (C). W hen AN P was used phosphoram idon was 
pre-incubated to prevent its degradation. Responses are expressed as a % of the control 
m axim um  response. W hen pre-incubated at concentrations of 3 x l0 '7M and 10-6M, 
A N P significantly  (P<0.05 and P<0.001, respectively) attenuated m ethacholine-induced 
contractions. N um ber of observations (n) = 6 in each case.
Figure 3.11
129
3
eoa
150
125
100
75
50
25
0
-10 9 -8 •7 6 -5 ■34
log[methacholine](M )
B 125
100
75
50
25
0
-10 9 8 -7 6 ■5 -3■4
log[methacholine](M)
C 125 -1 130
100Ea
B
B
ou
25 -
-10 9 •8 ■3■7 6 ■5 4
log[methacholine](M )
Figure 3.11
In norm oxia (20%  O2 ), cum ulative concentration response curves evoked by 
m ethacholine (M Ch, 10‘9- 3 x l 0 4M ) were constructed in bovine bronchial rings in the 
absence (■ ) and in the presence o f atrial natriuretic peptide (ANP) at concentrations o f 
10_7M (A), 3 x l0 _7M (B) and 10_6M  (C). W hen AN P was used phosphoram idon was 
pre-incubated to prevent its degradation. Responses are expressed as a % o f the control 
m axim um  response. Pre-incubation o f A N P had no effect on m ethacholine-induced 
contractions. N um ber o f observations (n) = 6 in each case.
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Figure 3.12
In hypoxia (0% O 2 ), cum ulative concentration response curves evoked by m ethacholine 
(MCh, 10‘9-3x10 '4M ) were constructed in bovine bronchial rings in the absence (■ ) 
and in the presence o f atrial natriuretic peptide (ANP) at concentrations o f 10‘7M (A), 
3 x l0 '7M (B) and 10_6M (C). W hen AN P was used phosphoram idon was pre-incubated 
to prevent its degradation. Responses are expressed as a % o f the control m axim um  
response. W hen pre-incubated at concentrations o f 3 x l0 '7M and 10 '6M, AN P 
significantly (P<0.01 and P<0.001, respectively) enhanced m ethacholine-induced 
contractions. N um ber of observations (n) = 6 in each case.
Salbutamol
In hyperoxia, salbutamol produced a similar pattern of responses to ANP, namely a 
concentration-dependent inhibition of the methacholine response. At a concentration of 
10*7M, salbutamol did not alter the contractions evoked by methacholine (methacholine 
pD2 values; control for salbutamol 10*7M; 5.21±0.09, n=6, methacholine plus
salbutamol 10*7M; 5.18±0.13, Figure 3.13A). After pre-incubation of either 3xlO*7M or 
10*6M salbutamol, the methacholine concentration-response curve was significantly 
(P<0.05 and P<0.001 for data sets, respectively) attenuated compared to control 
responses. As was the case with ANP, this attenuation was not manifested as a change 
in the sensitivity of the tissue (methacholine pD2 values; control for salbutamol 3x10*
7M; 5.01±0.10, n=6, plus salbutamol 3xl0*7M; 4;81±0.13. Control for salbutamol 10* 
6M; 5.37±0.15, n=6, plus salbutamol 10*6M; 5.01±0.18 (Figure 3.13B and C, 
respectively). In each case there was no significant (P>0.05) difference between 
corresponding data points and controls.).
As was the case with ANP, when the oxygen tension was reduced to normoxic levels, 
salbutamol did not confer protection against subsequent challenge with methacholine 
(methacholine pD2 values; control forsalbutamol 10*7M; 5.20±0.15, methacholine plus
salbutamol 10*7M; 5.02±0.17, control for salbutamol 3xl0*7M; 5.17±0.12,
methacholine plus salbutamol 3xlO*7M; 5.02±0.12 and control for salbutamol 10*6M; 
4.96±0.11, methacholine plus salbutamol 10*6M; 4.80±0.16 (Figure 3.14). In each case 
there was no significant (P>0.05) difference between corresponding data points and 
controls).
Therefore, like ANP, salbutamol conferred protection against methacholine challenge 
in hyperoxia but did not alter responses in normoxia. In hypoxia, pre-incubation of 
salbutamol at concentrations of 10*7M, 3xl0*7M and 10*6M did not alter contractions 
evoked by subsequent addition of methacholine (methacholine pD2 values; control for
salbutamol 10*7M; 5.08±0.09, methacholine plus salbutamol 10*7M; 4.98±0.10, control 
for salbutamol 3xl0*7M; 5.20±0.13, methacholine plus salbutamol 3xl0*7M; 5.12±0.19 
and control for salbutamol 10*6M; 5.08±0.09, methacholine plus salbutamol 10*6M; 
4.95±0.15 (Figure 3.15 A, B and C, respectively). In each case there was no significant 
(P>0.05) difference between corresponding data points and controls).
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Figure 3.13
In hyperoxia (95%  O2 ), cum ulative concentration response curves evoked by 
m ethacholine (M Ch, 10'9-3xl0~4M) were constructed in bovine bronchial rings in the 
absence (■ )  and in the presence of salbutam ol at concentrations o f 10_7M (A), 3 x l0 _7M 
(B) and 10'6M (C). Responses are expressed as a % of the control m axim um  response. 
W hen pre-incubated at concentrations o f 3x10 7M and 10-6M, salbutam ol significantly  
(P<0.05 and PcO.OOl, respectively) attenuated m ethacholine-induced contractions. 
N um ber o f observations (n) = 6 in each case.
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Figure 3.14
In norm oxia (20%  O 2 ), cum ulative concentration response curves evoked by 
m ethacholine (M Ch, 10~9-3 x lO 4M) were constructed in bovine bronchial rings in the 
absence (■ ) and in the presence o f salbutam ol at concentrations of 10_7M (A), 3 x l0 '7M 
(B) and 10~6M (C). Responses are expressed as a % of the control m axim um  response. 
Pre-incubation o f salbutam ol had no effect on m ethacholine-induced contractions. 
N um ber o f observations (n) = 6 in each case.
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Figure 3.15
In hypoxia (0% O 2 ), cum ulative concentration response curves evoked by m ethacholine 
(M Ch, 10‘9-3 x l0 '4M) were constructed in bovine bronchial rings in the absence (■ ) 
and in the presence o f salbutamol at concentrations o f 10‘7M (A), 3xl0*7M (B) and 10" 
6M (C). Responses are expressed as a % of the control m axim um  response. Pre­
incubation of salbutam ol had no effect on m ethacholine-induced contractions. N um ber 
of observations (n) = 6 in each case.
Sodium nitroprusside
In hyperoxia pre-incubation of SNP at concentrations of 10_6M and 3xlO_6M did not 
alter subsequent contractions evoked by methacholine (methacholine pD2 values;
control for SNP 10_6M; 5.37±0.14, n=6, plus SNP 10_6M; 5.23±0.19. Control for 
sodium nitroprusside 3xlO_6M; 4.95±0.16, n=6, plus SNP 3xlO_6M; 5.10±0.18. In each 
case there was no significant (P>0.05) difference between corresponding data points 
and controls, Figures 3.16 A and B). When the concentration of SNP was increased to 
10'5M however, methacholine-induced responses were significantly (PcO.Ol, for data 
set) attenuated, albeit with no change in the sensitivity of the tissue (methacholine pD2
values; control for SNP 10-5M; 5.05±0.12, plus SNP 10-5M; 5.02±0.14 (Figure 3.16C). 
In each case there was no significant (P>0.05) difference between corresponding data 
points and controls.).
Lowering the oxygen tension to normoxic levels did not alter the ability of 10_6M SNP 
to protect against subsequent challenge with methacholine. As was the case under 
hyperoxia, pre-incubation with this concentration of SNP did not protect against 
methacholine-induced contractions (methacholine pD2 values; control for SNP 10-6M;
5.04±0.10, n=6, plus SNP 10_6M; 4r‘89±0.18, in each case there was no significant 
(P>0.05) difference between corresponding data points and controls, Figure 3.17A). 
When the concentration of pre-incubated SNP was increased to 3x10’6M, the 
methacholine response curve was significantly (P<0.05, for data set) attenuated albeit 
with no change in the sensitivity of the tissue (methacholine pD2 values; control for
SNP 3xlO'6M; 5.17±0.12, plus SNP 3xlO_6M; 4.83±0.09, in this case there was no 
significant (P>0.05) difference between corresponding data points and controls.
(Figure 3.17B). Furthermore, when the concentration of SNP was increased to 10_5M 
(Figure 3.17C), the methacholine concentration-response curve was also attenuated 
(PcO.OOl, for data set), in this case with a concomitant decrease in the sensitivity of the 
tissue (methacholine pD2 values; control for SNP 10_5M; 5.17±0.12, plus SNP 10_5M;
4.77±0.10, representing a significant (P<0.05) difference between the corresponding 
data points and the controls.).
This pattern of responsiveness was similar in hypoxia, with SNP being ineffective at 
the 10_6M level (methacholine pD2 values; control for SNP 10-6M; 5.11±0.15, n=6,
plus SNP 10"6M; 4.98±0.16. There was no significant (P>0.05) difference between 
corresponding data points and controls, Figure 3.18A), while significantly (PcO.Ol and 
PcO.OOl for data sets, respectively) attenuating methacholine-induced contractions 
when pre-incubated at concentrations of 3x1 O'6 and 10_5M. This attenuation occurred 
without any significant change in the sensitivity of the tissue (methacholine pD2 values;
control for SNP 3xlO_6M; 5.22±0.06, plus SNP 3xlO_6M; 4.91±0.12 and control for 
SNP 10_5M; 5.22±0.06, plus SNP 10'5M; 4.91±0.07 (Figures 3.18B and C). In each 
case there was no significant (P>0.05) difference between corresponding data points 
and controls.).
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Figure 3.16
In hyperoxia (95%  O2 ), cum ulative concentration response curves evoked by 
m ethacholine (M Ch, 10'9-3xl0*4M) were constructed in bovine bronchial rings in the 
absence (■ ) and in the presence of sodium  nitroprusside (SNP) at concentrations o f 10* 
6M (A), 3x10~6M (B) and 10‘5M (C). Responses are expressed as a % of the control 
m axim um  response. W hen pre-incubated at a concentration o f 10'5M , SNP 
significantly (P<0.01) attenuated m ethacholine-induced contractions. N um ber of 
observations (n) = 6 in each case.
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Figure 3.17
In norm oxia (20%  O 2 ), cum ulative concentration response curves evoked by 
m ethacholine (M Ch, 10'9- 3 x l0 '4M) were constructed in bovine bronchial rings in the 
absence (■ ) and in the presence of sodium  nitroprusside (SNP) at concentrations o f 10' 
6M (A), 3 x 10 '6M  (B and 10'5M (C). Responses are expressed as a % o f the control 
m axim um  response. W hen pre-incubated at concentrations o f 3 x l0 ‘6M and 10'5M, SNP 
significantly (P<0.05 and P<0.001, respectively) attenuated m ethacholine-induced 
contractions. N um ber of observations (n) = 6 in each case.
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Figure 3.18
In hypoxia (0% O 2 ), cum ulative concentration response curves evoked by m ethacholine 
(M Ch, 10_9-3x10‘4M ) were constructed in bovine bronchial rings in the absence (■ ) 
and in the presence o f sodium  nitroprusside (SNP) at concentrations o f 10_6M (A), 
3x10 '6M (B) and 10"5M (C). Responses are expressed as a % of the control m axim um  
response. W hen pre-incubated at concentrations o f 3x10_6M and 10‘5M, SNP 
significantly (P<0.01 and P<0.001, respectively) attenuated m ethacholine-induced 
contractions. N um ber o f observations (n) = 6 in each case.
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Isosorbide Dinitrate
In hyperoxia, pre-incubating ISDN at concentrations of 10_5M and 3xlO_5M did not 
alter contractions evoked by subsequent challenge with methacholine (methacholine 
pD2 values; control for ISDN 10-5M; 4.98±0.09, plus ISDN 10_5M; 5.04±0.12 and
control for ISDN 3xlO"5M; 4.95±0.12, plus ISDN 3xlO_5M; 4.89±0.16. In each case 
there was no significant (P>0.05) difference between corresponding data points and 
controls. Figures 3.19A and B). At the 10'4M level, however, ISDN significantly 
(P<0.05 for data set) attenuated methacholine-induced responses, albeit with no change 
in the sensitivity of the tissue (methacholine pD2 values; control for isosorbide dinitrate
10"4M; 5.01 ±0.24, plus ISDN 10_4M; 4.69±0.13 (Figure 3.19C). There was no 
significant (P>0.05) difference between corresponding data points and controls.). 
Lowering the oxygen tension in the gas mixture to 20% did not alter the effect of 10“ 
5M ISDN on methacholine challenge. As was the case in hyperoxia, pre-incubation 
with this concentration of bronchodilator had no effect on the methacholine-response 
curve (methacholine pD2 values; control for ISDN 10“5M; 5.14±0.15, plus ISDN 10“
5M; 5.02±0.14. There was no significant (P>0.05) difference between corresponding 
data points and controls. Figure 3.20A). In contrast to hyperoxia, however, pre­
incubation of 3xl0_5M ISDN in normoxia significantly (P<0.01 for data set) attenuated 
methacholine-induced contractions albeit with no change in the sensitivity of the tissue 
(methacholine pD2 values; control for ISDN 3xl0_5M; 4.95±0.16, plus ISDN 3xl0"5M;
4.78±0.17. There was no significant (P>0.05) difference between corresponding data 
points and controls. Figure 3.20B). Furthermore, increasing the concentration of ISDN 
to KMM, evoked a greater (P<0.001) attenuation of the methacholine-response curve, 
in this case with a corresponding decrease in the sensitivity of the tissue (methacholine 
pD2 values; control for ISDN 10“4M; 5.21±0.10, plus ISDN 10“4M; 4.81±0.06 (Figure
3.20C). This reflects a significant (P<0.01) difference between the corresponding data 
points and controls.).
When the oxygen tension was lowered to hypoxic levels, ISDN, at both the 10“5M and 
3xlO"5M level, did not alter the methacholine-induced contractions (methacholine pD2
values; control for ISDN 10*5M; 5.01±0.08, plus ISDN 10_5M; 5.12±0.14 and control 
for ISDN 3xl0_5M; 4.98±0.10, plus ISDN 3xlO“5M; 4.89±0.11. There was no 
significant (P>0.05) difference between corresponding data points and controls. Figures
3.21 A and B, respectively). As was the case in hyperoxia and normoxia, pre-incubating 
ISDN at the 10_4M level significantly (P<0.01 for data set in 0% 0 2) attenuated
responses to subsequent challenge with methacholine. In this instance, ISDN also 
evoked a significant rightward shift of the methacholine response (methacholine pD2
values; control for ISDN 1(HM; 5.14±0.10, plus ISDN 10_4M; 4.63±0.05 (Figure
3.21 C). This reflects a significant (P<0.001) difference between the corresponding data 
points and controls.).
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Figure 3.19
In hyperoxia (95%  O 2 ), cum ulative concentration response curves evoked by 
m ethacholine (M Ch, 10~9-3xl0~4M) were constructed in bovine bronchial rings in the 
absence (■ ) and in the presence of isosorbide dinitrate (ISDN) at concentrations o f 10' 
5M (A), 3x10‘5M (B) and 10_4M (C). Responses are expressed as a % o f the control 
m axim um  response. W hen pre-incubated at a concentration o f 10'4M, ISDN 
significantly (P<0.05) attenuated m ethacholine-induced contractions. N um ber of 
observations (n) = 6 in each case.
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Figure 3.20
In norm oxia (20% O 2 ), cum ulative concentration response curves evoked by 
m ethacholine (M Ch, 10'9-3 x l0 '4M) were constructed in bovine bronchial rings in the 
absence (■ ) and in the presence of isosorbide dinitrate (ISDN) at concentrations o f 10' 
5M  (A), 3x10 '5M (B) and 10'4M (C). Responses are expressed as a % o f the control 
m axim um  response. W hen pre-incubated at concentrations o f 3 x l0 '5M and 10'4M, 
ISDN significantly (P<0.01 and P<0.001, respectively) attenuated m ethacholine- 
induced contractions. N um ber of observations (n) = 6 in each case.
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Figure 3.21
In hypoxia (0% O 2 ), cum ulative concentration response curves evoked by m ethacholine 
(M Ch, 10'9-3x10 '4M ) were constructed in bovine bronchial rings in the absence (■ ) 
and in the presence o f isosorbide dinitrate (ISDN) at concentrations o f 10_5M  (A), 
3x10~5M (B) and 10_4M (C). Responses are expressed as a % of the control m axim um  
response. W hen pre-incubated at a concentration o f 10~4M, ISDN significantly 
(P<0.01) attenuated m ethacholine-induced contractions. N um ber o f observations (n) = 
6 in each case.
3.4 DISCUSSION 154
Changing the oxygen tension had a marked effect on the responses evoked by both 
methacholine and the bronchodilators presently studied.
Contractile responses to methacholine
It was found that responses evoked by methacholine were significantly enhanced when 
the oxygen tension was reduced from 95%. This was true for either the addition of a 
single concentration of methacholine or for responses throughout the whole 
concentration-response curve. It has previously been suggested that the hypoxia- 
induced enhancement of airway reactivity to spasmogens may be mediated by a vagal 
reflex (Vidruk & Sorkness, 1985), however, the fact that we found a similar 
enhancement of responses using isolated tissue suggests that reflex pathways are not 
the only mechanisms involved. The hypothesis put forward by D'Brot and Ahmed 
(1988) that leukotrienes (or some other mediator) may cause the enhancement of 
spasmogen responses remains more likely, given that a number of contractile 
substances are released in response fcThypoxia. While the studies conducted by D'Brot 
and Ahmed involved whole animals, it remains possible that the epithelial layer or even 
the smooth muscle of an isolated bronchial ring could be a site for release of mediators 
causing enhancement of the smooth muscle reactivity. In fact, the potent 
bronchoconstricting peptide endothelin-1 is released from isolated bovine endothelial 
cells in response to hypoxia (Hieda & Gomez-Sanchez, 1990). Several other 
possibilities exist regarding this enhancement of methacholine responses; our group has 
previously shown that the vasoactive peptide hormone angiotensin II (AH), in 
concentrations below those which evoke significant contractions per se, can potentiate 
methacholine responses in human and bovine bronchi in vitro (Nally et al., 1994c) and 
that angiotensin II is released during acute asthma (Millar et al., 1994). It is therefore 
possible that angiotensin II or another spasmogenic substance is released locally from 
isolated tissue in concentrations which potentiate responses to methacholine, however 
this remains to be established.
Reversal of methacholine-induced tone
In the experiments involving reversal of methacholine-induced tone, we found 
salbutamol to be extremely effective in all three oxygen tensions, however it was most 
potent in normoxia, producing almost 100% reversal of the induced contraction. Since 
hypoxia can result in a loss of B-adrenoceptors in cardiac muscle (Voelkel et al., 1981) 
and since weTftund salbutamol to be significantly less effective in low oxygen, it would 
be tempting to speculate that hypoxia may also cause a reduction in B-adrenoceptors in 
the bronchi.
The bronchodilating abilities of atrial natriuretic peptide have been studied in airways 
both in vivo and in vitro (Angus et al., 1994a and b) Its mechanism of action is
proposed to be via activation of particulate guanylyl cyclase leading to elevation of 
cGMP (Ishii & Murad, 1989). We found atrial natriuretic peptide to be most effective in 
0% O2, reversing approximately 50% of the induced tone, suggesting that this drug
may be more potent in hypoxic conditions. This enhancement in hypoxia was not seen 
with either salbutamol or isosorbide dinitrate.
The nitrate drug isosorbide dinitrate was also effective at reversing methacholine- 
induced tone. Given that both isosorbide dinitrate and atrial natriuretic peptide are 
thought to evoke their responses by stimulation of guanylyl cyclase (Ishii & Murad, 
1989; Ignarro & Kadowitz, 1985), one would perhaps expect similarities in the 
responses evoked by these drugs in different oxygen tensions. Indeed, both of these 
dilators were significantly more effective in hypoxia than hyperoxia. There were some 
differences, however, in the pattern of responses evoked by each drug. For example, 
isosorbide dinitrate was more effective in normoxia than hyperoxia, whereas atrial 
natriuretic peptide was equipotent in these two oxygen tensions. These differences may 
be due to the fact that atrial natriuretic peptide stimulates particulate guanylyl cyclase 
(Ishii & Murad, 1989) whereas isosorbide dinitrate stimulates soluble guanylyl cyclase 
(Ignarro & Kadowitz, 1985). Activation of soluble guanylyl cyclase is also the 
mechanism of action of sodium nitroprusside. The results from this study showed that 
responses to sodium nitroprusside were greater in hyperoxia than normoxia, therefore 
the pattern of responses differed between sodium nitroprusside and isosorbide. This 
was unexpected given that both agents are purported to act via the same mechanism. 
These differences may be due to the fact that sodium nitroprusside can stimulate 
soluble guanylyl cyclase directly (Ignarro et al., 1981), whereas isosorbide must first 
form an intermediate complex (Ignarro and Gruetter, 1980; Ignarro et al., 1981).
A cautionary note must be added regarding the use of sodium nitroprusside, since it is 
possible that prolonged exposure to high concentrations of this agent might have a non­
specific toxic effect due to release of cyanide from its ferricyanide complex. Indeed 
sodium nitroprusside has been shown to be cytotoxic in cultured endothelial cells under 
hypoxic conditions (Ioannidis et al., 1996). In the study in question, however, the 
endothelial cells were exposed to extremely high (20mM) concentrations of sodium 
nitroprusside over a prolonged (8 hours) period. Furthermore, the chemically unrelated 
nitric oxide donor, S-nitroso-N-acetylpenicillamine (SNAP), was also cytotoxic under 
these conditions, despite the fact it does not possess a cyanide moiety (Ioannidis et a l , 
1996).
It is now generally well accepted that the smooth muscle relaxant effects of SNP and 
SNAP are mediated via increases in cellular cGMP (see Warner et al., 1994 for review) 
and that this~xffect is due to release of nitric oxide either spontaneously or upon 
enzymatic degradation of the original compound. Nitric oxide, not the parent 
compound, is believed to be responsible for the activation of soluble guanylyl cyclase 
and the resulting elevation of cGMP (Schmidt et al., 1993). Indeed both SNP and 
SNAP evoke a dose-dependent increase in cGMP in cultured human airway smooth
muscle cells (Hamad et al., 1997). In certain smooth muscle preparations, for example 
vascular smooth muscle, SNAP has been shown to be a more potent nitric oxide donor 
than SNP (Marks et al., 1995), however, SNP remains widely used as a 
pharmacological means of activating soluble guanylate cyclase (for example, Hennan & 
Diamond, 1998).
Salbutamol was the only bronchodilator used in this study which was more effective in 
normoxia than hypoxia. In every other case, the dilators were either equally (isosorbide 
dinitrate, sodium nitroprusside) or more (atrial natriuretic peptide) effective in hypoxia. 
This may be of importance given the potential for hypoxia during an asthmatic attack. 
It could therefore be postulated that isosorbide dinitrate would retain its 
bronchodilating abilities in a hypoxic situation, indeed this drug has been shown to be a 
useful bronchodilator in asthmatic patients (Okayama et al., 1984). Our results show 
that the potency of atrial natriuretic peptide is actually enhanced under hypoxic 
conditions and more importantly, salbutamol becomes less effective. This finding 
perhaps suggests a role for combining O2 therapy with salbutamol in patients already in
a hypoxic state. ^
Protection against subsequent challenge with methacholine
Changing the oxygen tension had a marked effect on the ability of the bronchodilators 
used in this study to protect against methacholine-induced contractions. The pattern 
varied however, between the bronchodilators used which may reflect the different 
second-messenger pathways utilised by each of these agents. For example, atrial 
natriuretic peptide, which acts via opening of potassium channels (Winquist et al., 
1984; Ohlstein & Berkowitz, 1985) and stimulation of particulate guanylyl cyclase 
(Ishii & Murad, 1989), significantly attenuated methacholine-induced contractions in 
hyperoxia whereas in normoxia this effect was lost. Furthermore, when the oxygen 
tension was lowered to hypoxic levels, ANP actually enhanced methacholine responses. 
The attenuation of methacholine responses in hyperoxia is in keeping with results from 
a previous study where pre-incubating ANP at a concentration of 10_6M significantly 
reduced contractions evoked by methacholine in isolated human and bovine bronchi 
(Angus et al., 1994a). Under normoxic conditions, inhaled ANP protects against 
methacholine challenge in asthmatic patients (Angus et al., 1994b), however, in the 
present study, ANP failed to produce a similar effect in isolated bovine bronchi. It 
would be interesting to determine if, in isolated human bronchi, ANP protects against 
methacholine challenge under normoxia.
The enhancement of methacholine responses in hypoxia remains to be explained, 
however it cannot be attributed to phosphoramidon since when pre-incubated alone, 
this neutral endopeptidase inhibitor had no effect on methacholine responses. In 
addition to hydrolysis by neutral endopeptidases, the principal mechanism by which 
ANP is removed from the circulation is via binding to a non-guanylyl cyclase clearance
157receptor (Maak et al., 1987). These “C”-receptors have been shown to internalise ANP, 
thus performing a major role in the clearance of ANP from plasma (Chiu et al., 1991). 
While the presence of these C-receptors in bovine bronchi remains to be established, 
they are expressed in rat airway smooth muscle cultures (James & Bumstock, 1991). It 
may be that changing the oxygen tension alters the ratio between the biologically 
active, G-protein coupled ANP receptors and the uncoupled clearance receptors. For 
example, lowering the oxygen tension from hyperoxia may increase the relative number 
of C-receptors, thus explaining the loss of ANP's effectiveness in normoxia. This 
would not, however, explain the enhancement of methacholine-induced contractions in 
hypoxia.
Salbutamol, a agonist acting via potassium channel opening (Miura et al.,* 1992) as 
well as stimulation of adenylyl cyclase (Rinard et al., 1983), was effective only in 
hyperoxia. In normoxia and hypoxia, pre-incubation with salbutamol had no effect on 
the methacholine concentration-response curve. The ability of salbutamol to protect 
against bronchoconstrictors remains controversial; studies conducted upon isolated 
human bronchi have shown little (Advenier et al., 1988) or no (Gustaffson & Persson, 
1991; Advenier et al., 1991) pre-protectant effect of this drug. In contrast, clinical 
studies (e.g. Tattersfield, 1987; Britton et al., 1988) have shown an ability of 
salbutamol to inhibit bronchial reactivity to spasmogens. In addition, a previous study 
by this group showed that salbutamol, in hyperoxia, significantly attenuated 
methacholine-induced contractions in human isolated bronchi (Nally et al., 1994b) and 
the results from this present study appear to indicate a similar effect in bovine bronchi 
at this oxygen tension. When the oxygen tension was lowered to normoxic or hypoxic 
levels however, this pre-protectant effect of salbutamol was lost. While the reasons for 
this remain unclear, hypoxia has been shown to cause, in cardiac muscle, uncoupling of 
p2-adrenoceptors from their regulatory G proteins (Richalet, 1990). It is possible,
therefore, that lowering the oxygen tension reduces the number of functionally coupled 
fo-adrenoceptors in the bronchi. This may explain the loss of salbutamol's pre-
protectant effect in hypoxia, however, one would expect salbutamol to retain its 
effectiveness in normoxia, especially as fo-agonists confer protection in vivo at this 
oxygen tension. It has been suggested however (Persson et al., 1982), that p2-agonists 
have effects on cells other than airway smooth muscle (for example, inhibition of 
mediator release, Gorenne et al., 1995) and that this may contribute to their protective 
effects in vivo.
Since both sodium nitroprusside and isosorbide dinitrate are purported to act via similar 
second-mess^iTger systems (nitric oxide donation resulting in stimulation of soluble 
guanylyl cyclase, Feelisch & Novak, 1987) one would expect similarities in their 
pattern of responses. In hyperoxia, SNP, at the 10~5M level, evoked a slight attenuation 
of the methacholine response whereas this attenuation was significantly greater in both 
normoxia and hypoxia. Pre-incubation of isosorbide dinitrate at a concentration of 10“
more marked shift in hypoxia, however, isosorbide dinitrate was most effective in 
normoxia. Thus the pattern of responses evoked by these two dilators are similar but 
not identical. This may be due to the fact that sodium nitroprusside stimulates soluble 
guanylyl cyclase directly (Ignarro et al., 1981) whereas isosorbide dinitrate interacts 
with a cellular constituent, such as a sulfhydryl, to form an intermediate which then 
activates guanylyl cyclase (Ignarro et al., 1981; Ignarro & Gruetter, 1980).
It is interesting to note that atrial natriuretic peptide and salbutamol only protected 
against methacholine challenge in hyperoxia, whereas both sodium nitroprusside and 
isosorbide dinitrate were least effective in this oxygen tension. This may suggest that 
agonists acting via stimulation of soluble guanylyl cyclase would be more effective in 
oxygen tensions less than hyperoxia.
Comparing the ability of these dilators to reverse methacholine induced tone with the 
ability to protect against subsequent challenge, there are some interesting differences. 
For example, the ability of ANP to reverse methacholine-induced contraction was 
enhanced under hypoxic conditions, whereas in the present study, the ability of ANP to 
protect against subsequent challenge was lost when the oxygen tension was reduced 
from hyperoxia to either normoxia or hypoxia. Preincubation of salbutamol (at 
concentrations of 3xlO'7M and 10'6M) attenuated the methacholine concentration- 
response curve, although only under hyperoxic conditions. In terms of reversing tone 
however, salbutamol was most effective in normoxia. Sodium nitroprusside was more 
effective at reversing tone in hyperoxia than normoxia, whereas in terms of protecting 
against subsequent challenge, its effectiveness increased as the oxygen tension was 
lowered from hyperoxia to either normoxia or hypoxia. In both cases, however, 
isosorbide dinitrate was shown to be more effective in normoxia and hypoxia than in 
hyperoxia. Therefore, the effect of changes in oxygen tension on the ability of 
isosorbide dinitrate to, firstly, reverse induced tone and secondly, protect against 
subsequent challenge was consistent between the two studies. In contrast, the effects of 
oxygen tension on ANP and salbutamol responses varied between the two studies, 
indicating that the pharmacology of relaxation may be dissimilar to that of protection.
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In summary, changes in oxygen tension can alter: i)contractile responses to 
methacholine ii)the ability of bronchodilators to reverse methacholine-induced tone and 
iii)the ability of bronchodilators to protect against methacholine-induced contraction. 
Contractile responses to methacholine were enhanced when the oxygen tension of the 
gas mixture was lowered from 95% to 20 or 0%, although the direction of the changes 
varied among the dilators. This suggests that the responses evoked by bronchodilators 
in hyperoxic conditions may not necessarily predict those in the physiological range of 
oxygen tensions and that the relative effectiveness of bronchodilators may vary between 
normoxic and hypoxic conditions.
CHAPTER 4
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THE EFFECT OF CHRONIC HYPOXIA ON THE 
RESPONSIVENESS OF RAT ISOLATED AIRWAYS 
TO CONTRACTILE AND RELAXATORY
AGONISTS
4.1 INTRODUCTION 161
As stated in section 1.6.4.2, the effect of chronic hypoxia on airway responsiveness has 
not been extensively studied. In contrast, the effect of chronic hyperoxia on airway 
responsiveness has been more clearly defined. Chronic exposure to hyperoxia induces 
airway hyperresponsiveness, both in vivo and in vitro, to contractile agents such as 5- 
hydroxytryptamine and methacholine (Szarek, 1989; Hershenson et al., 1992a; 
Hershenson etal., 1994).
In this present study, we compared responses evoked by the spasmogens methacholine, 
endothelin-1 (ET-1) and potassium chloride (KC1) in isolated trachea from control and 
chronically hypoxic rats. Our initial results indicated that the contractile responses 
evoked by each of these agonists were significantly reduced in trachea from chronically 
hypoxic rats, therefore further experiments were carried out in an attempt to elucidate 
the mechanisms underlying this attenuation. Several studies indicate that chronic 
hyperoxia increases airway epithelial and smooth muscle layer thickness (Szarek, 1989; 
Hershenson et al., 1992a and b; Hershenson et a l, 1994) and that this increase in 
airway "wall thickness correlates witlFthe increase in airway reactivity (Hershenson et 
a l, 1992). More recently, however, Szarek and co-workers (1995) showed that in 
hyperoxic rats, the increase in airway reactivity occurs before the remodelling process 
develops, indicating that other mechanisms are also involved in the development of 
hyperoxia-induced airway hyperresponsiveness. Interestingly, Hershenson et al (1992) 
showed that pretreatment with the cyclooxygenase inhibitor indomethacin or removal 
of the epithelium reversed hyperoxia-induced airway hyperresponsiveness in immature 
rats in vitro. This indicates that epithelium-derived prostanoids contribute to the 
development of hyperoxia-induced enhancement of airway responsiveness. In this 
present study, we sought to examine if the release of (inhibitory) cyclooxygenase 
metabolites could also be responsible for the attenuation of contractile responses caused 
by exposure to chronic hypoxia.
Alternatively, several studies indicate that nitric oxide synthase expression is 
upregulated in the lungs of chronically hypoxic rats (Shaul et al., 1995; Xue et al., 
1994). To test the hypothesis that release of nitric oxide was responsible for the 
attenuation of contractile responses in chronically hypoxic rat airways, we also studied 
the effect of the nitric oxide synthase inhibitor, 1-nitroarginine methyl ester (L-NAME), 
on responses to methacholine and ET-1 in trachea from control and chronically hypoxic 
rats. *
In the previous chapter, I demonstrated that acute exposure to hypoxia can significantly 
enhance contractions evoked by*methacholine in isolated bovine bronchi (section 3). It 
remained to be seen, however, if this is also the case in rat bronchi or indeed if chronic 
exposure to hypoxia alters the sensitivity of the airways to acute changes in oxygen 
tension. In this study, we measured, in vitro, responses evoked by methacholine and
1 fOET-1 in the three oxygen tensions used in the previous study; 95% O2 (hyperoxia), 20% 
(normoxia) and 0% (hypoxia).
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4.2.1 Development Of Chronic Hypoxia
Rats were made chronically hypoxic as described in section 2.1.7.4. Age matched 
control rats were reared alongside the hypobaric chamber but were maintained in room 
air throughout.
4.2.2 Tissue Preparation And Measurement Of Contractile Responses
Tracheal ring preparations were obtained from control and chronically hypoxic rats as 
described in section 2.1.2.1 and mounted in 5ml organ baths as described in section 
2.1.1. Contractile responses were measured in oxygenated (95% O2, 5% CO2) Krebs-
Henseleit solution at 37 ± 0.5°C. Pilot experiments were conducted to determine the 
optimum level of applied tension for trachea from both control and hypoxic animals 
(see Figure 4.1). Under hyperoxic conditions, an initial resting tension of 0.25g wt was 
applied to each tracheal ring. Tissues were allowed to equilibrate for 15 minutes before 
addition of a single concentration of methacholine (10'4M). This concentration was 
chosen "as it evoked a near maximal 'Contractile response. When the contraction had 
reached a plateau, the tissues were washed three times with fresh Krebs-Henseleit 
solution over a 15 min period, or until the tension returned to baseline. Tension was 
then removed before increasing the degree of initial tension to the next increment (0.5g 
wt).
For subsequent measurement of agonist responses, the optimum tension (l.Og wt) was 
applied and tissues were allowed to equilibrate for 45 minutes, during which time 
tension was reapplied where necessary. Cumulative concentration-response curves were 
then constructed to either methacholine (10"10-3xlO"4M), endothelin-1 (ET-1, 10-11- 
3xlO-7M) or potassium chloride (1-70'mM). Results are expressed in mg wt.
To test whether exposure to chronic hypoxia might induce the release of 
cyclooxygenase metabolites or nitric oxide from the tracheal epithelium, we examined 
responses evoked by both methacholine and ET-1 in intact and epithelium-denuded 
tracheal rings in the presence and absence of (1) the cyclooxygenase inhibitor 
indomethacin (3xlO_6M) and (2) the nitric oxide synthase inhibitor LNAME (10-4M). 
Responses to methacholine are expressed as a % of the first curve (methacholine alone) 
maximum. On each experimental day, one tissue was subjected to two consecutive 
concentration-response curves to methacholine alone to ensure that responses did not 
alter with time.
Due to tachyphylaxis, it is not possible to perform consecutive concentration-response 
curves to ET-4 (see section 2.1.6), therefore tissues were initially stimulated with a 
maximal concentration (10~4M) of methacholine and responses to ET-1 expressed as a 
% of this response. Removal of the epithelial layer from tracheal preparations was 
verified by light microscopy.
In a separate series of experiments, tracheal rings were preconstricted with a single 
concentration of methacholine (3xlO_7M for control rat trachea and 10_6M for hypoxic 
rat trachea). The concentrations used were approximately the EC30 for methacholine in
trachea from control and chronically hypoxic rats. Once contractions had plateaued, 
cumulative concentration-response curves were constructed to salbutamol (10~9-10_4M) 
and sodium nitroprusside (10_9-10"4M). Results are expressed as % reversal of the 
initial methacholine contraction. On each experimental day, one tissue acted as a time 
control to ensure that the methacholine contraction was sustained.
To examine the effect of acute changes in oxygen tension on responses to methacholine 
and ET-1, the oxygen tension in the organ bath was reduced from hyperoxic levels as 
previously described (3.2.2).
For methacholine, four consecutive cumulative concentration-response curves (10“10- 
3 x 1 0 " 4 M ) ,  were constructed in each of the three oxygen tensions, firstly in hyperoxia 
and then in either normoxia or hypoxia followed by a final curve in hyperoxia again. 
Results are expressed as a % of the maximum response of the initial curve under 
hyperoxia. On each experimental day, one tissue acted as a time control whereby three 
consecutive concentration-response^curves to methacholine were conducted in 
hyperoxia alone.
As stated above, it is not possible to conduct three consecutive concentration-response 
curves to ET-1 (10-11-3xl0“7M) in the same tracheal ring, therefore each oxygen 
tension was imposed upon a different tracheal ring. As before, tissues were initially 
stimulated with a maximal concentration (10'4M) of methacholine and responses to ET- 
1 expressed as a % of this response.
4.2.3 Materials
The following chemicals were used; endothelin-1, indomethacin, L-NAME, 
methacholine, potassium chloride, salbutamol and sodium nitroprusside (for a list of 
suppliers and full chemical names, see section 2.1.8). Concentrations in the text refer to 
the salts, with the exception of salbutamol which is expressed as the base. Stock 
solutions of drugs were prepared in distilled water and subsequent dilutions made in 
Krebs-Henseleit solution, with the exception of indomethacin which was dissolved in 
ethanol. In experiments where indomethacin was used, one tissue acted as a vehicle 
control whereby an appropriate volume of ethanol was added to the bath.
4.2.4 AnalysisOf Results
As stated in section 2.1.9, results are expressed as mean ± s.e.mean. Statistical 
significance between data sets was tested by two-way analysis of variance. Significance 
between maximum responses and pD2 values (the negative log of the concentration
evoking 50% of the maximum response) was calculated using Student's t-test. Due to
financial restraints, a maximum contractile response to ET-1 could not be obtained ana 
hence a pD2 value could not be calculated. In this study, therefore, results for ET-1 
have been expressed in terms of the negative log concentration of the EC4oomg (see
section 2.1.9.2). This system of expressing results is similar to that used by MacLean et 
al. (1992) and Nally et al. (1994b). Significance between EC400mg values was
calculated using Student's t-test. A probability level of P<0.05 was considered 
significant. Number of observations (n) refers to the number of animals used.
4.3 RESULTS
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4.3.1 Optim isation Of Initial Resting Tension
For both chronically hypoxic rat trachea and control rat trachea, changing the degree of 
applied (passive) tension significantly altered the contractile (active) response evoked by 
a near maximal concentration of methacholine (10_4M). The measured contractile 
response increased as the applied tension was increased from 0.25g wt to 0.5g wt, 
reaching a maximum contraction at l.Og wt (Figure 4.1). When the applied tension was 
increased beyond l.Og wt, there was no significant change in the contractile response to 
10"4M methacholine. For control rat trachea, the maximum response to methacholine, at 
a resting tension of l.Og wt, 1156.1±181.3mg wt, was not significantly different than 
the maximum response in chronically hypoxic rat trachea, 1121.4±193.0 mg wt. 
Number of observations (n) =6 in each case.
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Figure 4.1
The effect of changing the degree of initial resting tension on contractile responses. 
Under hyperoxic conditions, contractions evoked by a single concentration (lO^M) of 
methacholine were measured in tracheal rings from control (open columns) and 
chronically hypoxic rats (stipled columns). Responses are expressed in milligrams 
weight (mg~wt). For both control and chronically hypoxic rat trachea, the optimum 
resting tension was l.Og wt. At this tension, the contractile response to methacholine in 
control rat trachea was not significantly different from the response in trachea from 
chronically hypoxic rats. Number of observations (n) = 6 in each case.
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4.3.1 The Effect Of Chronic Hypoxia On Agonist Responses
Methacholine, ET-1 and KC1 each evoked concentration-dependent contractions of 
tracheal rings isolated from control rats (see Figures 4.2 and 4.3). The threshold 
concentration for contraction in each case was between 3x1 O'10 and 3xlO"9M for 
methacholine, between 10"10 and 3xlO_1^ M for ET-1 and between 1 and lOmM for 
KC1. Exposure to chronic hypoxia significantly attenuated contractile responses to 
methacholine (P<0.05 for data sets, n=32), ET-1 (PcO.Ol for data sets, n=16) and KC1 
(PcO.Ol for data sets, n=24) (Figure 4.3). Chronic hypoxia attenuated the sensitivity of 
the tissue to methacholine (pD2 values for methacholine in control rat trachea; 
5.99±0.08 and for methacholine in hypoxic rat trachea; 5.68±0.10, P<0.05 for data 
points, n=32), but not to ET-1 (-log EC400mg values for ET-1 in control rat trachea, 
8.29+0.12 and ET-1 in hypoxic rat trachea, 8.04±0.18, n=8). Maximum responses to 
methacholine were not altered by chronic hypoxia (maximum response to methacholine 
in control rat trachea; 1224.5+113.6mg wt and maximum response to methacholine in 
hypoxic rat trachea; 1067.4±121.3mg wt), however, the maximum responses to both 
ET-1 and KC1 were significantly attenuated by chronic hypoxia (maximum response to 
ET-1 in control rat trachea; 1539.0il57.4mg wt and maximum response to ET-1 in 
hypoxic rat trachea; 984.1+118.9, P<0.05 for data points, n=8. Maximum response to 
KC1 in control rat trachea; 789.3±49.3mg wt and maximum response to KC1 in hypoxic 
rat trachea; 600.1±56.1mg wt, P<0.05 for data points, n=24.).
Figure 4.2
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Figure 4.2
Representative traces depicting contractile  responses evoked by (A) m ethacholine and 
(B) endothelin-1 in rat tracheal rings. M ethacholine was added cum ulatively to give 
final bath concentrations of 10-1()M - 3xl()~4M. Endothelin-1 was added cum ulatively  
to give final bath concentrations o f 1()_11M - 3xl()~7M. Before addition o f endothclin- 
1, a single concentration  o f m ethacholine (1()~4M) was added to produce a reference 
contraction. C onsecutive concentrations w ere added after the previous response had 
reached a plateau.
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Figure 4.3
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Figure 4.3
C um ulative concentration-response curves to (A) m ethacholine, (B) ET-1 and (C) KC1 
in tracheal rings from  control ( • )  and chronically hypoxic (O ) rats. Chronic hypoxia 
significantly attenuated responses to methacholine (P<0.05 for data sets, n=32), ET-1 
(PcO.Ol for data sets, n=16) and KC1 (PcO.Ol for data sets, n=24).
4.3.2 The Effect Of Epithelial Removal On Agonist Responses
Consecutive concentration-response curves to methacholine alone were not 
significantly different from each other, indicating that methacholine responses did not 
alter with time (data not shown). In trachea from control rats, removing the epithelial 
layer significantly (P<0.05 for data sets, n=8) enhanced responses to methacholine 
(Figure 4.4A). Removing the epithelium enhanced the sensitivity of the tissue to 
methacholine (pD2 values for methacholine in intact control rat trachea; 6.32±0.08 and 
pD2 values for methacholine in denuded control rat trachea; 6.61±0.15, P<0.05 for data 
points, n=8) but did not alter the maximum contractile response (maximum response to 
methacholine in intact control rat trachea; 99.9±0.2% and maximum response to 
methacholine in denuded control rat trachea; 115.2±14.7%, n=8). Removing the 
epithelium had a similar effect on methacholine responses in trachea from chronically 
hypoxic rats. Responses to methacholine were significantly (P<0.05 for data sets, n=8) 
enhanced in epithelial-denuded tracheal rings from hypoxic rats (Figure 4.4B). Again, 
removing the epithelium increased the sensitivity of the tissue to methacholine (pD2 
values for methacholine in intact hypoxic rat trachea; 6.04±0.06 and pD2 values for 
methacholine in denuded hypoxic rafirachea; 6.26±0.08, P<0.05, n=8) without altering 
the maximum response to methacholine (maximum response to methacholine in intact 
hypoxic rat trachea; 99.9±1.1% and maximum response to methacholine in denuded 
hypoxic rat trachea; 111.6±13.9%, n=8).
In epithelium-denuded tracheal rings from control rats, contractile responses to ET-1 
were also significantly (P<0.05 for data sets, n=8) enhanced (Figure 4.5A). Removing 
the epithelium evoked a significant increase in the sensitivity of the tissue to ET-1 (-log 
EC400mg values for ET-1 in intact control rat trachea; 8.29±0.09 and -log EC400mg 
values for ET-1 in denuded control rat trachea; 8.69±0.12, P<0.05 for data points, n=8), 
albeit without altering the maximum response (maximum response to ET-1 in intact 
control rat trachea; 74.8±8.5% and maximum response to ET-1 in denuded control rat 
trachea; 84.1 ±9.9%, n=8). In chronically hypoxic rats, removing the epithelium again 
significantly (PcO.Ol, for data sets, n=8) enhanced responses to ET-1 (Figure 4.5B). 
Removing the epithelium increased the sensitivity of the tissue to ET-1 (-log EC4oomg 
values for ET-1 in intact hypoxic rat trachea; 7.92±0.11 and -log EC4oomg values for 
ET-1 in denuded hypoxic rat trachea; 8.42±0.09, PcO.Ol for data points, n=8), but did 
not alter the maximum response (maximum response to ET-1 in intact hypoxic rat 
trachea; 84.7± 10.6% and maximum response to ET-1 in denuded hypoxic rat trachea; 
92.4±13.7%, n=8).
Figure 4.4
150
125
|
E 100
E
ou
■*-* 75 -
50 -
-10 9 •8 •7 6 ■5 4 -3
log[MCh](M)
150
125
100
50 -
a
25 -
-10 9 ■8 ■7 6 ■5 4 ■3
log[MCh](M)
173
Figure 4.4
Cumulative concentration-response curves to methacholine (10-1°-3xl0-4M) in intact 
( • )  and epithelial-denuded (O) tracheal rings from (A) control rats and (B) chronically 
hypoxic rats. Removing the epithelium significantly (P<0.05 for data sets, n=8) 
enhanced responses to methacholine in both control and chronically hypoxic rats.
Figure 4.5
Cumulative concentration-response curves to ET-1 (10'11-3X10_7M) in intact ( • )  and 
epithelial-denuded (O) tracheal rings from (A) control rats and (B) chronically hypoxic 
rats. Removing the epithelium significantly (P<0.05 and PcO.Ol, respectively for data 
sets, n=8) enhanced responses to ET-1 in both control and chronically hypoxic rats.
Figure 4.5
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4.3.3 Effect Of Cyclooxygenase Blockade
Indomethacin (3xlO'6M) did not alter responses to methacholine in tracheal rings from 
either control (Figure 4.6A) or chronically hypoxic rats (Figure 4.6B). For control rats, 
the maximum response to methacholine alone was 99.6±0.3% and the maximum 
response to methacholine in control rat trachea pretreated with indomethacin was 
111.6±16.6%, n=8. The pD2 values for methacholine alone in control rat trachea were 
6.23±0.08 and pD2 values for methacholine in control rat trachea pretreated with 
indomethacin were 6.07±0.12, n=8. For chronically hypoxic rats the maximum 
response to methacholine alone was 99.1 ±4.7% and the maximum response to 
methacholine in hypoxic rat trachea pretreated with indomethacin was 95.3± 14.4%, 
n=8. The pD2 values for methacholine alone in hypoxic rat trachea were 6.21±0.06 and 
the pD2 values for methacholine in control rat trachea pretreated with indomethacin 
were 6.15±0.13, n=8.
In addition, indomethacin did not alter responses evoked by ET-1 in tracheal rings from 
control rats (Figure 4.7A, maximum response to ET-1 in control rat trachea; 71.5±8.2% 
and maximum response to ET-1 in control rat trachea pretreated with indomethacin; 
77.3±10.2%, n=8. -log EC400mg values for ET-1 in control rat trachea; 8.19±0.07 and 
pD2 values for ET-1 in control rat trachea pretreated with indomethacin; 8.08±0.12, 
n=8) or chronically hypoxic rats (Figure 4.7B, maximum response to ET-1 in hypoxic 
rat trachea; 87.8±8.2% and maximum response to ET-1 in hypoxic rat trachea 
pretreated with indomethacin; 87.9±7.6%, n=8. -log EC^Omg values for ET-1 in 
hypoxic rat trachea; 7.86±0.08 and -log EC400mg values for ET-1 in hypoxic rat trachea 
pretreated with indomethacin; 7.72±0.10, n=8).
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Figure 4.6
Cumulative concentration-response curves to methacholine (10 '10-3xlO~4M) alone ( • ) ,  
or in the presence of 3xlO‘6M indomethacin (O) in tracheal rings from (A) control rats 
and (B) chronically hypoxic rats. Pretreatment with indomethacin did not alter 
responses to methacholine in either control or chronically hypoxic rats.
Figure 4.7
Cumulative concentration-response curves to ET-1 (10-11-3xl0-7M) alone ( • ) ,  or in 
the presence of either 10"4M L-NAME (O) or 3xlO_6M indomethacin (□) in tracheal 
rings from (A) control rats and (B) chronically hypoxic rats. Pretreatment with 
indomethacin did not alter responses to ET-1 in either control or chronically hypoxic 
rats. In contrast, pretreatment with L-NAME significantly (P<0.05 and PcO.Ol, 
respectively for data sets) enhanced responses to ET-1 in trachea from both control and 
hypoxic rats.
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4.3.4 Effect Of Nitric Oxide Synthase Blockade
In tracheal rings from control rats, addition of the nitric oxide synthase blocker L- 
NAME to the organ bath resulted in a small (<200mg wt ) but sustained contractile 
response in 3 from 16 tissue preparations. In tissue from chronically hypoxic rats, the 
contractile response to L-NAME was of a similar magnitude, but was present in 5 from 
16 preparations.
L-NAME (10_4M) significantly (P<0.05 for data sets, n=8) potentiated methacholine 
responses in tracheal rings from control rats (Figure 4.8A, pD2 values for methacholine 
in control rat trachea; 6.29±0.10 and pD2 values for methacholine in control rat trachea 
pretreated with L-NAME; 6.62±0.14, P<0.05 for data points, n=8), albeit without 
altering the maximum response (maximum response to methacholine in control rat 
trachea; 99.9±0.1% and maximum response to methacholine in control rat trachea 
pretreated with L-NAME; 116.2±14.6%, n=8).
In trachea from chronically hypoxic rats, L-NAME significantly (PcO.Ol for data sets) 
enhanced responses to methacholine, in this case with a concomitant increase in the 
maximum response (Figure 4.8B, maximum response to methacholine in hypoxic rat 
trachea; 99.9±1.1% and maximum response to methacholine in hypoxic rat trachea; 
126.2±11.9%, P<0.05 for data points, n=8) as well as an increase in the sensitivity of 
the tissue to methacholine (pD2 values for methacholine in hypoxic rat trachea; 
5.98±0.09 and pD2 values for methacholine in hypoxic rat trachea pretreated with L- 
NAME; 6.49±0.11, P<0.01 for data points, n=8).
In addition, L-NAME (10_4M) significantly (P<0.05 for data sets, n=8) potentiated 
responses to ET-1 in tracheal rings from control rats (Figure 4.7A, -log EC4oomg values 
for ET-1 in control rat trachea; 8.20±0.11 and -log EC400mg values for ET-1 in control 
rat trachea pretreated with L-NAME; 8.51±0.07, P<0.05 for data points, n=8), albeit 
without altering the maximum response (maximum response to ET-1 in control rat 
trachea; 71.5±8.2% and maximum response to ET-1 in control rat trachea pretreated 
with L-NAME; 82.3±10.5%, n=8).
In trachea from chronically hypoxic rats, L-NAME significantly (PcO.Ol for data sets) 
enhanced responses to ET-1, in this case with a concomitant increase in the maximum 
response (Figure 4.7B, maximum response to ET-1 in hypoxic rat trachea; 87.8±8.2% 
and maximum response to ET-1 in hypoxic rat trachea; 110.2±7.2%, P<0.05 for data 
points, n=8) as well as an increase in the sensitivity of the tissue to ET-1 (-log EC400mg 
values for ET-1 in hypoxic rat trachea; 7.86±0.08 and -log EC400mg values for ET-1 in 
hypoxic rat trachea pretreated with L-NAME; 8.16±0.09, P<0.05 for data points, n=8).
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Figure 4.8
Cumulative concentration-response curves to methacholine (10"10-3xl0_4M) alone ( • ) ,  
or in the presence of 10_4M L-NAME (O) in tracheal rings from (A) control rats and 
(B) chronically hypoxic rats. Pretreatment with L-NAME significantly (P<0.05 and 
PcO.Ol, respectively for data sets, n=8) enhanced responses to methacholine in both 
control and chronically hypoxic rats.
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4.3.5 Effect O f Chronic Hypoxia On Relaxatory Responses To 
Salbutamol And Sodium Nitroprusside
Salbutamol and sodium nitroprusside both reversed methacholine-induced contractions 
in a concentration dependent manner. Salbutamol initiated responses at concentrations 
of 10-8M in control rat bronchi and between 10'8M and 3xlO"8M in hypoxic rat bronchi 
(Figure 4.9A). Chronic hypoxia did not alter the ability of salbutamol to reverse 
methacholine-induced contraction (mean maximal inhibitions, at the 10"4M level; 
36.6±6.0% in control rat bronchi and 40.7±6.3% in bronchi from chronically hypoxic 
rats).
Sodium nitroprusside was of similar potency to salbutamol, initiating responses at 
concentrations of 3xlO“8M in control rat bronchi and 10'8M in bronchi from hypoxic 
rats (Figure 4.9B). In contrast, chronic hypoxia significandy (PcO.OOl for data sets, 
n=8) enhanced responses evoked by sodium nitroprusside, albeit without altering the 
maximum responses (mean maximal inhibitions, at the 10“4M level; 54.6+3.1% in 
control rat bronchi and 64.1±6.4% in bronchi from chronically hypoxic rats).
Figure 4.9
Reversal of methacholine-induced tone in tracheal rings from control ( • )  and 
chronically hypoxic rats (O) by cumulative addition of (A) salbutamol (10"9-10'4M) 
and (B) sodium nitroprusside (10'9-10“4M). Responses to sodium nitroprusside, but 
not salbutamol, were significantly (PcO.OOl for data sets, n=8) greater in trachea from 
chronically hypoxic rats.
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4.3.6 Effect Of Acute Changes In Oxygen Tension On Methacholine And ET-1 
Responses
In trachea from control rats, changing the oxygen tension from 95% to 20% did not 
alter the responses evoked by methacholine (pD2 in 20% O2; 6.10±0.14 compared with 
the pD2 value in 95%; 6.28±0.11. Maximum response in normoxia; 96.8±10.9% 
compared with the maximum response in hyperoxia; 99.7±0.3%). When the oxygen 
tension was lowered to hypoxic levels, responses to methacholine were significantly 
(P<0.01 for data sets, n=6) attenuated, albeit with no change in the sensitivity of the 
tissue (pD2 in hypoxia; 6.27±0.19 compared with pD2 in 95%; 6.28±0.11). The
maximum response to methacholine, however, was significantly (P<0.05 for data 
points, n=6) attenuated in hypoxia (maximum response in hypoxia; 70.1±9.8% 
compared with the maximum response in hyperoxia; 99.7±0.3%, see Figure 4.10A). 
When the oxygen tension was returned to hyperoxic levels and a fourth concentration 
response curve constructed to methacholine, responses were not significantly different 
from the initial responses in hyperoxia (pD2 for second hyperoxic curve; 6.17±0.15 
compared with the pD2 value for the initial hyperoxic curve; 6.28±0.11. Maximum 
response for the second hyperoxic curve; 92.8±9.4% compared with the maximum 
response for the initial hyperoxic curve; 99.7±0.3%).
Trachea from hypoxic rats showed a similar pattern in that responses to methacholine 
were not altered by lowering the oxygen tension from 95% to 20% (pD2 in 20% O2; 
6.30±0.12 compared with pD2 in 95%; 6.08±0.16. Maximum response in 20% O2; 
107.8±13.4% compared with the maximum response in hyperoxia; 99.9±0.03%, 
whereas in hypoxia responses to methacholine were significantly (P<0.05 for data set, 
n=6) attenuated. Again there was no change in the sensitivity of the tissue to 
methacholine (pD2 in hypoxia O2; 6.14±0.10 compared with pD2 in hyperoxia;
6.08±0.16), while the maximum response in hypoxia was significantly (P<0.05 for data 
points, n=6) attenuated. (Maximum response in hypoxia; 75.1±10.3% compared with 
the maximum response in hyperoxia; 99.9±0.03%, see Figure 4.10B).
In addition, when the oxygen tension was returned to hyperoxic levels and a fourth 
concentration response curve constructed to methacholine, responses were not 
significantly different from the initial responses in hyperoxia (pD2 for second 
hyperoxic curve; 6.19±0.18 compared with the pD2 value for the initial hyperoxic 
curve; 6.08±0.16. Maximum response for the second hyperoxic curve; 90.8±10.4% 
compared withrthe maximum response for the initial hyperoxic curve; 99.8±0.2%).
There was no significant difference between the three consecutive methacholine- 
concentration response curves conducted in 95% O2 (data not shown), thus indicating
that responses to methacholine are not altered by time.
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Figure 4.10
Cum ulative concentration-response curves to m ethacholine (10“10-3 x l0 "4M ) in oxygen 
tensions o f hyperoxia (initial curve, • ) ,  norm oxia (O ), hypoxia (■ ) and hyperoxia 
again (final curve, □ )  in tracheal rings from  (A) control rats and (B) chronically 
hypoxic rats. Acute hypoxia significantly im paired responses to m ethacholine in both 
control (PcO.Ol, respectively for data sets, n=6) and chronically hypoxic (P<0.05, 
respectively for data sets, n=6) rats.
There were close similarities in the pattern of responses evoked by methacholine ana 
ET-1. In control rat trachea, changing the oxygen tension from 95% to 20% did not 
alter the responses evoked by ET-1 (-log ECz^Omg values for ET-1 in 20% O2; 
8.28±0.13 compared with -log EC400mg values in 95%; 8.34±0.12. Maximum response 
in normoxia; 76.1±10.6% compared with the maximum response in hyperoxia; 
70.7±9.9%). When the oxygen tension was lowered to hypoxic levels, however, 
responses evoked by ET-1 were significantly (PcO.Ol for data sets, n=6) attenuated, 
with a significant (P<0.05 for data points) decrease in the maximum response 
(maximum response in hypoxia; 48.5±7.9% compared with the maximum response in 
hyperoxia; 70.7±9.9%). There was no change, however, in the sensitivity of the tissue 
to ET-1 (-log EC400mg values for ET-1 in hypoxia; 8.08±0.19 compared with -log 
EC400mg values in hyperoxia; 8.34±0.12, see Figure 4.11 A).
To illustrate the comparability of expressing the data in different ways, results are 
expressed both in absolute terms (mg wt) and as a % of the reference contraction to 
methacholine. Expressing the results either as a % of the initial contractile response to 
methacholine (Figure 4.11 A) or in mg wt (Figure 4.1 IB) did not alter the overall 
pattern of responses. In both cases, contractile responses to ET-1 were not significantly 
different in hyperoxia or normoxia, but were significantly (PcO.Ol for data sets, n=6) 
attenuated.
In trachea from hypoxic rats, there was no difference between responses to ET-1 in 95 
and 20% O2 (-log EC4oomg values for ET-1 in 20% O2; 7.93±0.13 compared with -log 
EC400mg values in 95%; 7.89±0.12. Maximum response in normoxia; 85.6±11.2% 
compared with the maximum response in hyperoxia; 81.9±9.8%). In hypoxia, however, 
responses were significantly (PcO.OOl for data set, n=6) attenuated, with a significant 
(PcO.Ol for data points) decrease in the maximum response (maximum response in 
hypoxia; 42.2±7.9% compared with the maximum response in hyperoxia; 81.9±9.8%). 
There was no change, however, in the sensitivity of the tissue to ET-1 (-log EC4oomg 
values for ET-1 in hypoxia; 7.60±0.21 compared with -log EC400mg values in 
hyperoxia; 7.89±0.12, see Figure 4.12).
Expressing the results either as a % of the initial contractile response to methacholine 
(Figure 4.12A) or in mg wt (Figure 4.12B) did not alter the overall pattern of responses. 
In both cases, contractile responses to ET-1 were not significantly different in 
hyperoxia or normoxia, but were significantly (PcO.Ol for data sets, n=6) attenuated.
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Figure 4.11
Cum ulative concentration-response curves to ET-1 (10_11-3 x l0 "7M) in oxygen tensions 
o f hyperoxia ( • ) ,  norm oxia (O ) or hypoxia (□ ) in tracheal rings from  control rats. 
R esponses are expressed as (A) a % of the initial reference contraction to  m ethacholine 
and (B) in mg wt. In both cases, acute hypoxia significantly (in each case, PcO.Ol, 
respectively for data  sets, n=6) im paired responses to ET-1 in control rats.
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Figure 4.12
Cum ulative concentration-response curves to ET-1 (10_11- 3 \1 0 '7M) in oxygen tensions 
of hyperoxia ( • ) ,  norm oxia (O ) or hypoxia (□ ) in tracheal rings from  chronically 
hypoxic rats. R esponses are expressed as (A) a % of the initial reference contraction to 
m ethacholine and (B) in mg wt. In both cases, acute hypoxia significantly (in each case, 
P<0.01, respectively for data sets, n=6) im paired responses to ET-1 in chronically 
hypoxic rats.
4.4 DISCUSSION
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Our initial results showed that responses evoked by the bronchoconstrictors 
methacholine and ET-1 were significantly attenuated in tracheal rings from chronically 
hypoxic rats compared to controls. These results are perhaps in keeping with the 
finding that chronic hyperoxia potentiates contractile responses in rat airways both in 
vivo and in vitro (Szarek, 1989; Hershenson et al., 1992a and b; Hershenson et al., 
1994; Szarek et al., 1995). A number of possible mechanisms exist which could explain 
the attenuation which we found in this present study. Both methacholine and ET-1 bind 
to and activate membrane-bound receptors which are coupled to G proteins and both 
agonists are thought to initiate contraction of airway smooth muscle via generation of 
the second messengers IP3 and DAG (Grandordy et al., 1986; Mattoli et al., 1991).
This led us to speculate that chronic hypoxia may inhibit some part of the signalling 
process which occurs between receptor activation and initiation of contraction. For 
example, in cardiac tissue, chronic hypoxia has been shown to cause down-regulation 
of (3-adrenoceptors (Voelkel et al., l'9fTl) as well as uncoupling of these receptors from 
their regulatory G proteins (Richalet, 1990). Whether this occurs with airway 
muscarinic and ET-1 receptors is unknown, however, chronic hypoxia has been shown 
to cause a down-regulation in cholinergic responsiveness in rat pulmonary arteries 
(Orton et al., 1988). Furthermore, it has also been demonstrated that lung ET-1 levels 
are elevated by chronic hypoxia (Elton & Oparil, 1992), which would be expected to 
result in down-regulation of endothelin receptors.
Our results with KC1, however, would suggest that the attenuation of contractile 
responses is due to some reason other than alterations, in receptor number or impairment 
of signal transduction processes. KC1 evokes contraction of smooth muscle by causing 
depolarization of the smooth muscle membrane, resulting in the stimulation of 'L'-type 
voltage operated Ca2+ channels (see section 1.3.2.4). Contractions evoked by KC1 
therefore represent a direct stimulation of airway smooth muscle which does not 
involve receptor activation and generation of second messengers. The results for KC1 
followed a similar pattern to methacholine and ET-1, namely a significant impairment 
of contractile responses in trachea from chronically hypoxic rats. This indicates that 
some other mechanism(s) must be responsible for the attenuation of agonist-induced 
contractions.
A previous study by Hershenson et al (1994) demonstrated that hyperoxia-induced 
airway hyperresponsiveness was substantially reduced by either epithelial removal or 
treatment wiTFTthe cyclooxygenase inhibitor indomethacin. This strongly suggests that 
epithelium-derived cyclooxygenase metabolites contribute to the increased airway 
reactivity in rats exposed to chronic hyperoxia. This led us to postulate that release of 
cyclooxygenase metabolites (perhaps inhibitory prostaglandins or prostacyclin) could 
be responsible for the attenuation of contractile responses in chronically hypoxic rat
airways. In this present study, removing the epithelium enhanced responses to 
methacholine and ET-1 in tracheal rings from both control and chronically hypoxic rats, 
suggesting that the epithelium is indeed releasing an inhibitory factor in both of these 
preparations. Indomethacin, however, did not alter responses evoked by these agonists 
in either control or hypoxic rats, indicating that this inhibitory factor is not a 
cyclooxygenase metabolite. Our results suggest that this inhibitory factor may be nitric 
oxide or a nitric oxide-like substance, since the nitric oxide synthase inhibitor L-NAME 
enhanced contractions evoked by methacholine and ET-1. Chronic hypoxia increases 
nitric oxide synthase expression in the rat lung and induces de novo nitric oxide 
synthase expression in the rat pulmonary artery endothelium (Xue et al., 1994), 
supporting the suggestion of an increased basal release of nitric oxide in the chronically 
hypoxic rat lung. More recently Shaul et al (1995) demonstrated that expression of 
nitric oxide synthase I, the isoform of nitric oxide synthase localized to the airway 
epithelium in rats (Schmidt et al., 1992), is increased in rats exposed to chronic 
hypoxia. This suggests that an increased release of nitric oxide may be responsible for 
the attenuation in contractile responses in airways from chronically hypoxic rats. 
Perhaps in keeping with the finding that nitric oxide synthase is expressed in the airway 
epithelium of both control and chronically hypoxic rats (Xue et al., 1994), we found 
that L-NAME not only potentiated contractions in chronically hypoxic trachea, it also 
enhanced responses in control tissue. It would appear, therefore, that the 
hyporesponsiveness of chronically hypoxic rat trachea is not simply due to the release 
of nitric oxide, since nitric oxide is also released from control rat trachea. This led us to 
speculate that the responsiveness of the airway smooth muscle to nitric oxide may be 
altered by chronic hypoxia. To this end, we conducted experiments whereby the ability 
of the nitric oxide donor SNP to reverse methacholine-induced tone was compared in 
trachea from control and chronically hypoxic rats. As shown in Figure 4.7, responses to 
SNP were significantly greater in trachea from chronically hypoxic rats. This does not 
appear to represent a non-specific enhancement of bronchodilator responses, since 
responses to the p2-adrenoceptor agonist salbutamol, which acts via stimulation of
adenylyl cyclase (Rinard et al., 1983) as well as opening of membrane potassium 
channels (Miura et al., 1992), were not altered by chronic hypoxia. Mindful of the 
reduced contractile response to methacholine in hypoxic rat trachea, we used 
concentrations of methacholine which produced approximately 30% of the maximum 
contractile response in trachea from both control and hypoxic rats. This, together with 
the finding that salbutamol responses were unaltered by chronic hypoxia, indicates that 
the enhancement of SNP responses is unlikely to be due to the inverse relationship 
between the level of airway tone and the potency of relaxant agonists (Van den Brink, 
1973).
Interestingly, a recent study in Fisher rats, a strain of rats which exhibit airway 
hyperrresponsiveness, found results which are in direct contrast to our findings. Jia et al 
(1995) demonstrated that contractile responses to carbachol were potentiated in the
Fisher rats while relaxant responses to SNP were attenuated. The authors speculated ^  
that the increased responsiveness to spasmogens in these rats is due to a decreased 
guanylyl cyclase response to nitric oxide. In favour of this hypothesis is the finding that 
SNP produces significantly less cGMP in airway smooth muscle from Fisher rats than 
controls (Jia et al., 1995). Our results with L-NAME indicate that airways of 
chronically hypoxic and control rats release nitric oxide or a nitric oxide-like substance 
which opposes contractile responses. It may be possible, therefore, that the decreased 
response to spasmogens and increased response to SNP which we found in chronically 
hypoxic rats in our study is due to an increased guanylyl cyclase response produced by 
chronic exposure to hypoxia, although further studies must be undertaken to elucidate 
this.
Nitric oxide may be released from a number of potential sources within the airways, 
including airway smooth muscle (Xue et al., 1994), non-adrenergic non-cholinergic 
nerve terminals (Belvisi et al., 1991; Li & Rand, 1991), alveolar macrophages (Stuehr 
& Marietta, 1987) and inflammatory cells (McCall et al., 1989). Our results showed 
that removing the epithelium mimics the effect of L-NAME on contractile responses in 
both control and hypoxic rats, sugjgesting that nitric oxide or a nitric oxide-like 
substance is being released from the epithelial layer in our preparations. In dogs (Gao & 
Vanhoutte, 1993) and rabbits (Spina & Page, 1991) it has been proposed that the airway 
epithelium is not a major source for endogenous nitric oxide-like substances, however, 
previous studies have indeed confirmed nitric oxide synthase expression in the airway 
epithelium of both control and chronically hypoxic rats (Xue et al., 1994). Soluble 
guanylyl cyclase, however, appears to be localized to the airway smooth muscle and not 
the epithelium (Rengasamy et al., 1994), indicating that nitric oxide performs a 
paracrine role in the respiratory system, being produced by the airway epithelium and 
activating soluble guanylyl cyclase in airway smooth muscle. The functional role of the 
nitric oxide synthase signalling pathway in the control of airway function remains 
controversial (Munakata et al., 1990; Nijkamp et al., 1993; Spina & Page, 1991; Stuart- 
Smith, 1990), but our results support physiological studies which suggest that 
endogenous nitric oxide may act as a bronchodilator (Alving et al., 1993). In our 
present study, adding L-NAME to the organ baths resulted in a small contraction in 3 
from 16 tracheal rings from control rats and 5 from 16 from hypoxic rats. This indicates 
that there was basal release of nitric oxide in only a few tissue preparations, whereas L- 
NAME significantly potentiated contractions in almost all cases. This suggests that 
nitric oxide may be released in response to contraction of the airway smooth muscle 
and would then act to oppose the contractile response.
In addition, I chose to study the effect of acute changes in oxygen tension on contractile 
responses in both control and chronically hypoxic rats. Our results showed that 
lowering the oxygen tension from hyperoxic to normoxic levels did not alter responses 
to methacholine or ET-1, in either the control or the hypoxic rats. When the oxygen 
tension was lowered to hypoxic levels, however, responses to both methacholine and
ET-1 were significantly attenuated. The pattern of responses was similar between the' 
control and the chronically hypoxic rats, indicating that prior exposure to chronic 
hypoxia does not alter the sensitivity of the airways to acute changes in oxygen tension. 
Furthermore, returning the oxygen tension from hypoxic to hyperoxic levels returned 
the contractile responses to levels similar to those of the first hyperoxic response. This 
indicates that the attenuation of contractile responses caused by acute hypoxia are 
reversible and therefore not due to hypoxia-mediated apoptosis of the airway smooth 
muscle cells.
In summary, contractile responses to methacholine, ET-1 and KC1 were attenuated in 
isolated trachea from chronically hypoxic rats. Indomethacin did not alter responses to 
methacholine or ET-1, however, addition of L-NAME or removal of the epithelium 
significantly enhanced contractile responses in both control and chronically hypoxic 
rats. The ability of SNP to reverse methacholine-induced tone was enhanced in trachea 
from chronically hypoxic rats. These results show that, in both chronically hypoxic and 
control rats, contractile responses to methacholine and ET-1 are attenuated by nitric 
oxide which appears to be released from the airway epithelium. The attenuation of 
contractile responses in airways from chronically hypoxic rats may be due to an 
enhanced guanylyl cyclase activity and hence, an increased response to nitric oxide.
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CHAPTER 5
THE EFFECT OF CHRONIC HYPOXIA ON ENDOTHELIN 
RECEPTOR SUBTYPE-MEDIATED RESPONSES IN RAT
ISOLATED AIRWAYS
5.1 INTRODUCTION 194
Endothelin-1 (ET-1) is one of the most potent bronchoconstrictors yet isolated, 
producing prolonged contractions of airway smooth muscle both in vivo and in vitro 
(McKay et al., 1992). ET-1 is produced and released from airway epithelial cells (Black 
et al., 1989; Mattoli et al., 1990) as well as alveolar macrophages (Ehenreich et al., 
1990). Elevated levels of ET-1 have been reported in bronchoalveolar lavage from 
asthmatic patients (Nomura, 1989) and expression of ET-1 is increased in bronchial 
epithelial cells cultured from asthmatics (Springall et al., 1991; Vittori et al., 1992) 
suggesting a possible role for ET-1 as a mediator in asthma.
At least two distinct endothelin receptor subtypes, ETa and ETb, exist in mammalian 
tissues (Arai et al., 1990; Sakurai et al., 1990). The ETa receptor has a higher affinity 
for ET-1 or ET-2 compared with ET-3, whereas the ETb receptor has equal affinity for 
the three members of the ET family (Masaki, 1991). It is now established that both ETa 
and ETb receptors can mediate ET-1-induced contraction of airway smooth muscle 
(Hay, 1992; Hay et al., 1993; Henry, 1993), however, there appears to be considerable 
variation between species in termJPof which receptor subtype predominates. For 
example, in guinea-pig tracheal smooth muscle, ET-1 evokes contraction mainly via 
activation of ETb receptors (Hay, 1992), whereas in sheep airways, ET-1-induced 
bronchoconstriction is mediated by stimulation of ETa receptors (Abraham et al., 1993; 
Goldie et al., 1994). In rat trachea and also in human bronchus, ET-1-induced 
contractions appear to be mediated by activation of both ETa and ETb receptors 
(Henry, 1993; O' Donnell & Kay, 1995; Fukuroda et al., 1996).
Our preliminary experiments indicated that contractile responses to ET-1 were 
significantly attenuated in isolated airways from rats, exposed to chronic hypoxia (see 
section 4). This may be due to an alteration in the ET receptor population in the airways 
since hypoxia has been reported to alter the expression of ETA-receptor mRNA in rat
lungs (Li et al., 1994). Given that ET-1 appears to play a pathophysiological role in 
airway diseases such as asthma (Barnes, 1994), ET receptor antagonists may have a role 
in the clinical management of this disorder. It may be of importance, therefore, to 
discover if chronic hypoxia, which can often be a feature in severe asthma, alters the ET 
receptor subtypes which mediate contraction of airway smooth muscle. In this study, 
the ETb selective agonist sarafotoxin S6c (Williams et al., 1991), the ETa selective 
antagonist FR 139317 (Sogabe et al, 1993), the ETb selective antagonist BQ 788 
(Ishikawa et al., 1994) and the non-selective ET receptor antagonist SB 209670 
(Ohlstein et al., 1994) were used to characterize the ET receptor subtypes which 
mediate contraction of isolated trachea from chronically hypoxic and control rats. 
Furthermore experiments were undertaken to ascertain if ET receptor activation could 
induce reversal of agonist-induced tone in control and chronically hypoxic rats.
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5.2.1 Development Of Chronic Hypoxia
Rats were made chronically hypoxic as described in section 2.1.7.4. Age matched 
control rats were reared alongside the hypobaric chamber but were maintained in room 
air throughout.
5.2.2 Tissue Preparation
Tracheal ring preparations were obtained from control and chronically hypoxic rats as 
described in section 2.1.2.1 and mounted in 5ml organ baths as described in section 
2.1.1. Contractile responses were measured in oxygenated (95% O2, 5% CO2) Krebs-
Henseleit solution at 37 ± 0.5°C. Initial experiments indicated that, for both control and 
hypoxic animals, the optimum level of applied tension was 1.0 g wt. Tissues were 
allowed to equilibrate for 45 minutes, during which time tension was reapplied where 
necessary.
5.2.3 Measurement Of Contractile Responses
A reference response to methacholine (10“4M) was obtained for all preparations and 
tissues were allowed a further 45 minutes to equilibrate. Concentration-response curves 
were then constructed to either ET-1 (10_11-3xl0~7M) or sarafotoxin S6c (10-11-3xl0" 
7M) by cumulative addition to the organ baths. The ET receptor antagonists were added 
30 minutes before, and L-NAME 5 minutes before, addition of ET-1.
5.2.4 Measurement Of Relaxatory Responses
Rings of trachea from control and chronic hypoxic rats were prepared as above. 
Tracheal rings were preconstricted with a single concentration of methacholine (3xl0_ 
7M for control rat trachea and 10_6M for hypoxic rat trachea). The concentrations used 
were approximately the EC30 for methacholine in trachea from control and chronically
hypoxic rats. Endothelin receptor antagonists were then preincubated for 30 minutes 
prior to cumulative addition of either ET-1 (10_12-10'8M) or sarafotoxin S6c (10'12-10_ 
8M). In a separate series of experiments, cumulative concentration-response curves 
were constructed to sodium nitroprusside (10_9-10~4M) in tracheal rings preconstricted 
with methacholine. On each experimental day, one tissue acted as a time control to 
ensure that the methacholine contraction was sustained.
5.2.5 Data Analysis
Due to financial restraints, a maximum contractile response to ET-1 could not be 
obtained and hence a PEC50 value could not be calculated. In this study, therefore,
results for ET-1 have been expressed in terms of the negative log concentration of the 
EC200mg and the Echoing (see section 2.1.9.2). This system of expressing results is
196similar to that used by MacLean et al. (1992) and Nally et al. (1994b). Relaxatory 
responses are expressed as % reversal of the methacholine-induced tone.
As stated in section 2.1.9, results are expressed as mean ± s.e.mean. Statistical 
significance between data sets was tested by two-way analysis of variance. Significance 
between EC200mg and EC400mg values was calculated using Student's t-test. A
probability level of P<0.05 was considered significant. Number of observations (n) 
refers to the number of animals used.
5.2.6 Materials
The following chemicals were used; endothelin-1, BQ 788, FR 139317, L-NAME, 
methacholine, sarafotoxin S6c, sodium nitroprusside and SB 209670. For a list of 
suppliers and full chemical names, see section 2.1.8. Stock solutions of drugs were 
prepared in distilled water and subsequent dilutions made in Krebs-Henseleit solution.
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5.3.1 Responses To ET-1 And Sarafotoxin S6c In Control And Chronically 
Hypoxic Rats
Exposure to chronic hypoxia significantly (P<0.01 for data sets, n=8, Figure 5.1 A) 
attenuated contractile responses to ET-1 in rat isolated tracheal rings, with a significant 
attenuation of the maximum response to ET-1 (maximum response to ET-1 in control 
rat trachea; 1412.9±161.3mg wt and maximum response to ET-1 in hypoxic rat trachea; 
929.3± 129.7, P<0.05 for data points, n=8). The sensitivity of the tissue to ET-1 was 
not, however, altered by chronic hypoxia (see Table 5.1 for EC200mg and EC400mg
values).
The ETb receptor-selective agonist, sarafotoxin S6c, induced concentration-dependent 
contractions of isolated trachea from both control (Figure 5.IB) and chronically 
hypoxic rats (Figure 5.1C). Sarafotoxin was significantly more potent than ET-1 in 
control rat trachea, however, in trachea from chronically hypoxic rats, both sarafotoxin 
and ET-1 were equipotent (see Table 5.1 for EC200mg and EC^Omg values).
Table 5.1
Control and Chronically Hypoxic rat trachea
Group EC200mg 
(-log M)
EC400mg 
(-log M)
(n)
ET-1 control rat trachea 8.83 ±0.14 8.31 ±0.11 8
ET-1 hypoxic rat 8.73 ±0.12 7.98 ±0.16 8
trachea
Sx6c control rat trachea *9.33 ±0.18 *8.70 ±0.15 8
Sx6c hypoxic rat 8.82 ±0.16 8.12 ±0.17 8
trachea
Table 5.1: Responses to ET-1 and sarafotoxin S6c (Sx6c) in tracheal rings from control 
and chronically hypoxic rats. Sarafotoxin S6c was significantly more potent than ET-1 
in control rat trachea (*P<0.05 control S6c more sensitive than control ET-1). In 
chronically hypoxic rat trachea, ET-1 and sarafotoxin S6c were equipotent.
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Figure 5.1 A
C um ulative concentration-response curves to ET-1 (10_11-3xlO “7M) in tracheal rings 
from  control (■ ) and chronically hypoxic (□ ) rats. Responses to ET-1 were 
significantly  (P<0.01 for data sets) attenuated in tracheal rings from  chronically  
hypoxic rats (n=8).
Figure 5 .IB and 5.1C
C um ulative concentration-response curves to ET-1 (■ , 10“^ -3 x l0 " 7M ) and sarafotoxin 
S6C (□ , 10-1 1-3x 1 0 '7M) in tracheal rings from  (B) control rats and (C) chronically  
hypoxic rats. Sarafotoxin was significantly (P<0.05 for data sets) m ore poten t than ET-
J »
1 in tracheal rings from  control rat trachea, w hereas in chronically  hypoxic rat trachea, 
both peptides were o f sim ilar potency.
5.3.2 Antagonism Of ETa Receptors
In trachea from control rats, pre-incubating the ETa receptor antagonist, FR 139317, at a 
concentration of 10_8M significantly (P<0.05 for data sets) enhanced responses to ET-1 
(Figure 5.2A), albeit without altering the sensitivity of the tissue (see Table 5.2A for a 
summary of EC200mg and EC4oomg values). When the concentration of FR 139317 was
increased to 10-7 or 10_6M however, this enhancement of ET-1 contractions was lost 
(Figure 5.2A). At these concentrations, FR 139317 had no effect on responses to ET-1 in 
this tissue.
In trachea from chronically hypoxic rats, pre-incubation of FR 139317 at concentrations 
of 10'8, 10-7 or 10"6M had no significant effect on ET-1-mediated contractions (see 
Table 5.2B for a summary of EC200mg an(i EC^Omg values). Thus chronic hypoxia
appears to have "removed" the ability of low (10-8M) concentrations of FR 139317 to 
enhance ET-1 contractions (Figure 5.2B).
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Figure 5.2
Cum ulative concentration-response curves to ET-1 (10_11-3 x l0 ‘7M ) alone (■ ), or 
in the presence o f the ETa  receptor antagonist FR 139317 at concentrations o f (□ , 
10"8M ), (O , 10 '7M) or (A, 10-6M) in tracheal rings from  (A) control rats and (B) 
chronically hypoxic rats. At the 10_8M level, FR 139317 significantly potentiated  
responses to ET-1 in control rat trachea. At all other concentrations and in 
chronically hypoxic rat trachea, FR 139317 had no effect on E T-1-m ediated 
contractions.
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A
Control ra t trachea
Group EC200mg 
(-log M)
EC400mg 
(-log M)
(n)
ET-1 control 9.03 ±0.16 8.68 ±0.18 8
ET-1 plus 
FR 139317 10_8M 9.17 ±0.28 8.96 ±0.19 8
ET-1 plus 
FR 139317 10_7M 8.93 ±0.18 8.63 ±0.17 8
ET-1 plus 
FR 139317 10"6M 7.96 ± 0.29 8.88 ±0.15 8
it
i\
ti
i!
B
Chronically Hypoxic ra t tracheat1j Group EC200mg 
(-log M)
EC400mg 
(-log M)
(n)
i ET-1 control 8.75 ± 0.07 7.94 ±0.11 8
1!
\i
i
ET-1 plus 
FR 139317 10-gM 8.62 ±0.16 7.89 ±0.21 8
Ii1
[
ET-1 plus 
FR 139317 10-7M 8.95 ±0.25 7.82 ± 0.20 7
[t!|
ET-1 plus 
FR 139317 lO-^M 8.78 ± 0.24 7.79 ± 0.23 8
Table 5.2: EC200mg and EC4oomg values for ET-1 in the presence and absence of the 
ETa receptor antagonist FR 139317 in tracheal rings from (A) Control rats and (B) 
Chronically hypoxic rats. Statistical comparison between values was calculated by 
Student's t-test. In both control and chronically hypoxic rat trachea, FR 139317 did not 
alter the sensitivity of the tissue to ET-1.
5.3.3 Antagonism Of ETg Receptors
The selective ETb antagonist BQ 788 failed to inhibit ET-1 mediated contractions in 
trachea from control rats (Figure 5.3A). Instead it evoked a concentration-dependent 
enhancement (For data sets, BQ 788 10_6M; P<0.05 compared with controls and BQ 
788 3 x 1 0 ' 6 M ;  P<0.01 compared with controls) of the ET-1 response. As was the case 
for 10_8M FR 139317, BQ 788, at the 10_6M level, enhanced ET-1 responses without 
altering the sensitivity of the tissue (see Table 5.3A for a summary of EC200mg and 
EC400mg values) When pre-incubated at the 3xlO_6M level however, BQ 788 
significantly (P<0.05 for data points) enhanced the sensitivity of the tissue to 
concentrations of ET-1 at the lower end of the ET-1 concentration-response curve 
whereas the sensitivity of the tissue to higher concentrations of ET-1 was unaltered (see 
Table 5.3A for a summary of EC200mg and EC400mg values).
The results from chronically hypoxic rats followed a similar pattern (Figure 5.3B). BQ 
788, at concentrations of 10-6 and 3xlO_6M, significantly (P<0.05 and PcO.Ol for data 
sets, respectively) enhanced contractions to ET-1. In each case, BQ 788 also 
significantly (P<0.05 for data points, in each case) increased the sensitivity of the tissue 
to concentrations of ET-1 at the lower end of the ET-1 concentration-response curve. 
BQ 788 did not alter the sensitivity of the tissue to higher concentrations of ET-1, 
however (see Table 5.3B for a summary of EC200mg and EC4oomg values).
F igure 5.3
Cumulative concentration-response curves to ET-1 (10_11-3xl0_7M) alone (■), or in 
the presence of the ETb receptor antagonist BQ 788 at concentrations of (□, 10"6M),
(O, 3x10"6M) in tracheal rings from (A) control rats and (B) chronically hypoxic rats. 
In both control and chronically hypoxic rat trachea, BQ 788 potentiated ET-1 responses 
in a concentration-dependent manner.
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Table 5.3
205
A
Control rat trachea
Group EC200mg 
(-log M)
EC400mg 
(-log M)
(n)
ET-1 control 9.03 ±0.10 8.40 ±0.10 8
ET-1 plus BQ 788 10'6M 9.36 ±0.18 8.67 ±0.16 8
ET-1 plus BQ 788 3x10' *9.55 ± 0.21 8.40 ±0.10 8
6M
!
| B
I
j Chronically hypoxic rat trachea
[ Group! EC200mg
(-log M)
EC400mg 
(-log M)
(n) .
1 ET-1 control\ 8.85 ±0.17 7.98 ±0.16 8
| ET-1 plus BQ 788 10‘6M *9.30 ±0.11 8.05 ±0.12 8
; ET-1 plus BQ 788 3xl0‘6M *9.39 ±0.18 8.14 ±0.31 7
|
| Table 5.3: EC200mg and EC^Omg values for ET-1 in the presence and absence of the
| ~ ETb receptor antagonist BQ 788 in tracheal rings from (A) Control rats and (B)
Chronically hypoxic rats. Statistical comparison between values was calculated by 
| Student's t-test. In control rat trachea, BQ 788 at the 3xlO*6M level, significantly
enhanced the sensitivity of the tissue to ET-1 (*P<0.05, ET-1 plus BQ 788 3xlO'6M 
compared to ET-1 alone). In hypoxic rat trachea, the sensitivity of the tissue to ET-1 
was enhanced by BQ 788 at both the 10-6M and the 3xl0_6M level (*P<0.05, ET-1 
alone compared to either BQ 788 10_6M or BQ 788 3xl0"6M).
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5.3.4 Dual Antagonism Of ETa/ETb Receptors
In this study we used two methods of dual antagonism: in the first case, simultaneous 
addition of both BQ 788 (10_6M) and FR 139317 (10_6M) and in the second, addition 
of the potent, non-selective ET antagonist SB 209670. Combined treatment with both 
BQ 788 and FR 139317 significantly (P<0.01 for data sets) attenuated ET-l-induced 
contractions in trachea from control rats (Figure 5.4A), albeit without altering the 
sensitivity of the tissue (control -log EC200mg> 8.93±0.10, n=8; plus BQ 788 10-6M and 
FR 139317 10_6M, 8.75±0.10, n=6. Control -log EC400mg> 8.40±0.10, n=8; plus BQ 
788 10_6M andFR 139317 10'6M, 8.14±0.19, n=6).
In trachea from chronically hypoxic rats, however, simultaneous addition of both BQ 
788 and FR 139317 had no significant effect on ET-1 responses (Figure 5.4B, control - 
log EC200mg, 8.83±0.17, n=6; plus BQ 788 106M and FR 139317 10'6M, 8.65±0.20, 
n=6. Control -log EC400mg> 7.78±0.16, n=6; plus BQ 788 10-6M and FR 139317 10“ 
6M,7.83±0.17, n=6).
Incubating the non-selective ET antagonist SB 209670 at a concentration of 10_7M did 
not alter ET-1 contractions in control rat trachea (Figure 5.4A, control -log EC200mg> 
8.92±0.16, n=6; plus SB 209670 10_7M, 8.61±0.19, n=6. Control -log EC4oomg> 
8.31±0.16, n=6; plus SB 209670 10’7M, 8.05±0.18, n=6.). When the concentration of 
SB 209670 was increased to 10_6M however, it evoked a significant (P<0.001 for data 
sets) inhibition of the ET-1 concentration-response curve, including a significant 
(P<0.01 for data points) attenuation of the sensitivity of the tissue (control -log 
EC200mg, 8.89±0.14, n=6; plus SB 209670 10'6M, 7.93±0.18, n=6).
In trachea from chronically hypoxic rats, SB 209670 induced a concentration- 
dependent inhibition of the ET-1-evoked response (Figure 5.4B). At a concentration of 
10_7M, SB 209670 significantly (P<0.01 for data sets) inhibited the ET-1 
concentration-response curve, including a significant (P<0.01 for data points) 
attenuation of the sensitivity of the tissue (control -log EC200mg> 8.67±0.18, n=6; plus
SB 209670 10_7M, 7.84±0.22, n=6). This inhibition of ET-l-induced contractions was 
increased when the concentration of SB 209670 was increased to 10"6M. We were 
unable to calculate -log EC400mg values for the effect of 10*6M SB 209670 on ET-1
responses in control trachea or for the effect of 10_7M and 10_6M SB 209670 in trachea 
from chronically hypoxic rats, since the maximum response to ET-1 in each case was 
less than 400mg.
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Figure 5.4
C um ulative concentration-response curves to ET-1 (10_11-3 x l0 "7M ) alone (■ ), or in 
the presence o f the non-selective ET receptor antagonist SB 209670 at concentrations 
o f (□ , 10"7M ) or (O , 10“6M ), or in the presence o f a com bination o f the E T a  receptor 
antagonist FR  139317 (10"6M ) and the ET b receptor antagonist BQ 788 (10"6M , A) in 
tracheal rings from  (A) control rats and (B) chronically hypoxic rats. In control rat 
trachea, SB 209670 at a concentration o f 10 '6M significantly attenuated ET-1 responses 
as did  a com bination of FR 139317 and BQ 788. In chronically hypoxic rat trachea, a 
com bination o f FR 139317 and BQ 788 did not alter ET-1 responses, w hereas SB 
209670 significantly  attenuated ET-1 responses in a concentration-dependent m anner.
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5.3.5 The Effect Of L-Name On ET-1 Responses
Pre-incubating the nitric oxide synthase inhibitor, L-NAME, at a concentration of 10" 
4M significantly (P<0.05 for data sets) potentiated responses to ET-1 in control rat 
trachea (Figure 5.5A). L-NAME significantly (P<0.05 for data points) enhanced the 
sensitivity of the tissue to concentrations of ET-1 at the lower end of the ET-1 
concentration-response curve (control -log EC200mg> 9.01±0.14, n=6; plus L-NAME
10"4M, 9.49±0.20, n=6), whereas the sensitivity of the tissue to higher concentrations 
of ET-1 was unaltered (control -log EC400mg> 8.32±0.15, n=6; plus L-NAME 10_4M,
8.64±0.20, n=6).
L-NAME also significantly (P<0.01 for data sets) enhanced responses to ET-1 in 
trachea from the chronically hypoxic rats, in this case with a concomitant increase in 
the sensitivity at the lower and the higher end of the ET-1 concentration-response curve 
(control -log EC200mg> 8.81±0.14, n=6; plus L-NAME 10_4M, 9.39±0.16, n=6. Control 
-log EC400mg> 8.01±0.16, n=6; plus L-NAME 10"4M, 8.49±0.17, n=6, P<0.05 in each 
case, see Figure 5.5B).
Figure 5.5
Cumulative concentration-response curves to ET-1 (10_11-3xl0"7M) alone (■), or in 
the presence of the nitric oxide inhibitor L-NAME (10"4M, □) in tracheal rings from 
(A) control rats and (B) chronically hypoxic rats. L-NAME significantly (P<0.05 and 
P<0.01 for data sets, respectively) potentiated responses to ET-1 in both control and 
hypoxic rat trachea. In each case, (n)=6. Each point represents the mean ± SEM.
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5.3.6 ET Receptor-Mediated Relaxation
In trachea from control and chronic hypoxic rats, ET-1 and sarafotoxin S6c evoked only 
very small, non-reproducible relaxatory responses. Furthermore, in the presence of BQ 
788, relaxations to ET-1 were again small and non-reproducible (see Figure 5.6).
In contrast, the nitric oxide donor, sodium nitroprusside, reversed methacholine- 
induced contractions in a concentration dependent manner, producing a maximum 
relaxant response of 54.5±3.9%, n=6 in control rat trachea and 65.6±7.2%, n=6 in 
chronically hypoxic rat trachea (see Figure 4.7B). This compares with a maximum 
relaxant response to ET-1, at a concentration of 3xlO~10M, of 8.9±6.1%, n=6 in control 
rat trachea and 8.2±5.7%, n=6 in chronically hypoxic rat trachea.
Figure 5.6
The abilty of ET-1 (10'12-10"8M) alone (■), or in the presence of the ETb receptor 
antagonist BQ 788 (10_6M, □) and also the ability of the ETb receptor agonist 
sarafotoxin S6c (10 '12-10_8M, O) to reverse methacholine-induced tone in isolated 
tracheal rings from (A) control rats and (B) chronically hypoxic rats. Relaxatory 
responses to ET-1 and sarafotoxin were small and non-reproducible in both control and 
chronically hypoxic rat trachea.
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5.4 DISCUSSION 212
We have shown that the contractile response to ET-1 is significantly attenuated in 
tracheal rings from rats previously exposed to chronic hypoxia (see section 4). We 
aimed, in this study, to determine if this attenuation is due to alterations in the ET 
receptor subtype population. The ETb receptor selective agonist, sarafotoxin S6c
produced concentration-dependent contractions of isolated trachea from both control 
and chronically hypoxic rats. Sarafotoxin S6c was significantly more potent than ET-1 
in control rat trachea, a finding which is in keeping with a previous study conducted on 
rat isolated trachea (Henry, 1993). In contrast, in trachea from chronically hypoxic rats, 
sarafotoxin S6c and ET-1 were equipotent. The results with sarafotoxin S6c suggests 
that activation of ETb receptors contributes greatly to the contractile response to ET-1 
in both control and hypoxic rat trachea. It was surprising, therefore, that the ETb 
receptor selective antagonist, BQ 788, did not inhibit the contractile response to ET-1. 
In this study, ET-l-induced contractions of isolated trachea from control rats were not 
antagonized by either BQ 788 or by the ETa receptor antagonist, FR 139317. A
combination of these two antagonists, however, significantly inhibited the ET-1 
response in this tissue, as did the mixed ETa/ETb antagonist SB 209670, indicating
that simultaneous antagonism of both receptors is necessary to attenuate the response to 
ET-1. In some species, ET-l-induced contraction of airway smooth muscle appears to 
be mediated primarily via stimulation of either ETa  (for example sheep, Abraham et 
al., 1993; Goldie et a l, 1994) or ETb (for example, guinea-pig bronchus, Hay, 1992) 
receptors. The results from the present investigation, which are in accordance with 
those from previous studies conducted upon rat isolated trachea (Henry, 1993; 
O’Donnell & Kay, 1995), suggest that both ETa and ETb receptors are involved in
mediating contraction in rat trachea. This finding is not unique to rat airways; in human 
isolated bronchus (Fukuroda et al., 1996) and also in the pulmonary arteries from rats 
(MacLean et al., 1995) and rabbits (Fukuroda et al., 1994), ET-l-induced contractions 
are thought to be mediated via stimulation of both ETa and ETb receptors.
The inability of an ETa  antagonist (in the present study, FR 139317) to block ET-1 
contractions has previously been shown in rat isolated trachea (O' Donnell & Kay, 
1995) and human isolated bronchus (Fukuroda et al., 1996). In the present study, low 
concentrations of FR 139317 actually enhanced ET-l-induced contractions in trachea 
from control rats. Similarly, the ETb antagonist BQ788 failed to inhibit the ET-1
response in control rat trachea and instead enhanced contractions in a concentration 
dependent manner. These results suggest the presence of an inhibitory ETA-mediated 
and also an ^ inhibitory ETB-mediated component which, in each case oppose 
contraction. An inhibitory ETa receptor-mediated response has been demonstrated in 
the rat fundic strip (Gray & Clozel, 1993) and more recently, in the rat pulmonary 
resistance arteries (McCulloch & MacLean, 1995). It is not known if an inhibitory 
ETA-receptor mediated response exists in the airways, but a recent study found results
similar to our own, in that the bronchoconstrictor response to ET-1 was significantly 
augmented in rat isolated perfused lungs by an ETa receptor antagonist, in this case BQ
123 (Lai e ta l , 1995).
It is believed that the initial depressor effect of ET-1 in the cardiovascular system is 
mediated by ETb receptors (Saeki et al., 1991; Douglas & Hilley, 1991), possibly by
the release of vasodilating substances such as nitric oxide from the endothelium 
(Warner et al., 1989; Filep et al., 1993). This group has previously shown in bovine 
isolated bronchi that the selective ETb receptor agonist sarafotoxin S6c relaxed
methacholine-induced tone in a concentration-dependent manner and furthermore, 
desensitization of the ETb receptor enhanced ET-l-induced contractions in this tissue 
(Nally et al., 1994c). This suggests that airways may express an inhibitory ETb
receptor similar to that found in the vasculature. Sokolovsky et al (1992) reported a 
subclassification of the ETb receptor subtype (termed ETbi and ETb2 based on
differing binding properties. It is now widely accepted that the different cell-type 
locations of the ETb receptors are responsible for their opposing effects, with ETb2
receptors localized on vascular smooth muscle evoking the contractile responses to ET- 
1 (Moreland et al., 1992; Sumner efal. ,  1992), whereas the ETbi receptors which
mediate vasodilation are located on the endothelium (Sakuri et al., 1990; Vane; 1990; 
Shetty et al., 1993). It is not known if a similar system operates in the airways, with the 
inhibitory ET receptors (if present) being located on the epithelial layer. Removal of the 
epithelial layer significantly enhances contractile responses to the endothelins in human 
bronchus (Candenas et al., 1992), indicating that the epithelia does indeed exert an 
inhibitory effect on ET-l-induced contractions. This inhibitory effect, however, may be 
due to the degradation of ET-1 by endopeptidases or indeed, the release of an epithelial- 
derived relaxant factor (Bames et al., 1985), rather than the actions of an inhibitory 
ETb receptor. Indeed, in this present study, the nitric oxide synthase blocker, L-NAME,
significantly potentiated responses to ET-1 in trachea from both control and chronically 
hypoxic rats. This would suggest that activation of ET receptors in these tissues 
stimulates the release of nitric oxide, which would tend to oppose the contractile 
response to ET-1. Contractile responses to the cholinergic agonist, methacholine, 
however, were also potentiated by L-NAME (see section 4.3), indicating that nitric 
oxide or a nitric oxide-like substance is released in response to contraction of the 
airway smooth muscle, rather than stimulation of ET receptors. Furthermore, we 
demonstrated that ET-1 evoked only small, non-reproducible relaxations of 
methacholine-induced tone. In addition, stimulation of either the ETa (ET-1 in the 
presence of BQ 788) or the ETb (sarafotoxin S6c) receptor subtypes failed to uncover 
any significant relaxation in trachea from control or chronically hypoxic rats. This is 
unlikely to be due to a loss of relaxant activity in these vessels as the nitric oxide donor, 
sodium nitroprusside, produced marked reversal of the induced tone (see Figure 4.7B). 
This adds evidence to our suggestion that activation of ET receptors per se does not 
stimulate release of nitric oxide from rat isolated tracheal preparations.
Our results show that antagonism of either ETa or ETb receptors alone does not inh ib i?^  
ET-l-induced contractions in control rat trachea, whereas simultaneous blockade of 
both receptors significantly inhibited the ET-1 response. We have suggested the 
presence of inhibitory ETa  and ETb receptors to explain our findings that both ETa  
and ETb receptor antagonists enhanced ET-l-induced contractions. Alternatively, it has
been speculated that a cross-talk mechanism exists in the signal-transduction pathways 
between ETa  and ETb receptors. For example Fukuroda et al., (1996) postulate a 
mechanism whereby activation of ETa receptors by ET-1 leads to moderate inhibition 
of the ETb receptor-mediated signal and vice versa. Thus, activation of only ETa  or 
only ETb receptors would be sufficient to produce the full signal, whereas simultaneous 
activation of both ETa  and ETb receptors by ET-1 would produce a reduced response. 
One would therefore expect that blockade of either ETa  or ETb receptors would free
the signal transduction pathways from the inhibitory cross-talk mechanism. This was 
indeed what we found in this study; in the presence of either an ETa antagonist or an 
ETb antagonist, ET-l-induced contractions were significantly enhanced. Furthermore, 
the ETb receptor agonist sarafotoxin S6c was significantly more potent than ET-1 in 
trachea from control rats. ^
We found that the ability of FR 139317, at the 10"8M level, to enhance ET-1-mediated 
contractions in rat trachea was not present in the chronically hypoxic rats and 
furthermore, combined treatment with FR 139317 and BQ 788 attenuated ET-1 
responses in control rat trachea but had no effect on responses in trachea from chronic 
hypoxic rats. In contrast, responses to ET-1 in the presence of BQ 788 alone or in the 
presence of the non-selective ET receptor antagonist SB 209670 were not altered by 
chronic hypoxia. Thus chronic hypoxia alters the pattern of responses to ET-1 in the 
presence of some, but not all, ET receptor antagonists. .
Previous studies indicate that chronic exposure to hypoxia enhances the pulmonary 
vasoconstrictor response to ET-1 (McCulloch & MacLean, 1995; MacLean et al.,
1995). The reasons underlying this are unclear, but may be due to a reduction in the 
vasodilator response to ET-1. For example, Eddahibi and co-workers have shown that 
ET-1 induces concentration-dependent relaxation in rat pulmonary arteries via 
stimulation of ETb receptors, and that this effect is completely abolished in lungs from
chronically hypoxic rats (Eddahibi et al., 1993). Alternatively, chronic hypoxia may 
attenuate the influence of the inhibitory ETa receptors which are postulated to exist in
various tissues including pulmonary arteries. For example, a recent study found that the 
ETa receptor antagonist BMS 182874 potentiated responses to ET -1 in control rat
pulmonary resistance arteries, but had no effect on ET-1 responses in vessels from 
chronically Hypoxic rats (McCulloch & MacLean, 1995). Interestingly, our results 
followed a similar pattern in that the ETa receptor antagonist FR 139317 potentiated
ET-1 responses in trachea from control rats whereas it did not alter responses to ET-1 in 
chronic hypoxic rat trachea.
It remains unclear whether the altered responsiveness to ET-1 by chronic hypoxia is 
due to changes at the receptor level. Since lung ET-1 levels are increased by chronic 
hypoxia (Elton et al., 1992), one would expect a relative decrease in ET receptors due 
to down regulation. Indeed in the monocrotaline lung injury model of pulmonary 
hypertension, lung ET-1 levels are raised and expression of ETb receptor mRNA was
subsequently found to be decreased (Yorikane et al., 1993). In contrast, however, 
chronic hypoxia actually increases the level of ETa receptor mRNA in whole rat lung 
and raises the level of ETb receptor mRNA in the rat main pulmonary artery but does 
not change ETa receptor mRNA in these vessels (Li et al., 1994). Only one study has 
assessed the effect of chronic hypoxia on ET binding, finding no change in total or 
subtype-specific ET receptor binding in pulmonary vessels and airways from 
chronically hypoxic rats compared with normoxic animals (Eddahibi et al., 1993).
In summary, the results of this study indicate that both ETa and ETb receptors mediate
ET-l-induced contraction in rat isolated trachea and that simultaneous blockade of both 
receptor subtypes is required for inhibition of this response. Furthermore, our results 
suggest the existence of an inhibitory ETa  and ETfi-mediated component since 
blockade of either ETa  or ETb receptors by FR 139317 or BQ 788, respectively,
actually potentiated ET-1-mediated contractions. It would appear unlikely that these 
inhibitory components are due to the existence of ETa ° r ETb receptor subtypes which
oppose contraction by releasing relaxant factors, since we demonstrated that sarafotoxin 
S6c or ET-1 in the presence of FR 139317 or BQ 788 produced little or no reversal of 
methacholine-induced tone in rat isolated trachea. We also found that the inhibitory 
ETa receptor mediated, but not the ETb receptor mediated component was lost in rats
exposed to chronic hypoxia.
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CHAPTER 6
THE EFFECT OF HYPOXIA ON THE 
PROLIFERATION OF CULTURED HUMAN 
AIRWAY SMOOTH MUSCLE CELLS
6.1 INTRODUCTION 217
The previous results in this thesis have focussed upon the effects of changes in oxygen 
tension on the pharmacological responsiveness of airway smooth muscle. As stated in 
section 1.7, changes in oxygen tension may also have an effect on the growth of airway 
smooth muscle cells. This may be of clinical relevance given that airway remodelling is 
a pathological feature of many respiratory disorders such as asthma and chronic 
bronchitis.
In the present series of experiments I examined the mitogenic effects of ET-1 and 
platelet-derived growth factor (PDGF) on cultured human airway smooth muscle cells 
under both normoxic and hypoxic conditions. As stated in section 5.1, ET-1 is a potent 
bronchoconstrictor which evokes its responses by binding to and activating specific ET 
receptors (ETa  and ETb ). In addition to its contractile responses on airway smooth
muscle, there is evidence that activation of ET receptors may also induce proliferation 
of airway smooth muscle.
As mentioned in section 5.1, ET-l-induced contraction of human bronchial smooth 
muscle is thought to be mediated predominantly via activation of ETb receptors (Hay et
al., 1993a and b; Goldie et a l, 1995). In contrast, the mitogenic effect of ET-1 in this 
tissue appears to occur through stimulation of ETa receptors (Tomlinson et al., 1994;
Panettieri et al., 1996b). ET-1 per se evokes only a modest proliferation of human 
airway smooth muscle (Tomlinson et al., 1994), however in the presence of another 
growth factor (for example, epidermal growth factor, Panettieri et al., 1996), the 
mitogenic effects of ET-1 are significantly potentiated. In this study we attempted to 
characterise the ET receptor subtype(s) involved in ET-l-induced mitogenesis under 
normoxic and hypoxic conditions .
PDGF has been shown to be a potent mitogen in a number of cell types, including 
airway smooth muscle (Hirst et al., 1992). In contrast to ET-1, PDGF acts by 
stimulating receptors with intrinsic tyrosine kinase activity (see section 1.5.2.1.1).
Our preliminary results showed that hypoxia per se stimulated proliferation and also 
enhanced the mitogenic effect of both ET-1 and PDGF. In an attempt to elucidate the 
mechanism(s) underlying these findings, I studied the effect of the protein kinase C 
(PKC) inhibitor, staurosporine, on ET-1 and PDGF-mediated mitogenesis in normoxia 
and hypoxia.
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6.2.1 Airway Smooth Muscle Cell Culture
Human airway smooth muscle cells were harvested from bronchial segments obtained 
from thoracic surgery (as described in section 2.2.1). The cells used in this study were 
derived from three individual human patients.
The identity of the bronchial smooth muscle cells was confirmed by 
immunocytochemical staining as described in section 2.2.3.
6.2.2 Assessment Of Proliferation
Proliferation of human airway smooth muscle cells was assessed by measuring the 
uptake of radiolabelled thymidine (see section 2.2.4.3).
Cells were stimulated with ET-1 or the ETb receptor agonist sarafotoxin S6c (1 0 '^ M  - 
lO'^M) or PDGF-BB (lOng/ml) for 24 hours, either in a normal CO2 incubator (5% 
CO2) or in a hypoxic incubator (again 5% CO2) under an environmental O2 tension of 
~30mm Hg.
To characterise the ET receptors involved in mitogenesis in the hypoxic cells, the ETa 
receptor antagonist BQ 123 (3xlO~7M) or the ETb receptor antagonist BQ 788 (3x10" 
7M) were added 30 minutes prior to addition of ET-1.
To study the involvement of PKC activation in the mitogenic response to ET-1 and 
PDGF, the PKC inhibitor, staurosporine (10~7M), was added 30 minutes prior to 
addition of either ET-1 or PDGF, in both normoxic and hypoxic cells.
In all experiments, for the last 4 hours of agonist stimulation, cells were labelled with 
[3H] thymidine (0.1 p,Ci/ml) before the reaction was stopped by washing in phosphate 
buffered saline (see section 2.2.4.3). Radioactivity was determined by liquid 
scintillation counting and results expressed as disintegrations per minute (DPM).
6.2.3 Materials
The following chemicals were used: BQ 123, BQ 788, ET-1, PDGF, sarafotoxin S6c, 
staurosporine and [3H] thymidine (see section 2.2.6 for full chemical and suppliers 
names).
6.2.4 Statistics
Results are expressed as the mean ± s.e.mean. Statistical analysis was undertaken as 
reported in section 2.2.7.
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6.3.1 Agonist response to hvpoxia
In normoxia, ET-1 showed no mitogenic effects, evoking a maximum response 
(mean±sem) (842.6±20.6 DPM, at a concentration of 10~7M) which was not 
significantly different from basal levels (827.5±84.5 DPM). Under hypoxic conditions, 
however, ET-1 produced a concentration-dependent increase in DNA synthesis which 
was significantly (PcO.OOl for data sets) greater than the concentration-response curve 
in normoxia. Furthermore, responses to ET-1 at concentrations of 10“9M (1945.1± 102.6 
DPM), 10“8M (2125.3±114.2 DPM) and 10-7M (2242.0±110.5 DPM) were 
significantly (P<0.05 for data points) greater than basal levels in hypoxia 
(1175.3±140.9 DPM, see Figure 6.1).
PDGF (lOng/ml) was found to be a potent mitogen under normoxic conditions, 
stimulating thymidine incorporation to a level (3247.8±112.7) which was significantly 
greater (P<0.01, for data points) than basal levels (887.9±94.1 DPM, see Figure 6.3). 
This mitogenic effect of PDGF was enhanced in hypoxia, with PDGF (lOng/ml) 
producing a response (5467.8±269.1’T)PM) which was significantly (P<0.001, for data 
points) greater than basal counts in hypoxia (1231.3±168.4 DPM) and significantly 
(P<0.05, for data points) greater than the response to PDGF in normoxia.
6.3.2 Characterisation of the ET receptor subvpes involved in mitogenesis 
The enhancement of ET-l-induced mitogenesis in hypoxic conditions was significantly 
(P<0.01 for data sets) attenuated by the ETa receptor antagonist BQ 123 (3xlO'7M), 
but not by the ETb receptor antagonist BQ 788 (3xl0"7M). In addition, the ETb 
receptor-selective agonist sarafotoxin S6c evoked no mitogenic response (see Figure 
6.2).
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6.3.3 Effect of the PKC inhibitor, staurosporine. on proliferation.
In normoxia, staurosporine (10"7M) did not alter the uptake of [3H] thymidine. In cells 
quiesced under hypoxia, however, the slight mitogenic effect of hypoxia was 
completely abolished by staurosporine (In the absence of staurosporine; 1286.7±134.8 
DPM, compared to in the presence of staurosporine; 816.5±80.9 DPM, P<0.05 for data 
points).
The mitogenic response to 10_7M ET-1 in hypoxic cells was also abolished by 
staurosporine (In the absence of staurosporine; 2340.5± 107.6 DPM, compared to in the 
presence of staurosporine; 837.5±88.1 DPM, P<0.01 for data points).
Proliferation induced by lOng/ml PDGF was again inhibited by prior incubation of 
staurosprine (PDGF in normoxia in the absence of staurosporine; 3247.8±112.7 DPM, 
and in the presence of staurosporine; 852.6±82.4 DPM, P<0.01 for data points. PDGF 
in hypoxia in the absence of staurosporine; 5467.8±269.1 DPM, and in the presence of 
staurosporine; 875.6±92.0 DPM, P<0.001 for data points).
Figure 6.1
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Figure 6.1
Uptake o f [3H] thym idine in human airway sm ooth m uscle cells in norm oxia (O ) and 
hypoxia ( • ) .  H ypoxia stim ulates thym idine uptake in basal cells (■ ) and "uncovers" 
the m itogenic effect o f ET-1. The concentration-response curve to ET-1 was 
significantly (P<0.001 for data sets) greater in hypoxia than in norm oxia and at 
concentrations of 10-9, 10~8 and 1 0 7M, E T -l-induced  DN A synthesis was significantly  
(P<0.05 for data points) greater than basal counts. Each data point represents the m ean 
±s.e.m ean of 4 individual wells from three separate experim ents.
Figure 6.2
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Figure 6.2
Uptake o f [3H] thym idine in hum an airway sm ooth m uscle cells under hypoxic 
conditions ( • ) .  At concentrations o f 10 '9, 10 '8 and 10_7M, ET-1 significantly  (P<0.05) 
stim ulated m itogenesis. This enhancem ent o f E T -l-induced  m itogenesis was 
significantly (P<0.01 for data sets) attenuated by the ETa  receptor antagonist BQ 123 
(3 x l0 "7M, O ), but was not altered by the ET b antagonist BQ 788 (3 x l0 -7M , □ ). 
Furtherm ore, the ET b receptor agonist sarafotoxin S6c (■ ) evoked no m itogenic 
response, indicating that this effect of ET-1 is m ediated via activation o f ET a  receptors. 
Each data point represents the mean ±s.e.m ean of 4 individual wells from  three separate 
experim ents.
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Figure 6.3
U ptake o f [3H] thym idine in hum an airway sm ooth m uscle cells in the presence 
(stippled colum ns) and absence (clear colum ns) o f the PKC inhibitor staurosporine (10‘ 
7M). Thym idine incorporation, stim ulated by either hypoxia alone, ET-1 (1 0 '7M ) in 
hypoxia, PD G F (lO ng/m l) in norm oxia or PD GF (lO ng/m l) in hypoxia was inhibited in 
the presence o f staurosporine. Each data point represents the m ean ±s.e.m ean of 4 
individual wells from  three separate experim ents. A bbreviations: ET-1 N; ET-1 in 
norm oxia, ET-1 H; ET-1 in hypoxia, PD G F N; PD G F in norm oxia, PD G F H; PD G F in 
hypoxia.
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The main findings of the present study were: (1) Hypoxia stimulated thymidine uptake 
in unstimulated human airway smooth muscle cells; (2) ET-1 alone had little or no 
mitogenic effects on these cells under normoxic conditions, but in the presence of 
hypoxia, ET-1 significantly stimulated DNA synthesis (3) PDGF was a potent mitogen 
in normoxic conditions and this effect was enhanced under hypoxia; (4) the mitogenic 
effect of ET-1 in hypoxia appears to be mediated via activation of ETa receptors; (5)
the protein kinase C inhibitor, staurosporine, completely abolished thymidine uptake 
stimulated by either hypoxia alone, ET-1 or PDGF.
The mitogenic effects of ET-1 in vascular smooth muscle have been well documented 
(Komuro et al., 1988; Nakaki et al., 1989; Eguchi et al., 1992), although in human and 
animal cultured airway smooth muscle, ET-1 on its own has only weak mitogenic 
effects (Tomlinson et al., 1994; Panettieri et al., 1996b; Noveral et al., 1992; Stewart et 
al., 1994; Glassberg et al., 1994). Interestingly, Panettieri and co-workers (1996b) 
found that, although ET-1 produced little mitogenic effect on its own, it significantly 
augmerfted the mitogenic effect of the growth factor EGF in human airway smooth 
muscle. Furthermore, this enhancement of the mitogenic effect was blocked by the ETa
receptor antagonist, BQ 123 (Panettieri et al., 1996b). This is in keeping with our 
present study, in that ET-1, in the presence of hypoxia, stimulated DNA synthesis in 
cultured human airway smooth muscle cells via activation of ETa receptors.
While it has previously been shown that ET-1 can potentiate the mitogenic effect of 
growth factors such as EGF (Panettieri et al., 1996b) and PDGF (Fujitani & Bertrand,
1996), we believe that this is the first report of a synergistic relationship between ET-1 
and hypoxia in the proliferation of airway smooth muscle. The precise mechanism(s) by 
which ET-1 synergises with hypoxia or, for that matter, growth factors remain 
unknown, but may reflect interactions at certain points on the intracellular pathways 
through which these mediators transduce their mitogenic effects.
In this current study I examined the effect of protein kinase C inhibition on hypoxia- 
and agonist-induced mitogenesis. Various lines of evidence point to the involvement of 
protein kinase C in cellular growth. For example, proliferating cells exhibit greater PKC 
activity than do quiescent cells (Adamo et al., 1986). In addition, direct activation of 
PKC by phorbol esters induces smooth muscle cell growth, whereas PKC inhibitors 
reduce cell replication (Owen, 1985; Newby et al., 1994; Panettieri et al., 1993). 
Previous studies in airway smooth muscle cells demonstrated that PKC inhibition 
markedly attenuates the proliferation induced by either ET-1 or PDGF (Malarkey et al., 
1995). The results from the present-study are in agreement with this and in addition, the 
small mitogenic effect of hypoxia alone was blocked by staurosporine. This indicates 
that hypoxia induces its effect on cell growth via stimulation of PKC.
While G protein receptor agonists such as ET-1 are thought to be almost exclusively 
PKC-dependent, receptor tyrosine kinase-mediated cell proliferation is believed to
225include both PKC-dependent and independent pathways (Stumpo & Blackshear, 1983).
It was perhaps surprising therefore, to find that PDGF-induced mitogenesis, under both 
normoxic and hypoxic conditions, was completely abolished by staurosporine. It is 
possible that the concentration of staurosporine used was too high, leading to inhibition 
of other intracellular kinases (for example, MAP kinases). It may be, however, that 
PKC inhibition is indeed the principle event in both ET-1 and PDGF mediated 
mitogenesis in these cells.
Interestingly, Dempsey et al (1991) showed that PKC was a required step in allowing 
cultured pulmonary artery smooth muscle cells to proliferate in response to hypoxia. In 
contrast to my findings, however, Dempsey and co-workers found that pulmonary 
artery smooth muscle cells did not proliferate in response to hypoxia per se, but rather 
PKC stimulation was essential to "prime" the cells to respond to hypoxia. Our findings 
are more in keeping with the response of fibroblasts, since cultured fibroblasts have 
been shown in several studies to have a direct proliferative response to hypoxia (Taylor 
etal., 1978; Storch & Talley, 1988).
It is important to be cautious in considering the potential relevance of these in vitro 
observations to events occuring in vivo. Several points must be considered. Firstly, the 
cells used in this study were quiesced before stimulation, which would not relate to the 
proliferative state in vivo. Secondly, the homogeneous population of airway smooth . 
muscle cells used in this study has been removed from the influence of other cell types 
such as epithelial and mast cells. Thirdly, our measurements were limited to 
proliferation, whereas other forms of response such as hypertrophy are also potentially 
important in a remodelling process. Fourthly, the definitions of hypoxia and normoxia 
were by convention and may not relate well to the oxygen tension surrounding airway 
smooth muscle cells in vivo. Lastly, the cells used in this study were cultured from 
patients undergoing thoracic surgery for bronchial carcinoma. As a rule, these patients 
were of poor health, and the effect of bronchial carcinoma on the lungs would be 
expected to involve some degree of hypoxia. Thus the cells cultured from these patients 
may have become adapted to a more hypoxic environment.
On a further cautionary note, as mentioned in section 2.2.4.3, there are a number of 
potential artefacts in relating thymidine uptake to cellular proliferation. While, in the 
present study, I have taken the increase in thymidine uptake under hypoxic conditions 
to be indicative of cell proliferation, one may speculate that hypoxia may increase the 
incorporation of thymidine into macromolecules other than DNA or increase the 
synthesis of DNA for reparative purposes. This would lead to an increase in 
assimilation of tritiated thymidine without any significant enhancement of cell 
proliferatiorirSlnce we had no means of testing this experimentally, this remains purely 
speculative and I would tentatively conclude that our measurements of thymidine 
uptake under hypoxic conditions are indeed representative of cellular proliferation.
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In summary, the present data indicates that hypoxia stimulates mitogenesis in cultured 
human airway smooth cells and enhances the mitogenic effect of ET-1 and PDGF on 
these cells. ET-1-induced mitogenesis of these cells in hypoxia is mediated by 
activation of ETa receptors and PKC inhibition appears to abolish hypoxic-, ET-1 and
PDGF-induced proliferation.
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CHAPTER 7
THE EFFECT OF ACUTE ALTERATIONS IN 
OXYGEN TENSION ON SALBUTAMOL-INDUCED 
RESPONSES IN HUMAN ISOLATED BRONCHI 
AND ASTHMATIC PATIENTS IN  VIVO
7.1 INTRODUCTION 228
As reported in section 3, changing the O2 tension of the environment can alter the 
ability of various bronchodilators, including salbutamol, to reverse induced tone in 
bovine isolated bronchial rings. While bovine bronchial tissue is thought to be a 
reasonable model for human bronchial tissue, it is obviously of importance to conduct 
key experiments on human airways wherever possible. In this group of experiments, the 
ability of salbutamol to reverse methacholine-induced tone was studied in human 
isolated bronchial rings under hyperoxic, normoxic and hypoxic conditions.
Measuring isometric contractions and relaxations in isolated tissue provides useful 
information on the pharmacology and physiology of the airways at the level of the 
airway smooth muscle. As mentioned in section 1.6, however, the effects of hypoxia on 
airway smooth muscle in vitro do not always predict what would happen to the airways 
in vivo. Thus, there is a need to measure the effect of changes in inspired oxygen 
tension on bronchial reactivity in human subjects in vivo.
This group has previously shown that the bronchodilator effects of salbutamol are not 
altered by changing from a normoxic;to a hyperoxic gas mixture in asthmatic patients 
(Dagg et al., 1996). This previous study did not examine the effect of hypoxia on 
bronchodilator responses, therefore in this present series of experiments, we compared 
the ability of salbutamol to induce bronchodilation under hyperoxic and hypoxic 
conditions.
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7.2.1 In-vitro study
7.2.1.1 Tissue collection and preparation
Macroscopically normal human bronchi (2nd to 4th order, internal diameter 3-5mm) 
were obtained from patients undergoing thoracic surgery and dissected as described in 
section 2.1.2.3. Rings of human bronchi were suspended in vertical organ baths (as 
described in section 2.1.4) under a resting tension of 2g wt. Alterations in gas tension 
from hyperoxia to either normoxia or hypoxia were achieved by substituting oxygen 
with nitrogen as stated in section 2.1.5. Hyperoxic, normoxic and hypoxic gas mixtures 
produced final bath O2 tensions of 520-525mm Hg, 142-145mmHg and 24-28mmHg,
respectively.
7.2.1.2 Experimental Protocol
Tissues were pre-incubated with 10 6M methacholine (approximately the EC50 for 
methacholine in this tissue, personal observations) and the contraction allowed to reach 
a plateau. Cumulative concentration-response curves were then constructed to 
salbutamol (lOMCHM). To avoid tachyphylaxis, only one concentration-response 
curve was conducted to salbutamol in each tissue, therefore the three different oxygen 
tensions were imposed upon three separate bronchial rings. In each experiment one 
tissue acted as a time control to ensure that the methacholine-induced contraction was 
maintained.
7.2.1.3 Materials
The following chemicals were used: methacholine and salbutamol (see section 2.1.8 for 
full chemical and suppliers names). Concentration in the text refers to the salts, with the 
exception of salbutamol which is expressed as the base. Stock solutions of drugs were 
prepared in distilled water and subsequent dilutions made in Krebs-Henseleit solution.
7.2.2 In-vivo study
7.2.2.1 Patient Information
Twelve adult asthmatic patients (2 female) with a mean (SD) age 39 (8) years agreed to 
participate in the study*(see Table 7.1). All of the patients gave a history of asthma and 
none had any other significant cardiac or respiratory disease. All of the patients were 
taking i n h a l e 62-agonists as required and eleven regularly inhaled corticosteroids. 
Three were also receiving the long acting 62-agonist salmeterol and one had been 
provided with a home nebuliser to take salbutamol on an "as required" basis. One 
patient was receiving a short acting oral theophylline. All of the patients gave written
informed consent to the study protocol which had the approval of the West Ethics 
Committee.
12.2.2 Study design
Patients were asked to attend the study laboratory on five separate days at 
approximately the same time each day. Prior to each study day patients were asked to 
withhold their inhaled and nebulised 62-agonists for 8 hours and inhaled salmeterol for
24 hours. Oral theophyllines were discontinued 48 hours prior to each study day. 
Patients were asked to continue taking their inhaled corticosteroids as usual. Patients 
who at an initial visit, following 30 minutes of supine rest, demonstrated an 
improvement in FEVi of more than 15% after inhaling salbutamol were deemed
eligible for the remaining four study days.
On subsequent study days on arrival at the laboratory, patients were rested in a supine 
position for 30 minutes following which they were connected to a closed breathing 
circuit for the delivery of all study gases. After breathing air (Fi02 0.21) for 10 minutes
through the closed breathing circuit, baseline measurements of oxygen saturation 
(Sa02%), heart rate (HR), respiratory rate (RR), inspired oxygen and carbon dioxide 
levels (insp 0 2%, insp C02%) and end-tidal oxygen and carbon dioxide levels 
(pET02%, pETCC>2%) were made (see section 2.3.3).
After the baseline measurements had been recorded patients breathed either a hypoxic 
gas mixture (FiC>2 0.15) on two days or oxygen (FiC>2 1.0) on two further study days for
the remainder of that day. All gases were administered in a randomised double blind 
manner by a second operator obscured from the vision of both the patient and the 
doctor performing the salbutamol test. Ten minutes after commencing the study gas for 
that day the measurements made at baseline were repeated. Subsequently at fifteen 
minute intervals in a randomised double blind fashion patients received either three 
incremental doses of nebulised salbutamol: (0.05 mg/ml, 0.17 mg/ml, 5 mg/ml) on two 
days or placebo (nebulised saline) on two further days. Measurements were repeated 
thirteen minutes after each nebulisation until completion of the study day. The solutions 
of salbutamol and saline were made up by the pharmacy department of our hospital and 
were given through a micro cirrus nebuliser driven by a hypoxic gas mixture (British 
Oxygen Corporation, Special Gases Division, Manchester) or oxygen (Fi02 1.0) at a
predetermined flow rate to produce a nebuliser output of 0.13 mls/min.
7.2.2.3 Measurements
Heart rate, oxygen saturation, inspired and expired oxygen and carbon dioxide levels 
were measured as reported in section 2.3.3.1 and FEVi values were measured as stated
in section 2.3.3.2. Study gases were generated as described in section 2.3.4.
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7.2.3 Statistical analysis
For the in-vitro studies results for the reversal experiments are expressed in terms of the 
mean maximum inhibition. Results are expressed as mean (SEM). Statistical 
significance between the data sets was tested by two-way analysis of variance 
(ANOVA). Significance between mean maximum inhibitions was calculated by 
Students t-test (see section 2.1.9.3). Number of observations (n) refers to the number of 
patients from whom tissues were obtained.
For the in-vivo studies, analysis of Variance (ANOVA) corrected for multiple 
comparisons was used to compare measurements made at baseline and following each 
dose of nebulised saline or salbutamol between study days.
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Table 7.1: Patient characteristics
FEVi
Patient Age Sex absolute value (L) % predicted Current
No (years)___________ pre-salb post-salb___________ treatment
1 44 M 2.14 2.82 83 Apm, B
2 52 M 2.70 3.15 91 Apm, B
3 39 M 3.12 3.60 90 Apm
4 52 M 2.31 2.72 66 Apm, B
5 34 F 3.02 3.52 106 Apm, B
6 35 M 3.15 3.80 88 Apm,B
7 49 M 2.08 2.75 77 Apm, B, S, Neb
8 36 M 2.85 3.29 98 Apm
9 , 29 M 2.94 3.59 79 Apm, B
10 32 F 2.33 2.73 107 Apm, B, S
11 29 M 3.34 3.93 87 Apm, B
12 36 M 2.52 2.97 75 Apm, B, S, Th
Mean 39 2 .7 1 3 .2 4 87
(SD) (8) (0 .4 2 ) (0 .4 4 ) ( U )
Apm = inhaled salbutamol as required, B = inhaled steroid (beclomethasone or 
budesonide), S = inhaled salmeterol twice daily, Th = oral theophylline, Neb = 
nebulised salbutamol and ipratropium bromide as required, pre-salb = pre-salbutamol 
FEVi, post-salb = post-salbutamol FEVi.
7.3 RESULTS
7.3.1 In-vitro study
The tim e control studies indicated that contractions evoked by m ethacholine (10"6M) 
were sustained throughout the experim ental day (data not shown). Contractions 
evoked by the single concentration o f m ethacholine did not d iffer significantly 
between the three oxygen tensions: in hyperoxia; 761.3±178.9m g wt, in norm oxia; 
613.8±156.2 mg w t and in hypoxia; 483.5±149.9m g wt.
Salbutam ol evoked a m arked, concentration dependent reversal o f the m ethacholine- 
induced contraction (see Figure 7.1 A). U nder hyperoxic and hypoxic conditions, 
responses to salbutam ol were initiated at betw een 3x10 9M and 10'8M and betw een 
1()'9M and 3x lO '9M in norm oxia (F igure 7 .IB ). Low ering the oxygen tension from 
95% to 20% oxygen did not significantly  alter the ability o f salbutam ol to reverse 
m ethacholine-induced tone (mean m axim al inhibition at 10 4M: 103.02 ± 9.04 % in 
hyperoxia and 74.07 ± 11.65 % in norm oxia, n=8). In contrast, responses evoked by 
salbutam ol were significantly  (PcOOOl for data sets) attenuated in hypoxia when 
com pared to hyperoxia (m ean m axim al inhibition at 10 4M: 103.02 ± 9 .04 % in 
hyperoxia and 59.36 ± 7 .8 5  % in hypoxia, P<0.01 for data points, n=8). Responses to 
salbutam ol w ere also significantly  (P<0.01 for data sets) less in hypoxia com pared 
with norm oxia, although there was no significant d ifference betw een the m axim um  
responses (m ean m axim al inhibition at 10'4M: 74.07 ± 11.65 % in norm oxia and 
59.36 ± 7.85 % in hypoxia, n=8).
Figure 7.1A
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Figure 7.1 A
Representative trace depicting the ability o f salbutam ol to reverse m ethacholine- 
induced contraction in hum an bronchial rings. A fter a stable contraction to 
m ethacholine (10_6M) was produced, salbutam ol was added cum ulatively  w ith each 
concentration being added after the previous response had reached a plateau.
Figure 7.1B
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Figure 7 . IB
The ability o f salbutam ol to reverse m ethacholine-induced tone in hum an isolated 
bronchi in hyperoxia (■ ), norm oxia (□ ) and hypoxia (O ). Salbutam ol was added 
cum ulatively to give final bath concentrations of 10'9-1 0 '4M. R esponses are expressed 
as a percentage reversal o f the m ethacholine contraction. Salbutam ol was significantly  
(P<0.001) m ore effective in hyperoxia than in hypoxia and significantly (P<0.01) m ore 
effective in norm oxia than in hypoxia. N um ber of observations (n)=8 in each case.
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7.3.2 In-vivo  s t u d y
Baseline measurements: There were no significant differences in the baseline 
measurements made between any of the study days (Table 7.2).
Table 7.2: Baseline measurements
Oxygen (FiQ2 1.0)_________ Hypoxia (FiO^O.15)
Baseline
measurements Placebo Salbutamol Placebo Salbutamol
FEVi
(L) 2.49 (0.12) 2.54 (0.10) 2.52 (0.12) 2.36 (0.12)
Heart rate
(beats/min) 73 (2.5) 72 (2.8) 71 (2.6) 70 (2.9)
Resp. rate
(breaths/min) 14 (1.7) 16 (1.3) 15 (1.3) 15 (1.4)
Sa02
(%) 96 (0.3) 96 (0.3) 96 (0.2) 96 (0.2)
Inspired O2
(%) 21 (0.2) 21 (0.0) 21 (0.1) 21 (0.1)
Expired CO2
(%) 4.8 (0.1) 4.7 (0.1) 4.7 (0.2) 4.7 (0.2)
Mean (SEM) baseline measurements of FEVi, respiratory rate, heart rate, oxygen 
saturation, inspired oxygen % and expired carbon dioxide % for each study day.
There was no significant differences between any of the study days
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% change in FEVi from baseline: The mean (SEM) maximum % change in FEVi from 
baseline was significantly greater (P<0.05) on the days on which nebulised salbutamol 
was administered: hyperoxia/salbutamol 21 (4.7) %, hypoxia/salbutamol 18 (3.6) % 
when compared to the study days on which nebulised saline was administered: 
hyperoxia/saline 1 (2.1) %, hypoxia/saline -2 (2.9) %. There was however no 
significant difference in the mean maximum % change in FEVi from baseline at any
time point between the study days on which nebulised salbutamol was given ( see Table 
7.3, Figure 7.2). There was no significant difference in the mean % change in FEVi
from baseline on any study day 10 minutes after being commenced on the study gas for 
that day but prior to inhalation of nebulised salbutamol or saline. Therefore, changing 
the inspired oxygen tension did not appear to alter the airway calibre.
The mean (SEM) % change in FEVi from baseline 10 minutes after commencing each
study gas was: hyperoxia/salbutamol: -3 (3.5)%, hypoxia/salbutamol: -2 (3.6)%, 
hyperoxia/saline 4: (2.1)% and hypoxia/saline: 3 (2.5)%.
Oxygen saturation: Oxygen saturation was significantly higher (P<0.05) on the days 
on whidh oxygen was administered when compared to the days on which the hypoxic 
gas mixture was inhaled at all time points (see Table 7.3, Figure 7.3).
Change in heart rate from baseline: The fall in heart rate from baseline was
significantly greater (P<0.05) on the days that patients inhaled oxygen when compared 
to the days on which they inhaled the hypoxic gas mixture (Table 7.3).
End-tidal carbon dioxide: There were no significant differences in end-tidal carbon 
dioxide levels between any of the study days at any time point (Table 7.3).
Respiratory rate There were no significant differences in respiratory rate between 
study days at any time point (Table 7.3).
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T ab le  7,3 :
Measurement Oxygen (FiC>2 1.01 Hvpoxia (FiO^O. 15)
(Post agonist
challenge)_______Placebo______Salbutamol________ Placebo________Salbutamol
F E V i  
(L) 2.54(0.10) *3.01 (0.14) 2.47(0.12) *2.78(0.11)
Heart rate 
(beats/min) +65 (2.1) +69 (2.8) 77 (3.6) 79 (3.1)
Resp. rate
(breaths/min) 14 (1.7) 15 (1.3) 16(1.3) 16(1.4)
O2 saturation
(%) +98 (0.3) +98 (0.3) 91 (0.1) 90 (0.2)
Expired CO2
(%)  4.9 (0.1) 4.8 (0.1) 4.8 (0.2) 4.7 (0.3)
Table 7.3.
The effect of nebulised salbutamol or saline on FEVi, oxygen saturation, heart rate and 
end-tidal CO2 levels whilst breathing either oxygen (FiC>2 1.0) or a hypoxic gas mixture 
(FiC>20.15) in twelve stable asthmatic patients. FEVi values were significantly higher 
on salbutamol days compared to placebo days (* denotes P < 0.05 for salbutamol 
versus placebo). Heart rate was significantly lower on hyperoxia days than on hypoxia 
days (+ denotes P < 0.05 for hyperoxia versus hypoxia). Oxygen saturation values were 
significantly higher on hyperoxia days compared to hypoxia days (+ denotes P < 0.05 
for hyperoxia versus hypoxia). There was no significant difference in expired CO2 
levels or respiratory rate between the diferent study days.
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 1 , , 1------------------------------------
Baseline 15 m inutes > 30 m inutes 45 m inutes
Hyperoxia (FiO^ 1.0) + inhaled saline 
Hypoxia (F i0 2 0.15) + inhaled saline 
Hyperoxia (FiO^ 1.0) + inhaled salbutamol 
Hypoxia (F i0 2 0 .1 5 )+  inhaled salbutamol
Figure 7.2
Effect o f nebulised salbutam ol or saline (inhalation 1: salbutam ol 0.05 m g/m l or 
saline, inhalation 2: salbutam ol 0.17 mg/ml or saline, inhalation 3: salbutam ol 5 m g/m l 
or saline) on m axim um  % change in FEV i from baseline (%) w hilst breathing oxygen 
(F i0 2 1.0) or hypoxia (F i0 2 0.15) in tw elve asthm atic patients.
* denotes P < 0.01 for salbutam ol versus saline at each tim e point.
Figure 7.3
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Baseline Pre 15 m inutes 30 m inutes 45 m inutes
 □ ----- Hyperoxia (FiO^ 1.0) + inhaled saline
 O—  Hypoxia (F i0 2 0.15) + inhaled saline
 O  Hyperoxia (FiO^ 1.0) + inhaled albuterol
 &-----  Hypoxia (F i0 2 0.15) + inhaled albuterol
Figure 7.3
Effect o f nebulised salbutam ol or saline on oxygen saturation (S a 0 2%) w hilst 
breathing either oxygen (F i0 2 1.0) or hypoxia (FiO2 0.15) in tw elve asthm atic patients. 
* denotes P< 0.01 for hyperoxia versus hypoxia at each tim e point.
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The results from our in-vitro experiments suggest that the ability of salbutamol to 
reverse methacholine-induced tone in human isolated bronchial rings is dependent upon 
the ambient oxygen tension of the environment. This is in keeping with our previous 
study in bovine isolated bronchial rings, although the pattern of responses differed 
slightly between the two studies (see section 3). In bovine bronchi, there was no 
difference between responses in hyperoxia and hypoxia, whereas in human bronchi 
responses to salbutamol were significantly greater in hyperoxia than hypoxia. A few 
notable features were in common between the two studies, namely that there was no 
difference between responses to salbutamol in hyperoxia and normoxia and also that 
lowering the oxygen tension from normoxia to hypoxia significantly attenuated the 
relaxatory effect of salbutamol.
Several possible factors for this hypoxic attenuation, such as 6-adrenoceptor-down 
regulation or uncoupling of the 6-adrenoceptors from their regulatory G-proteins, have 
been discussed in section 3. It remains possible, however, that hypoxia may have other 
effects t>n airway smooth muscle. For example, hypoxia has been shown to induce 
opening of membrane-bound potassium channels in isolated bronchial rings 
(Lindemann et al., 1994). Under an oxygen tension of 26 mm Hg it is likely that the 
majority of these channels will be open. Salbutamol is thought to mediate smooth 
muscle relaxation, at least partly, by opening membrane-bound potassium channels 
(Miura et al., 1992). If the majority of potassium channels are already open then the 
ability of salbutamol to cause further smooth muscle relaxation will be significantly 
attenuated under hypoxic conditions.
In contrast to our in-vitro experiments, it was found that acute hypoxia has no effect on 
the bronchodilator response to salbutamol in patients with asthma. The changes we 
observed in oxygen saturation would suggest that our closed breathing circuit had 
achieved significant changes in vascular oxygen tensions. Hypoxia and hyperoxia in 
man may cause increases in minute ventilation (Dripps & Comroe, 1947) and a 
subsequent fall in end-tidal carbon dioxide levels leading to bronchoconstriction 
(O'Cain et al., 1979; Newhouse et al., 1964; Sterling, 1968; Elshout et al., 1991). In our 
study we have observed no significant differences in end-tidal carbon dioxide levels 
suggesting this was not a factor in influencing our results. Prior to the study the 
nebuliser output for both the hypoxic and hyperoxic gas mixtures was found to be 0.13 
mls/min at a flow rate of 7 1/min.
There are several possible explanations for the differences we have observed between 
our in vitro and in vivo studies. The lowest concentration of O2 in the gas mixture used
in the in-vitro study was 0%, whereas in the in vivo study, for reasons of safety, the 
lowest concentration was 15%. As stated in section 1.6 changes in circulating humoral
factors or neural innervation caused by hypoxia and hyperoxia alone may have 
influences on airway tone in vivo which may offset the effects of the bronchodilator 
salbutamol. For example, circulating catecholamine levels may affect airway tone in 
vivo (see section 1.4.2). This would appear to be unlikely, however, since we have 
shown in previous in vivo studies using the same closed breathing circuit and inspired 
hyperoxic gas mixture that no significant changes in circulating catecholamine levels 
occurs (Dagg et al., 1996, see also section 8). It must also be remembered that the 
actual concentration of nebulised salbutamol administered to the asthmatic patients is 
not known, but is likely to be several orders of magnitude less than the concentrations 
of salbutamol used in the organ baths and this may go some way to explaining the 
differences between the in vivo and in vitro results.
As pointed out in section 1.6.2, isolated airway preparations are useful for studying the 
direct effect of hypoxia on airway smooth muscle function. In the in vivo situation, 
however, the effect of hypoxia on the airway smooth muscle may be opposed by 
various factors, with perhaps the most important control mechanism being neural 
reflexes. The inability to isolate these various other control mechanisms makes the task 
of elucidating the response all the more difficult.
We conclude that acute hypoxia attenuates the bronchodilator response to salbutamol in 
human isolated bronchial rings but has no effect on salbutamol induced bronchodilation 
in patients with stable asthma.
CHAPTER 8
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THE EFFECT OF ACUTE ALTERATIONS IN 
OXYGEN TENSION ON METHACHOLINE- AND 
HISTAMINE-INDUCED RESPONSES IN HUMAN 
ISOLATED BRONCHI AND ASTHMATIC 
PATIENTS IN  VIVO
8.1 INTRODUCTION 243
In the previous section we investigated the effect of changes in oxygen tension on 
salbutamol-induced bronchodilation in human airways. As reported in section 3, 
changing the O2 tension of the environment can also alter contractile responses, at least
in bovine bronchial rings. In this present study, responses to the bronchoconstrictors 
methacholine and histamine were measured in human isolated bronchial rings under 
hyperoxic, normoxic and hypoxic conditions. In addition, the ability of methacholine 
and histamine to induce bronchoconstriction in patients with asthma was compared 
after inhalation of hyperoxic, normoxic and hypoxic gas mixtures.
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8.2.1 In-vitro study
8.2.1.1 Tissue collection and preparation
Rings of human bronchi were dissected and mounted in organ baths as described in 
section 7.2.1.1.
8.2.1.2 Experimental Protocol
Initial experiments were conducted to ascertain the optimum level of applied resting 
tension for contractile responses in human bronchial rings. Under hyperoxic conditions, 
an initial resting tension of 0.5g wt was applied to each bronchial ring. Tissues were 
allowed to equilibrate for 15 minutes before addition of a single concentration of 
methacholine (ICHM). This concentration was chosen as it evoked an approximately 
maximal contractile response. When the contraction had reached a plateau, the tissues 
were washed three times with fresh Krebs-Henseleit solution over a 15 min period, or 
until th£ tension returned to baselinet^Tension was then removed before increasing the 
degree of initial tension to the next increment (l.Og wt).
Human bronchial tissue tends to be of variable condition, therefore the viability of each 
ring was ascertained by the addition of a single concentration (10'4M) of methacholine 
to evoke a reference contractile response. Once the response reached a plateau, the 
vessels were than washed 3 times with fresh Krebs-Henseleit solution and allowed to 
return to baseline tensions. Alterations in gas tension from hyperoxia to either 
normoxia or hypoxia were achieved by substituting oxygen with nitrogen as stated in 
section 2.1.5. Tension was adjusted if necessary and the vessels were left for a further 
45 minutes before the addition of any drugs.
Cumulative concentration-response curves (CCRCs) were then conducted to either 
methacholine (10"9-3xl0_4M) or histamine (10_9-3xl0_4M) in each of the oxygen 
tensions. In the case of methacholine, four consecutive concentration response curves 
were conducted upon the same bronchial ring; first in hyperoxia, then normoxia 
followed by hypoxia or vice versa. Lastly, a second concentration response curve was 
conducted in hyperoxia. In addition, on each study day, one ring acted as a time control 
whereby three consecutive concentration response curves to methacholine were 
conducted in hyperoxia alone.
In the case of histamine, to avoid tachyphylaxis, only one concentration response curve 
could be conducted in each bronchial tissue, therefore the three different oxygen 
tensions were imposed upon three separate bronchial rings. Results for histamine are 
expressed both in absolute terms and as a % of the initial reference contraction to 
methacholine.
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8.2.1.3 Materials
The following chemicals were used: methacholine and histamine (see section 2.1.8 for 
full chemical and suppliers names). Stock solutions of drugs were prepared in distilled 
water and subsequent dilutions made in Krebs-Henseleit solution.
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8.2.2.1 Patient Information
Due to the large number of visits required to complete this study, patients were 
randomly divided into three study groups. All of the patients gave a history of asthma 
and none had any other significant cardiac or respiratory disease. All of the patients 
gave written informed consent to the study protocol which had the approval of the West 
Ethics Committee.
Study Group 1
Eleven mild asthmatic patients (five male) mean (SD) age 42 (12) years were recruited 
into the study (see Table 8.1). All eleven patients were receiving inhaled B2-agonists as
required and ten regular inhaled corticosteroids. Two were taking regular inhaled 
salmeterol and one a long acting oral theophylline. This group was used to study 
responses to methacholine in normoxia and hypoxia.
Study Group 2
Fourteen adult mild asthmatic patients (five male) mean (SD) age 36 (9.2) years were 
recruited into the study (Table 8.1). All patients were taking inhaled B2-agonists on an
as required basis. Ten were receiving regular inhaled corticosteroids and two were 
taking regular oral theophyllines and one patient inhaled salmeterol. This group was 
used to study responses to methacholine in normoxia and hyperoxia.
Study Group 3
Fourteen adult mild asthmatic patients (eight female) mean (SD) age 39 (13) years were 
recruited into the study (Table 8.1). All patients were taking inhaled B2-agonists on an
as required basis. Twelve were receiving regular inhaled corticosteroids and of these, 
two were also receiving salmeterol. This group was used to study responses to 
histamine in hyperoxia, normoxia and hypoxia.
For each group, inhaled B2~agonists were discontinued for 8 hours prior to attendance, 
salmeterol for 24 hours and oral theophyllines for 48 hours prior to attendance. Patients 
were asked to continue their inhaled corticosteroids as usual. Patients were asked to 
refrain from caffeine containing products for 8 hours prior to each study day. All 
patients had been stable for a period of two months prior to entry into the study with no 
significant change in their asthma symptoms or medication. Patients were excluded 
from the study if there was any significant change in their asthma symptoms or 
medication between visits. The maximum period between each visit was seven days.
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Table 8.1 Patient characteristics
Study No. of Mean age Mean FEVI Geometric mean
No. patients (years) litres % predicted PC20 (agonist) mg/m
1 11 42 2.76 86 1.13
(12.1) (0.49) (7.7) (0.04 - 7.90)
2 14 36 2.80 90 0.84
(9.2) (0.60) (8.6) (0.04 - 7.90)
3 14 39 3.04 91 1.79
(12,8) _ __(QJ21_ (9,2) (0.29 - 6.80)
Table 8.1 Patient characteristics
Abreviations: FEVI; forced expiratory volume in 1 second, PC20 (agonist); 
concentration of agonist (methacholine in studies 1 and 2, and histamine in study 3) 
provoking a fall in FEV1 of 20%. Data is expressed as mean (S.D).
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8.2.2.2 Study design
In Study Groups 1 and 2, patients were asked to attend the study laboratory on three 
separate days (one screening visit and two study days) at approximately the same time 
each day. In Study Group 3, patients attended on four separate days (one screening visit 
and three study days). During the initial screening visit, the patients in Study Groups 1 
and 2 underwent a methacholine inhalation challenge test to determine a PC20 value ie: 
that concentration of methacholine causing a 20% fall in FEVi. Patients in Study Group 
3 inhaled histamine to determine a PC20 value for this agonist. On the subsequent study
days, after thirty minutes of supine rest, the patients were commenced on a closed 
breathing circuit. Following a ten minute run in period breathing air (Fi02 0.21) 
baseline measurements of FEVi, respiratory rate (RR), heart rate (HR), oxygen 
saturation (Sa02%) inspired oxygen and carbon dioxide levels (insp 02%, insp C02%) 
and expired oxygen and carbon dioxide levels (PET02%, PETC02%) were made (see 
section 2.3.3). In Study Groups 1 and 2, venous blood was also taken for assay of 
plasma catecholamines.
In Study Group 1, patients then received either air (Fi02 0.21) or a hypoxic gas mixture 
(Fi02 0.15) and in Study Group 2, either air (Fi02 0.21) or oxygen (Fi02 1.0) for the 
remainder of the study day. Patients in Study Group 3 received either hyperoxia, air or 
hypoxia for the remainder of the study day. All gases were administered in a 
randomised double blind manner by a second operator obscured from the vision of both 
the patient and the doctor performing the bronchoconstrictor challenge. Ten minutes 
after commencing the study gas, all measurements made at baseline, except venous 
blood sampling, were repeated prior to commencing the bronchoconstrictor inhalation 
challenge. The study day was terminated when a PC20 value had been obtained and the
measurements made at baseline were then repeated.
249
8.2.2.3 Measurements
Heart rate, oxygen saturation, inspired and expired oxygen and carbon dioxide levels 
were measured as reported in section 2.3.3.1 and FEVi values were measured as stated
in section 2.3.3.2. Study gases were generated as described in section 2.3.4.
Bronchoconstrictor inhalation challenge: Baseline FEVi was measured by taking the 
best of three recordings, thereafter a saline inhalation was administered and then 
doubling doses of either nebulised methacholine (made up in normal saline), or 
nebulised histamine (made up in normal saline), were administered at 5 minute intervals. 
Each concentration was given for 2 minutes via a (micro-cirrus) nebuliser. All challenge 
tests were performed by the same person throughout both studies. The nebuliser output 
for all gases in Study Group 1 and Study Group 3 at a flow rate of 7 Litres per minute 
was 0.13 mls/min and in Study Group 2 at a flow rate of 6 Litres per minute the 
nebuliser output was 0.12 mls/min for both gases. The FEVi was measured at 0.5, 1.5 
and 3 minutes after each inhalation until a fall in FEVi of at least 20% was achieved as
determined by linear interpolation from the logarithmic dose-response curve. This result 
was then expressed as the methacholine PC20 (provocation concentration 20%) or the 
histamine PC20 (provocation concentration 20%). The methacholine and histamine 
solutions were made up by the sterile unit of our pharmacy department.
Plasma catecholamines: Adrenaline and noradrenaline levels in the plasma were 
measured as described in section 2.3.3.3.
8.2.3 Statistical analysis
For the in-vitro studies the results for methacholine are expressed as a % of the 
maximum response in the initial concentration-response curve, in hyperoxia, while 
results for histamine are expressed in mg wt. Results are expressed as mean (SEM). 
Statistical significance between the data sets generated by concentration response curves 
was tested by two-way analysis of variance (ANOVA). Significance between data points 
(mean maximum responses) was calculated by Students t-test (see section 2.1.9.3). 
Number of observations (n) refers to the number of patients from whom tissues were 
obtained.
For the in-vivo studies, analysis of variance (ANOVA) corrected for multiple 
comparisonsJUtfas used to compare-measurements between study days. The PC20 values
were logarithmically transformed before analysis. A P-value below 0.05 was accepted as 
significant.
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8.3.1 In-vitro study
Optimisation Of Initial Resting Tension
Changing the degree of applied (passive) tension significantly altered the contractile 
(active) response evoked by a maximal concentration o f m ethacholine (1 0 '4M ). The 
m easured contractile response increased as the applied tension was increased from  0.5g 
wt to 2.0g wt, reaching a m axim um  contraction at 2.0g wt. W hen the applied tension 
was increased beyond 2.0g wt, however, the contractile responses appeared to decline. 
The m axim um  response to m ethacholine, at a resting tension o f 2.0g wt, 2109.5±535.9 
mg wt, was significantly greater (P<0.05 for data points) than the response to 
m ethacholine at a resting tension o f 1.5g wt, 117 8 .2± 312.8 mg wt. N um ber of 
observations (n) =6 in each case.
Figure 8.1
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Figure 8.1
The effect o f changing the degree of initial resting tension on contractile responses. 
Contractions evoked by a single concentration (10‘4M) of m ethacholine were m easured 
in hum an bronchial rings in hyperoxia. Responses are expressed in m illigram s weight 
(mg wt). C ontractile responses were significantly (P<0.05 for data points) greater at a 
resting tension o f 2.0g wt than at a resting tension o f 1.5 g wt. N um ber o f observations 
(n) = 6 in each case.
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M ethacholine evoked contractile responses in hum an isolated bronchial rings in a 
concentration-dependent m anner (see F igure 8.2). In both hyperoxia and norm oxia, 
responses to m ethacholine were initiated at betw een 10"9M and 3x 10'9M  and betw een 
3x 10"8M and 10_7M in hypoxia (see F igure 8.3A). Reducing the oxygen fraction in 
the gas m ixture from  95%  to 20% significantly (P<0.05, for data sets) attenuated the 
contractions evoked by m ethacholine. Low ering the oxygen tension further, from 
hyperoxic to hypoxic levels, produced a further reduction in the contractile response 
to m ethacholine (responses in hyperoxia were significantly , P<0.001 for data sets, 
greater than responses in hypoxia). Responses to m ethacholine in norm oxia were 
significantly (PcO.Ol, for data sets) greater than in hypoxia. The m axim um  response 
to m ethacholine in hyperoxia was not significantly different from  the m axim um  
response in norm oxia (m axim um  response to m ethacholine in hyperoxia, at the 10"4M 
level; 2015.1±503.7m g wt, m axim um  response to m ethacholine in norm oxia, at the 
1()‘4M level; 1468.8.±609.3m g wt). The m axim um  response in hypoxia, how ever 
(m axim um  response to m ethacholine in hypoxia, at the 1()"4M level; 816.4±321.0m g 
wt), was significantly  less (PcO.Ol and P<0.05, for data sets, respectively) than in 
either hyperoxia o r norm oxia.
In the tim e control studies, there was no significant difference betw een the three 
consecutive concentration response curves to m ethacholine in hyperoxia (Figure 
8.3B), indicating that the contractile responses to m ethacholine in this tissue w ere not 
altered by time.
Figure 8.2
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Figure 8.2
Representative trace depicting m ethacholine-induced contractions in hum an bronchial 
rings. M ethacholine was added cum ulatively to give final bath concentrations o f 10~9M- 
3x 1() 4M. Each concentration was added after the previous response had reached a plateau.
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Figure 8.1 A
Contractions evoked by m ethacholine in hum an isolated bronchi in hyperoxia (■ ), 
norm oxia (□ ) and hypoxia ( • ) ,  follow ed by a final concentration-response curve in 
hyperoxia again (O ). M ethacholine was added cum ulatively to give final bath 
concentrations of 10~9M -3xl0~4M. Responses are expressed as a % o f the m axim um  
response in hyperoxia. M ethacholine was significantly (P<0.05 and PcO.OOl, 
respectively) more effective in hyperoxia than in norm oxia and hypoxia and 
significantly (P<0.01) more effective in norm oxia than in hypoxia. There was no 
difference between the first and the last concentration-response curves in hyperoxia. 
Num ber o f observations (n)=8 in each case.
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Figure 8.3B
Tim e control studies for m ethacholine in human isolated bronchi. C ontractions evoked 
by m ethacholine in hum an isolated bronchi in the first curve (■ ), second curve (□ )  and 
third curve (Q ). M ethacholine was added cum ulatively to give final bath concentrations 
of 10_9M -3x 10'4M. Responses are expressed as a % of the m axim um  response in the 
first curve. There was no significant difference between the three consecutive 
concentration response curves to m ethacholine in hyperoxia. N um ber o f observations 
(n)=8 in each case.
254
Histamine also induced concentration-dependent contractions of the human isolated 
bronchial rings. In each of the oxygen tensions, responses to histamine were initiated at 
between 10-7 M and 3x1 O'7 M, indicating that changes in oxygen tension did not alter 
the sensitivity of the tissue to histamine (see Figure 8.4). Throughout the whole 
concentration-response curve, contractions evoked by histamine were significantly 
(P<0.01 and PcO.OOl for data sets, respectively) greater in hyperoxia than in normoxia 
or hypoxia, and responses in normoxia were significantly (P<0.05 for data sets) greater 
than in hypoxia (n=8 in each case). There was no significant differences between the 
maximum response (at a concentration of 3xl0~4M) in hyperoxia (1995±509.7mg) and 
normoxia (1076.7±347.4mg), or between the maximum response in normoxia and 
hypoxia (683.3±199.2mg). The maximum response in hyperoxia, however, was 
significantly (P<0.05 for data points) greater than the maximum response in hypoxia.
In addition to expressing the results in absolute terms (mg wt.), I also expressed the 
results as a % of the initial reference contraction evoked by 10~4M methacholine for 
comparison (see Figure 8.4B). As shown in Figure 8.4B, expressing the results as a % of 
the methacholine contraction did not alter the pattern of responses. Responses to 
histamine were still significantly (PcO.Ol and PcO.OOl for data sets, respectively) greater 
in hyperoxia than in normoxia or hypoxia, and responses in normoxia were significantly 
(Pc0.05 for data sets) greater than in hypoxia (n=8 in each case).
Furthermore, expressing the results in either way did not alter the calculated EC50 values 
(EC50 values for histamine in hyperoxia; 5.1±0.7 for results expressed as mg wt, 5.2±0.8 
for results expressed as % methacholine. EC50 values for histamine in normoxia;
4.9±0.8 for results expressed as mg wt, 4.7±0.7 for results expressed as % methacholine. 
EC50 values for histamine in hypoxia; 4.6±0.6 for results expressed as mg wt, 4.4±0.8
for results expressed as % methacholine.).
Figure 8.4
Contractions evoked by histamine in human isolated bronchi in hyperoxia (■), normoxia 
(□) and hypoxia (O). Histamine was added cumulatively to give final bath concentrations 
of 10-9M-3x10'4M. Responses are expressed as (A) mg wt. and (B) as a % of the initial 
contractile response to methacholine 10_4M. In both cases, histamine was significantly 
(PcO.Ol and PcO.OOl, respectively) more effective in hyperoxia than in normoxia and 
hypoxia and significantly (Pc0.05) more effective in normoxia than in hypoxia. Number 
of observations (n)=8 in each case.
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8.3.2 In-vivo  s tu d y
Baseline measurements: For Study Groups 1 and 2, there were no significant differences 
in baseline measurements between study days in either study (see Table 8.2). For Study 
Group 3, there were no significant differences in the baseline measurements between the 
three study days (Table 8.3).
Tabic 8,2
Study 1 Study 2
Baseline
measurement
Normoxia 
study day
Hypoxia 
study day
Normoxia 
study day
Hyperoxia 
study day
FEVI (L) 2.67 (0.14) 2.63 (0.16) 2.71 (0.14) 2.71 (0.17)
Heart rate (bpm) 71.0 (4.0) 71.0. (4.7) 77.0 (4.3) 75.0 (3.7)
Respiratory rate 
(breaths/min) 15.0 (1.5) 16.0 (1.6) 14.0(1.4) 16.0 (1.3)
Sa02 (%) 96.5 (0.2) 96.3 (0.2) 96.5 (0.3) 96.7 (0.4)
Inspired 02% 20.8 (0.2) 21.0 (0.0) 21.0 (0.0) 20.9 (0.1)
End-tidal 002% 4.66(0.11) 4.64 (0.14) 4.49 (0.17) 4.47 (0.21)
Plasma noradrenaline 
(nmol/1) 1.72 (0.14) 1.61 (0.29) 2.14 (0.58) 1.80 (0.26)
Plasma adrenaline 
(nmol/1) 0.10 (0.02) 0.10 (0.02) 0.11 (0.02) 0.07 (0.02)
Table 8.2:
Baseline measurements for patients in Study Groups 1 and 2. Mean (SEM) baseline 
respiratory, heart rate and plasma catecholamine measurements for Study 1 (hypoxia v 
normoxia n = ll)  and Study 2 (hyperoxia v normoxia n=14). No significant differences 
between study days in either study.
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Tahle 8.3
Baseline Normoxia Hyperoxia Hypoxia
measurement study day study day study day
FEVi (Litres) 2.73 (0.2) 2.65 (0.21) 2.65 (0.20)
Heart rate (beats/min) 71 (3.7) 71 (3.0) 70 (3.0)
Respiratory rate (breaths/min) 16 (1.2) 16 (1.2) 16 (0.8)
Oxygen saturation (%) 96 (0.20) 96 (0.17) 96 (0.31)
Inspired oxygen (%) 20.8 (0.1) 20.8 (0.1) 20.9 (0.1)
Expired oxygen (%) 15.4 (0.3) 15.3 (0.2) 15.6 (0.1)
End-tidal C02(% ) 4.9 (0.1) 4.8 (0.1) 4.8 (0.1)
Table 8.3
Baseline measurements for patients in Study Group 3. Mean (SEM) baseline 
measurements of FEVi, oxygen saturation, heart rate, respiratory rate, inspired and 
expired oxygen tension and end-tidal carbon dioxide levels on the normoxic, hyperoxic 
and hypoxic study days. There were no significant differences between any baseline 
measurements on any study day.
Change from baseline
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Study 1
Methacholine PC20 values: The geometric mean PC20 methacholine value was 
significantly lower (P<0.05) on the hypoxic study day when compared to the normoxic 
day (Figure 8.5A). The mean difference in PC20 methacholine values (mg/ml) between 
the hypoxic and normoxic study days was 2.88 mg/ml (95% Cl 1.40 to 5.3 mg/ml). 
Oxygen saturation: Oxygen saturation was significantly lower (PcO.Ol) following 
hypoxia [mean (SEM) Sa02%: baseline 96.3 (0.24)%, pre-methacholine 91.0 (0.56)%, 
post-methacholine 90.5 (1.0)%] when compared to normoxia [mean (SEM) Sa02%: 
baseline 96.5 (0.16)%, pre-methacholine 96.3 (0.27)%, post-methacholine 96.0 
(0.43)%] (Figure 8.6A).
Heart rate: There was no significant difference in heart rate when the hypoxia and 
normoxia study days were compared at any time point (data not shown).
Forced expiratory volume in one second: The mean FEVi after 10 minutes breathing the 
hypoxic gas mixture alone, prior to inhalation of methacholine was not significantly'r*
different when compared to the normoxic study day. The mean FEVi (SEM) following 
10 minutes of hypoxia alone was 2.40 (0.15) Litres compared to 2.38 (0.14) Litres on 
the normoxic study day.
Study 2
Methacholine PC20 values: There was no significant difference in the geometric mean 
PC20 methacholine values between the normoxic and hyperoxic study days (Figure 
8.5B). The mean difference in PC20 methacholine values (mg/ml) between the hyperoxic 
and normoxic study days was 1.45 mg/ml (95% Cl 0.83 to 2.51 mg/ml).
Oxygen saturation: Oxygen saturation was significantly higher (PcO.Ol) following 
hyperoxia [mean (SEM) Sa02%: baseline 96.7 (0.35)%, pre-methacholine 98.1 
(0.23)%, post-methacholine 98.1 (0.20)%] than during the normoxic study day [mean 
(SEM) Sa02%: baseline 96.5 (0.33)%, pre-methacholine 96.7 (0.37)%, post- 
methacholine 96.0 (0.52)%] (Figure 8.6B).
Heart rate : Heart rate was significantly lower (Pc0.05) on the hyperoxic study day both 
before and after the methacholine inhalation test when compared to the normoxic study 
day. The mean (SEM) HR (bpm) on the hyperoxic study day was: baseline 75 (4), pre- 
methacholine 71 (4), post-methacholine 71 (4) and on the normoxic study day: baseline 
77 (4), pre-methacholine 75 (5), post-methacholine 77 (4).
There were no significant differences in respiratory rate, end-tidal carbon dioxide % or 
plasma catecholamine levels between study days in either study (Table 8.4 post 
methacholine values on each study day).
Table 8.4
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Study 1 Study 2
Post methacholine Normoxia Hypoxia Normoxia Hyperoxia
inhalation measurement study day study day study day study day
Respiratory rate (breaths/min) 15.0(1.6) 14.0(2.0) 14.0(1.0) 15.0(1.1)
End-tidal C02% 3.70(0.18) 3.86(0.17) 3.94(0.18) 3.87(0.22)
Plasma noradrenaline nmol/1 1.60 (0.16) 1.40 (0.25) 1.66 (0.29) 1.63 (0.28)
Plasma adrenaline nmol/1 0.08(0.02) 0.06(0.02) 0.07(0.02) 0.07(0.02)
Table 8.4
Mean (SEM) measurements of respiratory rate, end-tidal carbon dioxide % and plasma 
catecholamine levels following methacholine inhalation in study 1 (hypoxia v normoxia) 
n=lland study 2 (hyperoxia v normoxia) n=14.
No significant differences were found between study days in either study.
Figure 8.5A
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Figure 8.5A
Effect o f hypoxia and norm oxia on PC 20 m ethacholine values in patients with asthm a 
(Study Group 1 n= l 1). The y-axis represents PC 20 m ethacholine values in m g/m l. The 
geom etric m ean PC 20 m ethacholine value was significantly low er (P<0.05) on the 
hypoxic study day when com pared to the norm oxic day.
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Figure 8.5B
Not significant
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Figure 8.5B
Effect of hyperoxia and norm oxia on PC 20  m ethacholine values in patients with asthm a 
(Study Group 2, n=14). The y-axis represents PC 20  m ethacholine values in m g/m l. 
There was no significant difference betw een the geom etric m ean PC 20  m ethacholine 
values on the hyperoxic and hypoxic study days.
Figure 8.6A
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Figure 8.6A
Effect of hypoxia and norm oxia on oxygen saturation (SaC>2 ) in patients with asthm a 
(Study Group 1 n= l 1). The y-axis represents SaC>2 values in %. The SaC>2 values, both 
before and after m ethacholine challenge, were significantly lower (PcO.Ol) on the 
hypoxic study days ( • )  when com pared to the norm oxic days (■ ). * denotes PcO.Ol 
for data points.
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Figure 8.6B
Effect of hyperoxia and norm oxia on oxygen saturation (SaC>2 ) in patients with asthm a 
(Study Group 2 n=14). The y-axis represents SaC>2 values in %. The SaC>2 values, both 
before and after m ethacholine challenge, were significantly higher (P<0.01) on the 
hyperoxic study days (A ) when com pared to the norm oxic days (■ ). * denotes PcO.Ol 
for data points.
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F igure 8.7
Effect o f hyperoxia, norm oxia and hypoxia on PC 20  histam ine values in patients with 
asthm a (Study G roup 3, n=14). The y-axis represents PC 20  h istam ine values in m g/m l. 
There was no s ign ifican t difference betw een the geom etric m ean PC 20  h istam ine values 
betw een the hyperoxic, norm oxic and hypoxic study days.
Figure 8.8
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Figure 8.8
Effect o f hyperoxia, norm oxia and hypoxia on oxygen saturation (SaC>2 ) in patients 
with asthm a (Study Group 3 n=14). The y-axis represents SaC>2 values in %. The SaC>2 
values, both before and after m ethacholine challenge, were significantly  higher 
(PcO.Ol) on the hyperoxic study days ( • )  when com pared to the norm oxic (□ )  and 
hypoxic days (O ). * denotes PcO.Ol for data points.
Histamine PC20 values: Mean histamine PC20 values mg/ml were not significantly 
different between the three study days (Figure 8.7). The mean (range) PC20 value 
mg/ml on each study day was: hypoxia day; 1.91 (0.27-27.4) mg/ml, hyperoxia day; 
2.32 (0.29-19.0) mg/ml, normoxia day; 2.19 (0.3-15.4) mg/ml.
Oxygen saturation: Oxygen saturation was significantly higher (PcO.Ol) on the
hyperoxic study day when compared to the normoxic and hypoxic study days both 
before and after histamine inhalation. Oxygen saturation was significantly lower 
(PcO.Ol) on the hypoxic study day [mean (SEM) Sa02%: baseline 96.1 (0.31)%, pre­
histamine 96.3 (0.23)%, post-histamine 96.0 (0.20)%] when compared to the normoxic 
study day [mean (SEM) Sa02%: baseline 96.7 (0.20)%, pre-histamine 97.1 (0.23)%, 
post-histamine 97.1 (0.20)%]. Oxygen saturation was significantly higher on the 
hyperoxic study days [mean (SEM) Sa02%: baseline 96.1 (0.17)%, pre-histamine 99.3 
(0.13)%, post-histamine 99.2 (0.11)%] than the hypoxic days. (Figure 8.8).
Heart rate: Heart rate was significantly lower (PcO.Ol) on the hyperoxic study day 
when compared to both the normoxic and hypoxic study days both before and after 
inhalation of histamine. The mean (SEM) heart rate (bpm) on each study day at 
baseline, prior to histamine inhalation and after histamine inhalation was: hypoxia day
70 (3), 74 (3) and 72 (3): hyperoxia day 71 (3), 65 (3) and 67 (3): normoxia day 71 (4),
71 (4) and 74 (4). Heart rate was not significantly different when the hypoxic and 
normoxic study days were compared.
FEVi: There were no significant differences in FEVi values between the study days 10
minutes after commencing the study gases prior to inhalation of histamine. The mean 
(SEM) FEVi value litres 10 minutes after commencing the study gas on each day was:
hypoxia day 2.65 (0.18) litres, hyperoxia day 2.65 (0.18) litres and normoxia day 2.73 
(0.16) litres.
End-tidal carbon dioxide %,' respiratory rate: End-tidal carbon dioxide (%) and
respiratory rate measurements were not significantly different between study days both 
before and after histamine inhalation (data not shown).
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In this present study, we found that lowering the oxygen tension from hyperoxic to 
normoxic levels significantly attenuated contractile responses to methacholine and 
histamine in human isolated bronchi. Reducing the oxygen tension further, from 
normoxic to hypoxic levels, evoked a further reduction in contractile responses to these 
two spasmogens.
A previous study by Vidruk & Sorkness (1985) in anaesthetized dogs showed that 
histamine-induced tracheal constriction was potentiated by hypoxia and attenuated by 
hyperoxia. These responses were eliminated by denervation of the trachea, indicating 
that the bronchomotor responses were reflex rather than direct in nature. In contrast, the 
responses evoked by histamine in our in vitro studies reflect the direct effect of 
histamine on airway smooth muscle.
The prevailing pattern of histamine receptors determines the effect of histamine on 
airway smooth muscle. Since it varies considerably between species and even between 
different sites in the same airway (Chakrin & Krell, 1980), extrapolation of results from 
animal models to man has created considerable confusion. In most species, the 
predominance of bronchoconstricting Hi-receptors over bronchodilating H2-receptors 
ensures that histamine produces bronchoconstriction. In man, Hi-receptor mediated 
contraction of airway smooth muscle has been extensively demonstrated (Casterline & 
Evans, 1976; Woenne et al., 1978; Thomson & Kerr, 1980), although the existence of 
H2 receptors remains controversial. An early hypothesis (Chand, 1980) suggested that 
an absence of H2-receptors might be the cause of bronchial hyperrresponsiveness in 
asthma. The balance of evidence, however, indicates that bronchodilating H2-receptors
are present in insignificant numbers if at all in human airways (see Eiser, 1992).
Given that responses to methacholine (which of acts via muscarinic post-junctional M3 
and possibly M2, see section 1.4.1) were altered in a similar manner by changes in 
oxygen tension, the attenuation in histamine responses as the oxygen tension was 
decreased is therefore unlikely to be due to a change in the balance between excitatory 
Hi and inhibitory H2-receptors.
Another potential explanation is that lowering the oxygen tension from hyperoxic to 
normoxic and hypoxic levels increases the rate of cell death for the airway smooth 
muscle cells. Given that the attenuation of methacholine responses seen in normoxia 
and hypoxia were reversed when the oxygen tension was returned to hyperoxic levels, 
this remains unlikely. It is perhaps more plausible that the attenuation of contractile 
responses as the oxygen tension was reduced reflects an impairment of the airway 
smooth muscle contractile processes. Previous studies have shown that hypoxia reduces 
the force of contraction in airway smooth muscle (Stephens & Kroeger, 1970), possibly 
by impairing energy metabolism (Stephen & Chiu, 1970) or by inhibiting the entry of 
extracellular calcium (Fernandes et a l, 1993, see section 1.6).
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In our in vivo studies, we found that, compared to responses in normoxia, hypoxia 
potentiated methacholine-induced bronchoconstriction in asthmatic patients. 
Hyperoxia, however, did not alter methacholine-induced responses compared to 
normoxia. Histamine produced a different pattern of results in that bronchoconstrictor 
responses to histamine were not altered by changing the inspired oxygen tension from 
normoxia to either hyperoxia or hypoxia.
The rise in oxygen saturation and fall in heart rate seen on the hyperoxic study day and 
the fall in saturation on the hypoxic study day indicate that our closed breathing circuit 
has achieved the required changes in airway and vascular oxygen tension (Jennet, 1964; 
Watt et al., 1942; Dripps & Comroe, 1947). It could be postulated that hypoxia may 
cause an elevation of plasma adrenaline levels, which may then influence bronchial 
tone indirectly (see section 1.4.2). The absence of a significant rise in heart rate on the 
hypoxic study day, however, suggests that the level of hypoxia we have produced has 
not resulted in an increase in resting sympathetic tone. This is supported by our finding 
that plasma catecholamine levels were not altered on hypoxic study days.
Both hypoxia and hyperoxia cause an increase in minute ventilation and subsequent fall 
in end-tidal carbon dioxide levels (Jennet, 1964; Watt et al., 1942; Dripps & Comroe, 
1947). Hypocapnia in-vivo is associated with bronchoconstriction (Newhouse et al., 
1964; O'Cain et al., 1979; Sterling, 1968; Elshout et al., 1991), therefore it could be 
proposed that our results were influenced by a hypocapnia-mediated increase in airway 
tone. We, however, found no significant difference in end-tidal carbon dioxide levels 
between study days either before or after agonist-inhalation, suggesting that this factor 
did not influence our results.
Nebuliser output may be affected by the molecular weight of the gas used to drive the 
nebuliser, therefore in all the studies the nebuliser output was calculated on two 
occasions for each study gas. In all of the studies, the nebuliser output was within 
acceptable limits (Studies 1 and 3; 0.13 mls/min at a flow rate of 7 1/min and in study 2; 
0.12 mls/min at 6 1/min).
Our double blind study has demonstrated an increase in airway reactivity to 
methacholine following acute hypoxia in keeping with a previous single blind study 
reported by Denjean et al. (1988). Previous animal studies have suggested that the 
potentiation ofTnethacholine-induced bronchoconstriction by hypoxia is attenuated by 
prior surgical chemodenervation (Denjean et al., 1991), suggesting that the effect is 
mediated via peripheral chemoreceptors. In our study we have been unable to detect an 
increase in airway tone following 10 minutes of hypoxia as one would expect if this 
effect occured as a consequence of bronchoconstriction due to hypoxia alone. Thus, this
appears to be an enhancement of bronchial reactivity to methacholine, without any 
change in baseline tone.
Other animal studies have shown that potentiation of histamine and carbachol-induced 
bronchoconstriction in sheep is significantly reduced by both intravenous cromolyn 
sodium (Ahmed & Marchette, 1985) and FPL57231, (D'Brot & Ahmed, 1988) a 
leukotriene receptor antagonist, suggesting that alveolar hypoxia may stimulate release 
of inflammatory mediators. Hypoxia may also act on vagal nerve endings to stimulate 
neurotransmitter release and hence cause bronchoconstriction.
These findings may be of clinical relevance as the level of hypoxia we have induced is 
compatible with those seen in patients admitted to hospital with acute severe 
exacerbations of asthma. It would appear therefore that hypoxia occurs not only as a 
consequence of acute severe asthma but may also increase airway responsiveness to 
bronchoconstrictor stimuli.
We have not, in man demonstrated attenuation of methacholine-induced 
bronchoconstriction by hyperoxia in contrast to the findings of the in-vivo animal 
studies"of Vidruk & Sorkness (1985)7^0118 difference may best be explained by species 
variation or by differences in methodological approach and study design. Our results 
support and extend those of Wollner et al (1991). We have however also examined the 
potential influences of hypocapnia and circulating catecholamines on airway reactivity 
during hyperoxia and also demonstrated that our patients show the typical 
cardiovascular and respiratory responses to hyperoxia. Our results differ from those of 
Inoue et al (1989) who found that hyperoxia attenuated methacholine-induced 
bronchoconstriction in asthmatic subjects. They however used an inspired oxygen 
concentration of 30% whereas we used 100%. Six of their patients had arterial oxygen 
tensions below 10 Kpa, in keeping with resting hypoxaemia, and since inspiring 30% 
oxygen relieves hypoxic bronchoconstriction (Libby et al., 1981; Astin, 1970) this 
effect may have falsely influenced their results.
In addition, this study has also shown no change in airway hyperresponsiveness to 
histamine at various inspired oxygen tensions in patients with asthma. This contrasts 
with the findings of Vidruk & Sorkness (1985) who found hypoxia potentiated and 
hyperoxia attenuated histamine induced tracheal constriction in mongrel dogs. It is 
worth noting that the‘aforementioned study used an inspired oxygen tension of 12% 
which is less than our own and that the animals in his studies had been anaesthetised. 
As stated IfPsection 1.6, the use and level of anaesthesia in these studies can 
significantly alter the outcome of the study. The anaesthetic drugs in combination with 
the altered oxygen tensions used may have effects on circulating humoral factors or 
chemoreceptor activity which have influenced their results. Our study results also differ 
from those of Ahmed & Marchette (1985) and D'Brot & Ahmed (1988) who, using
conscious sheep, also showed potentiation of histamine induced bronchial reactivity by 
hypoxia. As stated earlier, the distribution of histamine receptor subtypes in the airways 
varies from species to species, thus it is possible that species variation could account 
for these differences.
Our findings for histamine also differ from the methacholine results, in which we 
demonstrated that hypoxia potentiates methacholine induced bronchoconstriction in 
patients with asthma. The study protocols were similar and performed using the same 
breathing circuit. In addition, the in vitro studies for methacholine and histamine 
produced a similar pattern of responses. It is difficult therefore to account for this 
difference. Clearly the precise mechanisms of these effects is complex and will require 
further work. We have shown no effect of hyperoxia on histamine induced 
bronchoconstriction which is in keeping with our own study examining the effect of 
hyperoxia on methacholine hyperresponsiveness.
In conclusion, we have shown that contractile responses to both methacholine and 
histamine in human isolated bronchi are attenuated by lowering the oxygen tension. 
Furthermore these results demonstrate that acute hypoxia potentiates methacholine- 
induced bronchoconstriction in patients with stable asthma, whereas raising the inspired 
oxygen tension to hyperoxic levels did not alter bronchial responsiveness to 
methacholine. In contrast, histamine-induced bronchoconstriction in patients with 
stable asthma was not altered by acute alterations in inspired oxygen concentration.
CHAPTER 9 
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It should be apparent from the results chapters in this thesis that changes in oxygen 
tension can have a marked effect on airway smooth muscle function. I have shown that 
hypoxia can:
(i) alter the responsiveness of isolated bronchial rings to both contractile and relaxatory 
agonists.
(ii) induce proliferation of cultured human airway smooth muscle cells and enhance the 
mitogenic effects of certain agonists on these cells.
(iii) potentiate the bronchoconstrictor response to methacholine, but not histamine, in 
asthmatic patients.
Closer examination of the results indicates that the effect of hypoxia on airway smooth 
muscle responsiveness is not always consistent between different species. The most 
notable example is the contractile response to methacholine in isolated bronchial rings. 
In bovine bronchi, lowering the oxygen tension from hyperoxic to either normoxic or 
hypoxic levels significantly enhanced responses to methacholine. In human and rat 
isolated airway preparations, the converse was true in that contractile responses were 
attenuated by hypoxia. This apparent conflict may be due to an underlying difference in 
the pharmacology or biochemistry of the airway smooth muscle of the various species. 
Alternatively, the difference may be due to the different order of airways used in the in 
vitro studies. For rats, the trachea was used, in humans the "upper bronchi" (2nd - 4th 
order) and in bovine, relatively "lower" bronchi (4th - 5th). As stated in section 1.6, the 
response of the airways to hypoxia may differ between the upper and lower regions of 
the respiratory tract. Thus, this may account for the experimental differences between 
the species. It would be interesting to conduct a study comparing various regions of the 
respiratory tract from each species. Unfortunately this was impractical for a number of 
reasons: firstly, the supply of human tissue was limited both in quantity and frequency. 
Secondly, the rat airways rapidly decrease in size after the tracheal stage and become 
beyond the reasonable limits of resolution for organ bath experiments. The opposite is 
true for bovine bronchi since bronchi of 2nd-4th generation, which would compare to 
generation of the human tissue, would be too large for practical use.
While the effect of hypoxia differs between species, there are also differences between 
various agonists in the same species. For example, in bovine bronchi salbutamol was 
more effective at reversing induced tone in normoxia than hypoxia, whereas the other 
dilators were either equipotent (isosorbide dinitrate) or more effective (atrial natriuretic 
peptide) in 0% than 20% O2. In contrast, sodium nitroprusside was more effective in
hyperoxia than normoxia.
I have postulated that this may be due to the different second-messenger pathways 
utilised by each of these agents. As stated in section 1.3.4, there are several intracellular
mechanisms thought to be involved in producing relaxation of airway smooth muscle. 
The idea of "multiplex" signalling suggests that a single agonist may activate more than 
one pathway simultaneously. It is possible that changes in oxygen tension affects these 
different pathways to varying degrees, which would perhaps explain the disparity 
between the various dilators.
This may also go some way to explaining why hypoxia potentiated methacholine- 
induced bronchoconstriction in asthmatic patients but did not alter histamine-induced 
bronchoconstriction. While histamine and methacholine are both thought to act via 
similar second-messenger mechanisms (G protein-linked hydrolysis of PIP2), there may
be slight differences in the intracellular circuitry stimulated by each of these agonists. 
Evidence against this, however, comes from the in vitro results, whereby the pattern of 
responses to methacholine in the different oxygen tensions was similar to that of 
histamine. Thus the results from the in vitro experiments did not predict the outcome of 
the in vivo studies.
As stated in section 1.4, airway responsiveness is dependent upon the balance between 
neural and humoral pathways as well as the intrinsic control of the airway smooth 
muscle. In this body of work, I used isolated airway preparations to examine the 
importance of the intrinsic muscular control elements in determining airway 
responsiveness under hyperoxic, normoxic and hypoxic conditions.
Previous studies have compared the results from human airways in vitro and in vivo. 
For example, Roberts and coworkers (1985) measured airway responses to histamine in 
20 patients prior to undergoing lung resection. The results were compared with the 
subsequent responses to histamine in isolated bronchi taken from the same patients 
during thoracotamy. There was a wide variation in the in vivo responses, with relatively 
small variation between the in vitro results. No correlation was found, however, 
between the in vitro and in vivo studies, a finding which is in agreement with other 
studies comparing in vitro and in vivo responses (Vincenc et al., 1983; Armour et al., 
1984; Cerrina et al., 1986).
This is not unique to histamine, since several other studies have failed to demonstrate 
any correlation between in vivo and in vitro airway responsiveness to methacholine 
(Roberts et al., 1984). Furthermore, in vivo airway responsiveness to LTD4 varied more
than 1000 fold whereas in vitro responses were much less variable. As was found with 
histamine and methacholine, there was no correlation between the in vivo and in vitro 
results (Roberts et al.* 1987).
There are several possible reasons which may explain the lack of correlation between 
the in vivo and in vitro airway responses. For example:
(i) As mentioned earlier, it is unknown whether responsiveness to agonists is uniform 
throughout the airways. For example, Raffestin and coworkers (1985) reported that the 
in vitro smooth muscle responses to constrictor agents were less in large airways 
(internal diameter, 6mm) than in smaller airways (internal diameter, 2mm). It has been 
postulated that in vivo airway responsiveness is representative of the average of the
range of responsiveness within the lung. Thus, it is possible that tissues studied in vitro 
are not responsible for the in vivo responses.
(ii) Studies comparing in vivo with in vitro responsiveness have measured in vitro 
sensitivity under conditions of isometric tension, as indeed was the case for my studies.
In vivo, however, airway narrowing involves shortening of smooth muscle and it is 
possible that an assessment of isotonic shortening of airway smooth muscle would be 
more relevant to in vivo conditions.
In addition to the effects of acute changes in oxygen tension on airway responsiveness,
I have shown that chronic exposure to hypoxia can also significantly alter responses to 
various agents. Using the hypobaric model of chronic hypoxia, I demonstrated that 
isolated airway preparations from rats exposed to 14 days of moderate hypoxia 
responded significantly less than controls to the contractile agents methacholine, 
endothelin-1 and potassium chloride. In chapter 5, I reported that chronic hypoxia 
altered the involvement of ETa and ETb receptors in the the contractile response to ET-
1 in raf trachea. This suggests that chronic hypoxia may induce alterations at the level 
of the membrane-bound receptor. Whether this represents a change in the expression of 
the receptor subtypes, or uncoupling of the receptors from their regulatory G proteins is 
unclear. It is possible that the behaviour of other G protein-linked receptors in airway 
smooth muscle, such as muscarinic recptors, may be altered by chronic hypoxia. As 
stated in chapter 4, however, this would not explain why responses to potassium 
chloride were also altered, since this agent does not act via receptor-stimulation. We 
have postulated in chapter 4 that the attenuation in responsiveness to contractile agents 
is due to some alteration in the intrinsic pharmacology/biochemistry of the airway 
smooth muscle. For example, we found responses to the dilator, sodium nitroprusside 
but not salbutamol, to be enhanced in chronic hypoxia, suggesting that chronic hypoxia 
may cause an increase in the responsiveness of airway smooth muscle to cGMP- 
mediated relaxation.
These findings are in opposition to the effect of chronic hypoxia on the responsiveness 
of pulmonary arteries to contractile agents. Several authors have reported that 
contractile responses to a wide variety of agents are enhanced in pulmonary arteries 
from chronically hypoxic rats (Eddahibi et al., 1991; MacLean et al., 1995). This 
enhancement is purported to be due to the increase in vascular smooth muscle mass in 
the blood vessels from the hypoxic rats. Interestingly, our cell culture studies showed 
that proliferation of airway smooth muscle cells was also stimulated by hypoxia. From 
this finding,"T5Iie may expect the airways of the chronic hypoxic rats to exhibit an 
increased muscularisation. This in turn would be expected to enhance contractile 
responses, as in the pulmonary arteries, due to an increase in the airway smooth muscle 
mass. While this has been shown to occur in rats exposed to chronic hyperoxia (Szarek
275et al., 1995; Hershenson et al., 1992a and b, see section 1.7), I found that chronic 
hypoxia actually attenuated the contractile responses.
Given that we did not compare the ultrastructure of the airways from control and 
chronically hypoxic rats, I cannot make any statements about the degree of 
muscularization in the airways of the chronically hypoxic rats. However, since chronic 
hyperoxia has been shown to induce thickening of the airway smooth muscle in rats 
with a concomitant increase in contractile responses, and since we found an attenuation 
in contractile responses in the hypoxic rats, one may tentatively conclude that 
thickening of the airway wall is unlikely to occur in the airways of our chronically 
hypoxic rats.
This would appear to be at odds with our cell culture studies, since I found hypoxia to 
potentiate mitogenesis in the cultured airway smooth muscle cells.
It may be difficult, however, to make a direct comparison between the cell culture 
studies and the chronically hypoxic rat studies for a number of reasons. Firstly, the cells 
used in the cell culture studies were human airway smooth muscle cells, thus there may 
be an underlying species difference Th terms of the proliferative response to hypoxia. 
Secondly, the duration and intensity of the hypoxic stimulus was clearly different 
between the two studies. The cultured cells were exposed to extremely low O2 tensions
(~30mm Hg) for a relatively short time (24 hours), whereas the rats received a less 
severe hypoxic exposure for a longer time period (-330 mm Hg for 14 days). It is 
possible that the effect of hypoxia on cell proliferation is dependent on both the 
intensity and the duration of the hypoxic stimulus, but this remains to be addressed by 
scientific investigation.
In conclusion, the responsiveness of airway smooth muscle may be significantly altered 
by either acute or chronic changes in oxygen tensions. This may be of clinical 
significance given that hypoxia can often be a feature of various respiratory disorders. 
The full mechanisms underlying the effect of hypoxia on airway smooth muscle 
function remain to be elucidated.
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